CN1694959A - Antiviral oligonucleotides targeting viral families - Google Patents

Abstract

Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.

Description

Non-sequence complementary antiviral oligonucleotides

Technical field

The present invention relates to have the oligonucleotide of antiviral activity and they virus infection, cancer and etiology be based on other disease of virus in as the application of therapeutical agent, described virus infection is caused by the human and animal virus, and described cancer is caused by oncogene virus.

Background of invention

Following discussion just is used to help the reader to understand, and is not to recognize that the information of any discussion or the reference of quoting have constituted prior art of the present invention.

The many important transmissible disease that the mankind suffer from is all caused by virus.These diseases comprise rabies, smallpox, poliomyelitis, hepatitis, yellow jack, immune deficiency and various encephalitis disease, and many in them usually are fatal.Giving prominence to of other because they be hyperinfection and produce acute discomfort, for example influenza, measles, parotitis and varicella, and respiratory tract disease or gastrointestinal disorder.Other for example rubella and cytomegalovirus can be caused congenital malformation.At last, known some virus is tumour virus, and they can cause cancer in the human and animal.

In virus, very interested is herpetoviridae family.Herpetoviridae is the ubiquitous icosahedron of a class (icoshedral), double-stranded DNA virus.In surpassing among the member of 100 kinds of signs of herpetoviridae (HHV), only there are 8 kinds can infect human.What wherein know the most is I type herpes simplex (HSV-1), II type herpes simplex (HSV-2), varicella zoster (varicella or zoster), cytomegalovirus (CMV) and Epstein-Barr virus (EBV).The sickness rate of simplexvirus in the mankind is higher, influences at least three of world population/one; In the U.S., the population of 70-80% has certain type herpes infection.Although the pathology of herpes infection are not dangerous usually, mostly just cause mouth and face short-term pathology on every side as HSV-1, also known these viruses are causes of many more serious symptoms, these symptoms from genital ulcer and obstacle to causing that encephalitis (15% mortality ratio) or dispersivity infect the fetal infection of (40% mortality ratio).

Simplexvirus is disperse in nature, and is Vi to the people.For example, known Epstein-Barr virus (EBV) can cause infectious monocytosis when late childhood or pubescence or person between twenty and fifty.The characteristics of acute infection mononucleosis be have a sore throat, fever, headache, lymphadenopathy, hypertrophy of tonsils and the atypical dispersion lymphocyte in peripheral blood.Other performance often comprises slight hepatitis, splenomegaly and encephalitis.EBV also with the related to cancer of two kinds of forms: Burkitt lymphoma (BL) and nasopharyngeal carcinoma (NPC).In equatorial Africa popularly, BL is modal children malignant tumors, accounts for about 80% of children's cancer.Although moderately observe in Caucasia, North America, NPC is in one of modal cancer of SOUTHERN CHINA, and age of onset is 25～55 years old.Similar with cytomegalovirus, EBV is also relevant with the lympahadenism after the transplanting, and this disease is the fatal complication of chronic immunosuppressant potential after organa parenchymatosum or the bone marrow transplantation.

Other disease is also relevant with HSV, comprises skin and eye infection, for example choroidoretinitis or keratoconjunctivitis.In the U.S., diagnose out about 300,000 routine HSV eye infection every year.

AIDS (acquired immune deficiency syndrome (AIDS)) is caused by human immunodeficiency virus (HIV).By killing or destroy the immune cell of health, HIV little by little destroys the ability of anti-infective and some cancer of health.At present, there is the forty-two million people to suffer from HIV/AIDS in the world approximately.In 2002, have 3,100,000 people and die from the reason relevant with HIV/AIDS.The ultimate aim of anti-HIV pharmacotherapy is to stop virus replication and destroy immunity system.Although in the struggle of resisting HIV, obtained substantial progress in the past 15 years, still be difficult on the medical science cure.At present, the doctor can come control disease with unnecessary a dozen the antiretroviral medicine in 3 kinds of different pharmaceutical types.Typically, the medicine of two or three type is left prescription with various combinations, be called HAART (efficient antiretroviral therapy).The HAART therapy typically comprises 2 kinds of nucleoside reverse transcriptase inhibitor medicines and the third medicine, and this third medicine is proteinase inhibitor or non-nucleoside reverse transcriptase inhibitor.Clinical study is verified, and HAART reduces viral load and makes drug-fast may be minimized effective means.

Can reduce the amount of intravital HIV (so-called viral load) although confirmed HAART, 10/1000ths patient uses this therapy significant problem can occur.Some side effects are serious, comprise unusual lipid metabolism, urinary stone disease and heart trouble.Other side effect is for example felt sick, vomiting and insomnia are not too serious, but remains problem for the HIV patient of the long-term pharmacological agent of lifelong needs.

At present the anti-HIV medicine of approval by enter the CD4+T cell that infected HIV and blocking virus enzyme (reversed transcriptive enzyme or proteolytic enzyme) be used for play a role.In order to duplicate, HIV needs these enzymes.But HIV often undergos mutation and becomes resistance, makes reversed transcriptive enzyme or the proteinase inhibitor medicine invalid.In case the generation resistance, viral load will raise, and indication needs to change invalid medicine into another kind of antiretroviral medicine.Unfortunately, when virus becomes when a kind of in the class medicine had resistance, it is not too effective that the other medicines in such also may become.This phenomenon is called cross-resistance, and its reason is that the medicine of many anti-HIV plays a role in a similar fashion.The medicine crossed resistance be very undesirable because it has reduced the quantity that the obtainable treatment of patient is selected.

Therefore, be starved of exploitation to effective other antiviral of HIV, its mechanism of action by other plays a role, and virus produces resistance to it as yet.This particularly important that becoming, because nearest data show, Europe has 1/10th the HIV strain that the patient infected of carrying HIV of being made a definite diagnosis recently the marketed drugs of at least a approval to be produced resistance.

Respiratory syncytial virus (RSV) can cause upper and lower respiratory tract infection.It is the RNA viruses of a kind of negative justice, coating, and is highly infective.It usually infects the child of tender age, and the modal reason of baby's lower respiratory illness normally.Rsv infection is usually with the symptom of moderate to serious flu sample.But serious lower respiratory illness can occur in any age, particularly in patient old age or the immunity infringement.The children of severe infection may need oxygen therapy, and need power ventilation in some cases.According to American Medical Association, increasing children are because bronchiolitis is in hospital, and this disease is caused by rsv infection usually.Rsv infection also accounts in the bone marrow transplantation about 1/3rd of the relevant respiratory virus infection of patient's in the heart colony.In old crowd, thought that the seriousness of rsv infection and influenza infection are closely similar recently.

Influenza (INF) is also referred to as influenza, is the communicable disease that is caused by influenza virus.It attacks human respiratory tract (nose, larynx and lung).In the U.S., 36,000 people that have an appointment every year on average die from influenza, and have every year 114,000 people to be in hospital because of influenza.

In all transmissible diseases, the effect of given therapy often depends on host's immune response.All the more so for simplexvirus, because at this moment the ability that causes latent infection of all simplexviruss can cause the very high incidence that activates infection again in the patient of immunity infringement.In the acceptor of renal transplantation, 40%～70% can activate the HSV that hides again infects, and 80%～100% can activate cmv infection again.Also having observed such virus in AIDS patient activates again.

Hepatitis B virus (HBV) is a kind of dna virus, and it belongs to the Hepadnaviridae virus family.HBV causes hepatitis B in the mankind.Estimate to have in the world 2,000,000,000 people to be subjected to infecting (3 philtrums have 1 people).About 3.5 hundred million people are chronically infected, and estimating has 1,000,000 people to die from hepatitis B and complication thereof every year.HBV can cause lifelong infection, liver cirrhosis, liver cancer, liver failure and death.This virus is by blood and body fluid communication.This can by direct blood to blood contact, unguarded sexual behaviour, use disinfectant syringe needle not and in birth process, take place to its baby's propagation from the women who infects.The grownup who is infected (90%) of most of health can recover, and produces the protection antibody to hepatitis B virus infection in the future.Minority (5-10%) can not be removed this virus and can develop into chronic infection, when having infected should virus the time, 90% baby is arranged and can develop into chronic infection up to 50% child of tender age.Alpha-interferon is the treatment type of modal employing.This treatment comprises influenza-like symptom, depression, fash, other reaction and unusual cytometry with pronounced side effects.Other treatment selects to comprise 3TC that it also has many side effects relevant with its application.In the past few years, had increasing report to show, the patient who treats with 3TC can produce the HBV resistant strain.For the patient colony that has infected HBV and HIV simultaneously, this is debatable especially.Obviously, press for the new antiviral therapy that exploitation can resist this virus.

It is the modal chronic infection of passing through blood of the U.S. that hepatitis C virus (HCV) infects, and infected patient's number might surpass 4,000,000 in the U.S..In the U.S., this common viral infection is the major cause of liver cirrhosis and liver cancer, also is the major cause of liver transplantation now.It is uncommon infecting the back recovery, and about 85% infected patient can become the chronic carrier of this virus, and 10～20% develop into liver cirrhosis.Estimate that it is chronic carrier that 1.7 hundred million people are arranged at present in the world.According to CDC, only in the U.S., chronic hepatitis C causes 8,000～10,000 people's death every year, and causes about 1,000 routine liver transplantation.There is not to be used for the vaccine of hepatitis C.Interferon alpha or Interferon, rabbit and ribavirin combined therapy are only effective in about 40% patient for a long time, and produce pronounced side effects.

Now, the treatment prospect of virus infection is also pessimistic generally.Usually, the treatment of virus has common effect, and with the intensive side effect, it has stoped using of effective dose or has stoped long-term treatment.3 kinds of clinical scenarios that these problems can be described are herpetoviridae, HIV and rsv infection.

In the situation of herpetoviridae, mainly contain 5 kinds of treatments at present and be approved for clinical: iodoxuridine, vidarabine, acycloguanosine, phosphine formic acid and ganciclovir.Although effect is limited, these treatments also have side effect.Reported that 35% the patient with the iodoxuridine treatment has anaphylaxis, vidarabine can cause gastrointestinal dysfunction in 15% patient, and nucleotide analog acycloguanosine, phosphine formic acid and ganciclovir can influence the dna replication dna of host cell.In 40% the AIDS patient with the ganciclovir treatment, report has neutrocytopenia and thrombocytopenia.

Infect although there are many different medicines can be used for the treatment of HIV at present, they are all with suitable significant side effects, and needing widely, complementary medicine comes to provide rational quality of life to the patient.The other problem of the drug-resistant strain of HIV (this problem also can appear in the herpetoviridae infection) needs the treatment of periodic variation cocktail usually, and is making infection be very difficult to treatment in some cases.

Treatment children baby's in age rsv infection is another example that presses for the developing new drug thing.In this case, common methods of treatment is to use the small-particle aerosol in the isolation pocket to carry ribavirin by sucking.Not only ribavirin is just effective slightly, and its application is with pronounced side effects.In addition, the potential release of medicine has caused healthcare givers's great attention, because the teratogenecity of known ribavirin.

Obviously, for any emerging antiviral of developing, it is desirable to very much to have the effect that following 3 feature: 1-improve; Side effect risk that 2-reduces and 3-virus are difficult to the mechanism of action that overcomes by sudden change.

Many trials of concrete virus have been carried out suppressing by various antisense methods.

Zamecnik etc. have used the ON (Zamecnik of target reversed transcriptive enzyme primer sites and donor splicing site/acceptor site specifically, Deng (1986) Proc.Natl.Acad.Sci.USA 83:4143-) (Goodchild and Zamecnik (1989) United States Patent (USP) 4,806,463).

Crooke and Coworkers. (Crooke etc. (1992) Antimicrob.Agents Chemother.36:527-532) have described the antisense of a kind of anti-HSV-1.

Draper etc. (1993) (United States Patent (USP) 5,248,670) reported have anti--HSV activity, contain the Cat sequence and can with the antisense oligonucleotide of HSV-1 gene UL13, UL39 and UL40 hybridization.

Kean etc. (Biochemistry (1995) 34:14617-14620) after tested as the antisense methyl-phosphorous acid oligomer ester of anti--HSV reagent.

(Biol Chem Hoppe Seyler (1995) Mar such as Peyman; 376:195-198) reported to the test of the specific antisense oligonucleotide that points to IE110 with to the test of the antiviral properties of the UL30mRNA of HSV-1.

Anderson etc. (1997) (United States Patent (USP) 5,591,720) have reported oligonucleotide or the oligonucleotide analogs that points to the CMV mRNA of coding IE1, IE2 or archaeal dna polymerase.

Hanecak etc. (1999) (United States Patent (USP) 5,952,490) have put down in writing the oligonucleotide of modifying, and it has the flanking nucleotide of conservative G tetrad sequence (G quartet sequence) and sufficient amount, with the remarkable activity that suppresses virus as HSV-1.

Jairath etc. (Antiviral Res. (1997) 33:201-213) have reported the antisense oligonucleotide of anti-RSV.

Torrence etc. (1999) (United States Patent (USP) 5,998,602) have reported the compound that contains with the oligonucleotide activator of strand part complementary antisense component, connector and the ribonuclease l of the anti-genome chain of RSV (mRNA chain).

Qi etc. (Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (2000) 14:253-256) have reported the test to the antisense PS-ODN in the Coxsackie B virus 3.

International open WO9203051 (Roizman and Maxwell) has put down in writing the methylphosphonate antisense scant polymer, itself and the virus genomic key area of HSV or its mRNA transcript complementation, and it shows antiviral activity.

Thiophosphatephosphorothioate (phophorothioate) oligodeoxynucleotide (GT-PS-ODN) of having reported guanosine-/thymidine or being rich in guanosine-has antiviral activity.This article is told about, " the abundant ODN (B106-140, I100-12 and G106-57) of several different GT-that contains PS of the length of 26 or 27 Nucleotide reduce HIV-2 tire aspect with by 36 (B106-96; B106-97) or 45 abundant ODN equally effective (table 4) of GT-that Nucleotide is formed " (Fennewald etc., Antiviral Res. (1995) 26:37-54).

At United States Patent (USP) 6,184, in 369, put down in writing the oligonucleotide of the anti-HIV of the guanosine-base that contains high per-cent, anti--HSV and anti--CMV.In preferred embodiments, this oligonucleotide has three-dimensional structure, and this structure is by guanosine-tetrad stabilization.In another embodiment, the oligonucleotide composition of this invention contains 2 adjacent pancreatic desoxyribonucleases of 2 or more a plurality of (two or more runs).The ODN that the claimed G-of this patent is abundant, it is included at least 2 G residues of at least 2 positions.

Cohen etc. (United States Patent (USP) 5,264,423 and 5,276,019) have put down in writing the inhibition that HIV is duplicated, and have more specifically put down in writing the PS-ODN analogue, and it can be used for stoping external nucleic acid duplicating at normal liver cell.Cohen etc. have described the antiviral activity to the specific antisense PS-ODN of virus sequence.They have also described 14,18,21 and the test of the PS-ODN sequence of polyA, the polyT of 28-mer and polyC, and have confirmed the antivirus action of these PS-ODN.

Matsukura etc. (Matsukura etc. (1987) Proc Natl Acad Sci USA 84:7706-7710) disclose the result described in the superincumbent United States Patent (USP)s such as Cohen after a while.

Gao etc. (Gao etc. (1989) J Biol Chem 264:11521-11526) have described by testing PolyA, polyT and the polyC PS-ODN sequence that size is 7,15,21 and 28 Nucleotide, the inhibition that PS-ODN duplicates HSV-2.

Archambault, Stein and Cohen (Archambault etc. (1994) Arch Virol 139:97109) report, the PS-ODN polyC of 28 Nucleotide is invalid to HSV-1.

Stein etc. (Stein etc. (1989) AIDS Res Hum Retrovir 5:639-646) disclose the result about other data of anti-HIV ODN, and it is 21-28 length of nucleotides normally.

Marshal etc. (Marshal etc. (1992) Proc.Natl.Acad.Sci.USA 89:62656269) have described thiophosphatephosphorothioate and length is anti-HIV-1 effect of the thiophosphatephosphorothioate poly-C oligomer of 4-28 Nucleotide.

Stein and Cheng (Stein etc. (1993) Science 261:1004-1012) have mentioned the antiviral activity of nonspecific ODN of 28 Nucleotide in one piece of summary, told about " non-sequence-specific effect remarkably influenced the anti-HIV character of PS oligomer; that is to say that restraining effect is independent of base sequence ".

In one piece of summary, Lebedeva and Stein (Lebedeva etc. (2001) Annul RevPharmacol 41:403-419) have reported nonspecific protein binding activity of multiple PS-ODN, comprise viral protein.They claim, " these molecules are high biological activities, and often relatively easily mistake is used as artifact as antisense ".

Rein etc. (United States Patent (USP) 6,316,190) have reported the abundant ON phantom target of GT that is connected to fusion partner and is attached to the HIV nucleocapsid, and it can be used as antiviral compound.Similarly, Campbell etc. (Campbell etc. (1999) J.Virol.73:2270-2279) have reported the PO-ODN with TGTGT motif, and this motif can be attached to the nucleocapsid of HIV specifically, but do not have antiviral activity.

Feng etc. (Feng etc. (2002) J.Virol.76:11757-11762) have described the A (n) and TG (n) PO-ODN of the nucleocapsid that is attached to Recombinant HIV, but do not have data to show that it has the anti-HIV activity.

Being developed the antisense ODN of making carcinostatic agent, antiviral agent or being used for the treatment of other disease typically long is about 20 Nucleotide.One piece of summary (Stein, CA, (2001) J.Clin Invest 108:641-644) confirms, " must optimize the length of antisense oligonucleotide: if antisense oligonucleotide is oversize or too short, can lack the specificity element.At present, the optimum length of antisense oligonucleotide seems about 16-20 Nucleotide ".Similarly, another piece of writing summary (Crooke, ST (2000) Methods Enzymol313:3-45) claims that " compare with the formation of RNA duplex with RNA, the thiophosphatephosphorothioate oligodeoxynucleotide has Tm-2.2 ° of reduction/units approximately.This means that for external effective, the thiophosphatephosphorothioate oligodeoxynucleotide is 17 to 20-mer length typically ... ".

Caruthers and colleague (Marshall etc. (1992) Proc.Natl.Acad.Sci.USA 89:6265-6269) have reported the anti-HIV activity of the phosphorodithioate ODN (PS2-ODN) of many cytidine(C-PS2-ODN of 12mer and 14mer PS2-ODN.Do not test other big or small anti-HIV activity.They also reported 12,14,20 and the many cytidine(C-PS2-ODN of 28mer to the inhibition of hiv reverse transcriptase (RT).Afterwards, (Marshal etc. (1993) Science 259:1564-1570) results reported had confirmed the sequence-specific inhibition of HIV RT.Identical group discloses the data of PS2-ODN in several patents.In United States Patent (USP) 5218103 and 5684148, the structure of having put down in writing PS2-ODN is with synthetic.At U.S. Patent number 5,452, in 496,5,278,302 and 5,695,979, put down in writing the PS2-ODN that is no more than 15 bases inhibition to HIV RT.At U.S. Patent number 5,750, in 666 and 5,602,244, put down in writing the antisense activity of PS2-ODN.

Summary of the invention

The present invention relates to a discovery, i.e. oligonucleotide (ON), for example oligodeoxynucleotide (ODN) antiviral activity that can have the non-sequence complementarity of widespread use.Thereby this oligonucleotide need not with any virus sequence complementation or has specific Nucleotide to distribute, and can have antiviral activity.Such oligonucleotide even can be used as at random thing and prepare makes any specific sequence of having only the minority copy in the preparation at the most, and for example in the preparation of thing at random of 15 μ mol, length is 32 or more Nucleotide.

In addition, the inventor finds that the oligonucleotide of different lengths has different antivirus actions, finds that also the length that can generate the antiviral oligonucleotides of maximum antivirus action is in the scope of 40-120 Nucleotide.Consider the discovery of the antiviral properties about oligonucleotide of the present invention, the invention provides the oligonucleotide antiviral agent, it can have the activity of anti-multiple different virus, and even can be elected to be the broad-spectrum disease resistance toxic agent.Consider the limited antiviral therapy selection that can obtain at present, such antiviral agent is useful especially.

Therefore, ON of the present invention (for example ODN) can be used for the treatment of or prophylaxis of viral infections or treatment or pre-anti-virus, for example tumour virus (for example retrovirus, papilloma virus and simplexvirus) inductive tumour or cancer and treatment or prevent other etiology to be based on the therapy of the disease of virus.This treatment can be used for the patient of many types, and treatment comprises the virus infection that for example prevents or treat immune vitiator or animal patient.

First aspect, the invention provides antiviral oligonucleotide agent, it comprises at least a antiviral oligonucleotides make antiviral agent that is suitable for, the length of at least 6 Nucleotide for example, and wherein the antiviral activity of oligonucleotide mainly is to produce by the non-sequence complementary mode of action.Said preparation can comprise the mixture of different oligonucleotide (for example at least 2,3,5,10,50,100 or more).

As employed about oligonucleotide or other material here, term " antiviral " is meant that there are the effect of the generation that suppresses virion in oligonucleotide or other material, promptly otherwise can be fit to reduce in the system of formation of infectious viral particle the number of the infectious viral particle that forms.

Term " antiviral oligonucleotide agent " is meant and comprises at least a goods that are suitable for the antiviral oligonucleotides of making antiviral agent.Said preparation comprises one or more oligonucleotide, and can contain and can not disturb other material of using in vivo as antiviral agent.Other material like this can include but not limited to thinner, vehicle, carrier substance and/or other antiviral substance.

As used herein, term " pharmaceutical composition " is meant antiviral oligonucleotide agent, and it comprises on the physiology or pharmaceutically acceptable carrier or vehicle.Said composition can also comprise other component, and its experimenter (for example people) that said composition is unsuitable for needs uses.

In the context of the present invention, unless stated otherwise, term " oligonucleotide (ON) " refers to oligodeoxynucleotide (ODN) or oligodeoxyribonucleotide or oligoribonucleotide.Thereby " oligonucleotide " is meant the oligomer or the polymkeric substance of Yeast Nucleic Acid (RNA) or thymus nucleic acid (DNA) or its analogue.This term comprises the oligonucleotide of being made up of (main chain) bonding between the nucleosides of naturally occurring nuclear base, sugar and covalency and has the oligonucleotide of the part of functionally similar non-natural existence.Oligonucleotide this modification or that replace is through being often better than natural form, because ideal character, for example enhanced cell absorption, enhanced are to the avidity in nucleic acid target site, the stability in the presence of nuclease of raising.This paper has described the example of operable modification.The oligonucleotide that comprises main chain and/or other modification may also be referred to as oligonucleoside.

As employed about anti-virus formulation, pharmaceutical composition or other material, phrase " be suitable for do antiviral agent " is meant that this material shows antivirus action, and does not comprise and can make it not be suitable for any component or the material that suppresses virus replication (for example to for example people experimenter's administration of experimenter) in the system in vivo.

Employed about the antivirus action of material as this paper, phrase " the non-sequence complementary mode of action " is meant that mechanism that this material shows antivirus action is not because the hybridization of complementary nucleotide sequence, for example antisense effect.On the contrary, " the sequence complementary mode of action " is meant that the antivirus action of material relates to the hybridization of complementary nucleotide sequence.Thereby, the antiviral activity of material " not being mainly due to the sequence complementary mode of action " is meant, the activity of oligonucleotide satisfies at least one in 4 tests provided herein (referring to embodiment 10), and whether described test is used to detect this antiviral activity " non-mainly due to the sequence complementary mode of action ".In specific embodiment, oligonucleotide satisfies test 1, test 2, test 3 or tests 4; Oligonucleotide satisfies the combination of 2 tests, promptly tests 1 and 2; Test 1 and 3; Test 1 and 4, test 2 and 3, test 2 and 4, or test 3 and 4; Oligonucleotide satisfies the combination of 3 tests, promptly tests 1,2 and 3, test 1,2 and 4, and test 1,3 and 4, or test 2,3 and 4; Oligonucleotide satisfies Total Test 1,2,3 and 4.

As employed about using of antiviral substance here, term " experimenter " is meant higher organism alive, comprise, for example, animal, Mammals for example, for example people, inhuman primates, ox, pig, sheep, horse, dog and cat; Birds; And plant, for example fruit tree.

A related aspect relates to antiviral oligonucleotide thing preparation at random, wherein this at random the antiviral activity of thing mainly be to produce by the non-sequence complementary mode of action.This preparation of thing at random can for example comprise the mixture of the thing at random of different lengths, for example at least 2,3,5,10 or more different lengths.

As employed about oligonucleotide sequence here, term " at random " has characterized not and virus mRNA complementary sequence or ON, and it can not form hair clip and not have the palindromic sequence that is contained in wherein.When term " at random " is used in the context of antiviral activity of the oligonucleotide that points to concrete virus, be hypodactylia and the complementarity of virus mRNA that should concrete virus.Complementary lacking can be generalized, for example for multiple virus, for from the virus of concrete virus family or for infective Human virus.

In this application, term " thing at random " means the single stranded DNA that swing (N), for example NNNNNNNNNN are all arranged in each position.Each base is all synthetic as swing, so the sequence that this ON is actually as the different identical size that produces at random of a group exists.

On the other hand, the invention provides the oligonucleotide of antiviral activity with anti-target viral, wherein this oligonucleotide is that the length of at least 29 Nucleotide is (perhaps in specific embodiments, the length of at least 30,32,34,36,38,40,46,50,60,70,80,90,100,110 or 120 Nucleotide), and the sequence of this oligonucleotide not with any part complementation of the genome sequence of target viral.

On the other hand, the invention provides oligonucleotide agent, it comprises at least a oligonucleotide with antiviral activity of anti-target viral, wherein oligonucleotide is that the length of at least 6 Nucleotide is (in specific embodiments, at least 29,30,32,34,36,38,40,46,50,60,70,80,90,100, the length of 110 or 120 Nucleotide), and the complementarity of any part of the sequence of oligonucleotide and the genomic nucleic acid sequence of target viral is lower than 70%, and is not by polyA basically, polyC, polyG, polyT, the abundant sequence of G tetrad or TG-is formed.In specific embodiments, the complementarity of any part of the genomic nucleic acid sequence of this oligonucleotide and target viral is lower than 65%, 60%, 55%, 50%, 80%, 90%, 95% or 100%.

As employed about oligomer of the present invention, term " TG-is abundant " is meant that antiviral oligonucleotide sequence is made up of at least 70% T and G Nucleotide, if perhaps specify, is at least 80,90 or 95% T and G, perhaps even 100% composition.

The antiviral oligonucleotide as described herein of isolating, purifying or enrichment that related fields relate to, the oligonucleotide agent of for example antagonism virus and other oligonucleotide goods (goods that for example are fit to external use) are described.

Being used for antiviral oligonucleotide of the present invention can be all lengths, for example at least 6,10,14,15,20,25,28,29,30,35,38,40,46,50,60,70,80,90,100,110,120,140,160 or the length of more a plurality of Nucleotide.Similarly, this oligonucleotide can be in certain scope, for example by getting the inclusive end points defined scope of any 2 aforementioned value as scope, for example 10-20,20-40,30-50,40-60,40-80, a 60-120 and 80-120 Nucleotide.In specific embodiments, minimum length or length range and this paper are that listed any other oligonucleotide explanation of antiviral oligonucleotide of the present invention is combined.

Antiviral Nucleotide can comprise various modifications, and for example stabilization is modified, thus can comprise in the phosphodiester bond and/or sugar on and/or base at least one modification.For example, this oligonucleotide can comprise one or more phosphorothioate bonds, phosphorodithioic acid ester bond and/or methyl-phosphorous acid ester bond; 2 of sugar '-modification of position, for example 2 '-the O-methyl modifies, 2 '-amido modified, 2 '-halo for example modifies 2 '-fluoro; The nucleotide analog of acyclic also can comprise at least one phosphodiester bond.Other modification also is known in the art, also can use.Containing 2 '-oligomer that the O-methyl is modified in, this oligomer should not have spread all over 2 '-the O-methyl modifies, because present result shows that this oligomer does not have stable activity.In specific embodiments, oligonucleotide has the modifier keys that spreads all over, for example thiophosphatephosphorothioate; Have 3 '-and/or 5 '-cap; Comprise 3 terminal '-5 ' key; Oligonucleotide is or comprises the concatermer that is connected to form by connector by two or more oligonucleotide sequences.

In specific embodiments, oligonucleotide can be incorporated on one or more viral proteins; The sequence of oligonucleotide (or its part, for example at least 1/2) is to be derived from viral genome; Have the oligonucleotide of thing at random or the random oligonucleotide that are not better than equal length from the activity of the oligonucleotide of virus genomic sequence; Oligonucleotide comprise with the part of virus sequence complementary and not with virus sequence complementary part; Oligonucleotide sequence is to be derived from viral packaging sequence or to participate in similar (aptameric) interactional other virus sequence; Except as otherwise noted, oligonucleotide sequence comprises A (x), C (x), G (x), T (x), AC (x), AG (x), AT (x), CG (x), CT (x) or GT (x), wherein x is 2,3,4,5,6, ... 60...120 is (in specific embodiments, oligonucleotide is the length of at least 29,30,32,34,36,38,40,46,50,60,70,80,90,100,110 or 120 Nucleotide, and the length of perhaps concrete tumor-necrosis factor glycoproteins is concrete at least length); Oligonucleotide is strand (RNA or DNA); Oligonucleotide is double-stranded (RNA or DNA); Oligonucleotide comprises at least one G tetrad or CpG part; Oligonucleotide comprises and virus mRNA complementary part, and is the length (perhaps aforesaid other length) of at least 29,37 or 38 Nucleotide; Oligonucleotide comprises that at least one Fei Wosen-Ke Like oligonucleotide and/or at least one participate in the Nucleotide that Fei Wosen-Ke Like combines with another Nucleotide; Oligonucleotide is a random oligonucleotide, and oligonucleotide is a thing or comprise thing part at random at random, for example has the part of thing at random of the length of top described oligonucleotide length; Oligonucleotide connects at one or more nucleotide residues place or is attached on the molecule, for example higher stability (for example stability in serum or the stability in particular solution), lower serum interact, higher cell is taken in, higher viral protein interacts, ability, detectable signal, the pharmacokinetics character of raising, specific tissue distribution and/or the lower toxicity of the conveying preparation of improvement in order to provide for the feature of described molecular modification oligonucleotide, described modification.

Oligonucleotide can also be used in combination, for example as mixture.Such combination or mixture for example can comprise at least 2,4,10,100,1000,10000,100,000,1,00,000 or more a plurality of different oligonucleotide.Such combination or mixture can for example be different sequence and/or different length and/or different modification and/or different connection or bonded molecules.In the specific embodiments of this combination or mixture, many oligonucleotide have minimum length, and as above are being in the described length range of oligonucleotide.In the specific embodiments of this combination or mixture, at least one, many or each oligonucleotide can have this paper and be described any other character of each antiviral oligonucleotides (it also can be the combination of any unanimity).

Phrase " is derived from viral genome " and is meant that the nucleotide base sequence that particular sequence has has at least 70% identity with viral genome nucleotide sequence or its complementary sequence (for example identical with this virus genome sequence or complementary), or corresponding RNA sequence.In specific embodiments of the present invention, this term shows that the virus genome sequence of sequence and specific virus (oligonucleotide points to it) or its complementary sequence have at least 70% identity.In specific embodiments, identity is at least 80,90,95,98,99 or 100%.

The present invention also provides antiviral medicinal composition, it comprises acceptable antiviral oligonucleotide and pharmaceutical carrier on the pharmacology for the treatment of significant quantity, at least 6 length of nucleotides of described oligonucleotide (or this paper list other length), wherein the antiviral activity of oligonucleotide mainly produces by the non-sequence complementary mode of action.In specific embodiments, the combination of oligonucleotide or oligonucleotide or mixture such as top be that the combination or the mixture of each oligonucleotide or oligonucleotide is illustrated.In specific embodiments, pharmaceutical composition goes through to be administered to people or inhuman animal, for example non-human primates.

In specific embodiments, pharmaceutical composition is to be used for the treatment of, to control or prevent virus causing disease to learn disease; Be used for the treatment of, control or prevent prion disease; Be be used for by intraocular use, per os is taken in, intestines are used, suck, in skin, subcutaneous, intramuscular, endoperitoneal, sheath, endotracheal or intravenous injection or topical application carry.In specific embodiments, said composition comprises delivery system, for example the specific cell or tissue of target; Liposomal formulation, another kind of antiviral, for example non-nucleotide antiviral polymeric, antisense molecule, siRNA or small-molecule drug.

In specific embodiments, antiviral oligonucleotide, oligonucleotide goods, oligonucleotide agent or antiviral medicinal composition to the IC50 of target virus (virus in for example any concrete virus or the virus group as described herein) be 0.50,0.20,0.10,0.09.0.08,0.07,0.75,0.06,0.05,0.045,0.04,0.035,0.03,0.025,0.02,0.015 or 0.01 μ M or still less.

In the specific embodiments of preparation, pharmaceutical composition and prevention or methods of treatment, said composition or preparation are to be used for the treatment of, to control or prevent virus causing disease to learn disease; Be used for the treatment of, control or prevent prion disease; Be to be used for carrying by being selected from following mode: absorption intraocular, per os, intestines, suck or through skin, subcutaneous, intramuscular or intravenous injection delivery; Also comprise delivery system, it can comprise and can strengthen and the molecule of the avidity of specific cells or relevant with it; Other antiviral that also comprises at least a combination; And/or also comprise the antiviral polymeric of combination.

Employed about antiviral oligonucleotide and preparation etc. as this paper, when mentioning concrete virus or virus group, term " target " is meant that oligonucleotide is selected to suppress this virus or virus group.As employed about concrete tissue or cell type, this term represents that oligonucleotide, preparation or the delivery system selected can make oligonucleotide in concrete tissue or cell type or preferably exist and/or preferably show antivirus action on every side.

As used herein, term " delivery system " is meant one or more components, when making up with oligonucleotide as herein described, amount and/or time length during with this delivery system are not compared, it can increase the amount of the oligonucleotide that touches body internal object position and/or prolong it in the target position lifetime, for example at least 20,50 or 100% or more, and/or prevention or minimizing can cause the interaction of side effect.

Employed about antiviral agent and other medicines or test compounds as this paper, term " small molecules " is meant that the molecular weight of this molecule is 1500 dalton or still less.In some cases, molecular weight is 1000,800,600,500 or 400 dalton or still less.

On the other hand, the invention provides a kind of test kit, it is included at least a antiviral oligonucleotide or oligonucleotide agent in the packing of tape label, wherein the antiviral activity of oligonucleotide mainly produces by the mode of action of non-sequence complementarity, and the label on the packing has illustrated that antiviral oligonucleotide can be used to resist at least a virus.

In specific embodiments, test kit comprises pharmaceutical composition, and it comprises at least a antiviral oligonucleotide as herein described; This antiviral oligonucleotide is fit to body and is used for animal interiorly, and/or label has illustrated that this oligonucleotide or composition are acceptable and/or are approved for animal; Animal is a Mammals, for example people or inhuman Mammals, for example ox, pig, ruminating animal, sheep or horse; Animal is inhuman animal; Test kit is by FDA (Food and Drug Adminstration) or be equal to mechanism approval and be used for animal, for example people for example of administration.

On the other hand, the invention provides a kind of method, it can screen the antiviral oligonucleotide as antiviral agent, the antiviral oligonucleotide of for example non-sequence complementary.This method relates to synthetic many different random oligonucleotides, and the activity of the ability of the inhibition virus generation infectious virus particle of test oligonucleotide and the active oligonucleotide that selection has pharmaceutically acceptable level are as antiviral agent.

In specific embodiments, different random oligonucleotides comprises the thing at random of different lengths; Random oligonucleotide can have different sequences maybe can have the common sequence, for example the great majority sequence of short oligomer; And/or different random oligonucleotides comprises many oligonucleotide, and it comprises the fragment of thing at random of at least 5 length of nucleotides, and perhaps this different random oligonucleotide comprises the thing at random of many different lengthss.Can test other oligonucleotide in particular system, for example be that antiviral oligonucleotide is described herein.

On the other hand, the invention provides a kind of method of in the experimenter, preventing or treating virus infection, it is by acceptable oligonucleotide as described herein at least a pharmacology of giving the experimenter's administering therapeutic significant quantity that needs this treatment, the oligonucleotide of the non-sequence complementarity of at least 6 length of nucleotides for example, or the antiviral medicinal composition or the preparation that contain this oligonucleotide carry out.In specific embodiments, this virus can be that being applicable to of listing of this paper utilized any in those that the present invention suppresses; Infect with as herein described relevant with virus infection diseases associated or illness; The experimenter is experimenter's type as herein described, for example people, inhuman animal, inhuman Mammals, plant etc.; Treatment is the disease at virus disease or virus causing disease, for example disease described in the background technology of this paper.

In specific embodiments, used antiviral oligonucleotide as herein described (or oligonucleotide agent or pharmaceutical composition); Using is method as herein described; Delivery system as herein described or method have been used; Virus infection is the infection of dna virus or RNA viruses; Virus is Parvoviridae, Papovaviridae, Adenoviridae, herpetoviridae, Poxviridae, Hepadnaviridae or Papillomaviridae; Virus is Arenaviridae, bunyaviridae (bunyaviridae), calciviridae, coronaviridae, filovirus section, flaviviridae (flaviridae), orthomyxoviridae family, Paramyxoviridae, picornaviridae, Reoviridae, Rhabdoviridae, Retroviridae or Togaviridae; The simplexvirus coe virus is EBV, HSV-1, HSV-2, CMV, VZV, HHV-6, HHV-7 or HHV-8; Virus is HIV-1 or HIV-2; Virus is RSV; Virus is influenza virus, for example influenza A; Virus is HBV; Virus is variola virus or vaccinia virus; Virus is coronavirus; Virus is SARS virus; Virus is west nile virus; Virus is Hantaan virus; Virus is parainfluenza virus; Virus is Coxsackie virus; Virus is rhinovirus; Virus is yellow fever virus; Virus is dengue virus; Virus is hepatitis C virus; Virus is Ebola virus; Virus is Marburg virus.

Similarly, in a related aspect, the invention provides a kind of human or animal's method for cancer that prophylaxis treatment causes that is used for, its at least a random oligonucleotide by at least 6 length of nucleotides (or other length as herein described) of giving the human or animal need this treatment and using acceptable on the pharmacology, treatment significant quantity or preparation or the pharmaceutical composition that contains this oligonucleotide carry out.

In specific embodiments, oligonucleotide be as this paper to of the present invention, for example have length as herein described; Used application process as described herein; Used delivery system as described herein.

Term " treatment significant quantity " is meant to be enough to produce when being administered to the typical experimenter who is intended to type treat goes up or prevents to go up the significantly amount of the effect of the generation of reduction infectious viral particle.Relate to the experimenter use antiviral oligonucleotide aspect, oligonucleotide, preparation or composition should be typically be used with the treatment significant quantity.

On the other hand, found that the interaction of non-sequence complementary can produce effective antiviral activity, this provides a kind of screening method to differentiate can change the bonded compound of oligonucleotide to virus component, described virus component for example one or more viral proteins (for example extract from the host's that infects viral cultures or purifying, or produce by recombination method).For example, this method can relate to, and detects test compounds and whether can reduce the combination of oligonucleotide to one or more virus components.

As used herein, term " screening " is that the multiple compound of finger to finger test determines whether they have ideal character.The quantity of compound can be for example at least 10,100,1000,10,000 or more test compounds.

In specific embodiments, any this variation that can be used for differentiating in the combination in multiple test frame and the detection method, for example by under the situation that is with or without the compound existence that to screen, making oligonucleotide contact (for example in the reaction that is separating) with virus component, compare with the situation of not this compound existence in the situation that has compound to exist with determining, whether oligomer produces difference with combining of virus component.The existence of this species diversity shows that this compound has changed the combination of random oligonucleotide to virus component.Perhaps, can use competitive displacement, oligonucleotide is attached on the virus component, and detect, perhaps on the contrary, make the test compounds combination, and detect by adding the displacement that oligonucleotide causes by adding the displacement that test compounds causes.

In specific embodiments, oligonucleotide is an antiviral oligonucleotide as described herein; Oligonucleotide is the length of at least 6,8,10,15,20,25,29,30,32,34,36,38,40,46,50,60,70,80,90,100,110 or 120 Nucleotide, perhaps this paper is the described another kind of length of antiviral oligonucleotide at least, or by getting in the defined scope of inclusive end points of any 2 aforementioned value as scope; Test compounds is a small molecules; The molecular weight of test compounds is lower than 400,500,600,800,1000,1500,2000,2500 or 3000 dalton, or by getting in the defined scope of inclusive end points of any 2 aforementioned value as scope; Virus extract or component are from the listed virus of this paper; At least 100,1000,10,000,20,000,50,000 or 100,000 compounds have been screened; The IC50 of oligonucleotide is equal to or less than 0.500,0.200,0.100,0.075,0.05,0.045,0.04,0.035,0.03,0.025,0.02,0.015 or 0.01 μ M.

As used herein, term " virus component " is meant the product by encoding viral, or the product that is generated by infected host cell that is caused by virus infection.Such component can comprise albumen and other biomolecules.Such virus component can for example be to derive from viral cultures, infected host living beings, animal and plant for example, or can be in recombination system (prokaryotic organism and eukaryote) generate from virus sequence, and have synthetic proteins with the corresponding aminoacid sequence of albumen of encoding viral.Term " viral cultures extract " has been meant the self-infection extract of viral cell, it comprises the product of virus-specific.Similarly, " viral protein " is meant the albumen of virus-specific, and it still can also be by the host sequences coding that is caused by virus infection at least in part usually by encoding viral.

At a related aspect, the invention provides the antiviral compound that identifies by preceding method, for example new antiviral compound.

On the other hand, the invention provides a kind of being purified into from oligonucleotide library can be in conjunction with the method for the oligonucleotide of at least a virus component, and it contacts at least a virus component (for example being attached to the stationary phase medium), and collects the oligonucleotide that is attached to this virus component and carry out by making oligonucleotide library.Usually, collect to relate to oligonucleotide is cemented out from virus component.This method can also relate to the oligonucleotide of collecting (promptly being attached to the oligonucleotide of viral protein) is checked order and/or tests its antiviral activity.

In specific embodiments, by appropriate method arbitrarily bonded oligonucleotide in the storehouse is cemented out from the stationary phase medium, for example use ion exchange, and collect the oligonucleotide that displaces.Typically, about various method of replacing, can replace (for example displacer that raises gradually of working concentration, for example concentration of salt in strict gradually mode, produce step or the successive gradient), thereby displace oligonucleotide with the order of the binding affinity that raises usually.In many cases, the washing that can hang down severity is with bonded oligonucleotide a little less than removing, and collection contains one or more fractions of the oligonucleotide that displaces, more combine closely.In some cases, it is desirable to select to contain in conjunction with the fraction of oligonucleotide (for example oligonucleotide from the fraction that the stricter displacement of permutizer condition obtains) very closely standby.

Similarly, the invention provides a kind of from oligonucleotide library enrichment in conjunction with the method for the oligonucleotide of at least a virus component, oligonucleotide library contacts one or more viral proteins, also amplification is attached to the oligonucleotide of this viral protein, obtains the oligonucleotide library of enrichment by making for it.Contact and amplification can be carried out a plurality of bouts, for example at least 1,2,3,4,5,10 or more times, use from the oligonucleotide library of the enrichment of preceding bout oligonucleotide library as second leg.This method checks order and tests its antiviral activity the oligonucleotide in the oligonucleotide library of enrichment after can also being included in one or more contacts and amplification bout.

This method can comprise with in the multiple technologies any oligonucleotide is cemented out that for example above-mentioned those for example use displacer from virus component (for example being attached to the viral protein on the solid-phase media).As mentioned above, can advantageously select compact oligonucleotide standby, for example be used for further combination and amplification bout.This method can also comprise that the oligonucleotide of the oligonucleotide of selecting one or more enrichments, for example high-affinity is standby.In specific embodiments, this selection can comprise eliminates the oligonucleotide have with host genome sequence (for example people) the complementary sequence of specific objective virus.Such elimination can comprise the contrast oligonucleotide sequence with from the sequence of the specific host in the sequence library, for example use sequence alignment program (for example blast search), and eliminate those and have oligonucleotide identical with host sequences or identical sequence on certain level.Can also for others of the present invention eliminate the sequence of such host's complementarity and/or select one or more not with host sequences complementary oligonucleotide.

In the method for aforesaid discriminating, purifying or enrichment oligonucleotide, this oligonucleotide can be a type as herein described.Aforesaid method can be advantageously used in the oligonucleotide of discriminating, purifying or enrichment high-affinity, for example from oligonucleotide at random the Tetramune.

At a related aspect, the present invention relates to antiviral oligonucleotide goods, it comprises and uses any aforesaid being used for to differentiate, obtain or be purified into one or more oligonucleotide that the method for antiviral oligonucleotide identifies from initial oligonucleotide library, and wherein the oligonucleotide in the oligonucleotide goods is that show higher than the average binding affinity of the oligonucleotide in the initial oligonucleotide library with average binding affinities one or more viral proteins.

In specific embodiments, the average binding affinity of oligonucleotide is higher than at least 2 times, 3 times, 5 times, 10 times, 20 times, 50 times or 100 times or higher of average binding affinity of the oligonucleotide in the initial oligonucleotide library; The intermediate value of this binding affinity is higher than at least 2 times, 3 times, 5 times, 10 times, 20 times, 50 times or 100 times of intermediate value of the binding affinity in initial oligomer storehouse, and wherein this intermediate value is meant intermediary numerical value.

On the other hand, the invention provides the mixture of antiviral polymeric, it comprises the antiviral polymeric of at least a antiviral oligonucleotide and at least a non-nucleotide.In specific embodiments, this oligonucleotide is an antiviral oligonucleotide as herein described, and/or this antiviral polymeric is as described herein or known in the art or identify subsequently.

On the other hand, the invention provides oligonucleotide thing at random, wherein this at random thing be the length of at least 6 Nucleotide.In specific embodiments, this at random thing have above-mentioned length about antiviral oligonucleotide; This at random thing comprise at least a phosphorothioate bond, this thing other modification of comprising at least a phosphorodithioic acid ester bond or listing at random as this paper; This at random the thing oligonucleotide comprise the fragment (for example with select nucleic acid sequence complementary fragment) of at least a nonrandom thing, it can have the above-mentioned length about oligonucleotide; This at random thing be in goods or goods storehouse, it contains at least 5,10,15,20,50,100,200,500 or 700 μ mol, 1,5,7,10,20,50,100,200,500 or 700mmol or 1mol thing at random, or by get any 2 different aforementioned value as the defined scope of inclusive end points in, or synthetic with a kind of above-mentioned numerical value or numerical range.

Similarly, the invention provides a kind of method for preparing antiviral thing at random, it is by synthetic at least a thing at random, and for example aforesaid thing at random carries out.

As mentioned above, about the risk that relates to virus infection or virus infection or any aspect of target specific virus, in specific embodiments, this virus as mentioned above.

Statement " human and animal virus " is intended to include but not limited to DNA and RNA viruses usually.Dna virus comprises for example Parvoviridae, Papovaviridae, Adenoviridae, herpetoviridae, Poxviridae, Hepadnaviridae and papillomavirus section.RNA viruses comprises for example Arenaviridae, bunyaviridae, calciviridae, coronaviridae, filovirus section, flaviviridae, orthomyxoviridae family, Paramyxoviridae, picornaviridae, Reoviridae, Rhabdoviridae, Retroviridae or Togaviridae.

About by connecting or in conjunction with the feature of other molecule or part modified oligonucleotide, the modification in the feature is to connect or the identical oligonucleotide of bonded molecule or part is estimated with respect to not containing.

From following detailed description and claims, other embodiment will be tangible.

Description of drawings

Fig. 1. the plaque that uses HSV-1 (strain KOS) to carry out in the VERO cell reduces test.REP 1001 (a), REP 2001 (b) or REP 3007 (c) with rising concentration handle infected cell.The IC50 value that calculates from linear regression is documented in every width of cloth figure.

Relation between the IC50 of Fig. 2 .PS-ODN size and anti-HSV-1.To map with respect to the concrete size of the every kind of PS-ODN that tests Fig. 1 from the IC50 value that Fig. 1 obtains.

Fig. 3. the plaque that uses HSV-1 (strain KOS) to carry out in the VERO cell reduces test.REP 2001 (a), REP 2002 (b) or REP 3003 (c), REP 2004 (d), REP 2005 (e), REP 2006 (f) and acycloguanosine (g) with rising concentration are handled infected cell.The IC50 value that calculates from linear regression is documented in every width of cloth figure.

Relation between the IC50 of Fig. 4 .PS-ODN size and anti-HSV-1.To show the concrete size mapping of anti--active PS-ODN of HSV-1 from the IC50 value that Fig. 3 obtains with respect to every kind that tests Fig. 3.The IC50 of the acycloguanosine of expression is used for clinical associated reference.

Fig. 5. the plaque that uses HSV-1 (strain KOS) to carry out in the VERO cell reduces test.The PS-ODN that has tested wide scope with REP 2003 (a), REP 2009 (b), REP 2010 (c), REP 2011 (d), REP2012 (e), REP 2004 (f), REP 2006 (g), REP 2007 (h) and the REP 2008 (i) of rising concentration is the thing size at random.The IC50 value that calculates from linear regression is documented in every width of cloth figure.

Fig. 6. by the isolating PS-ODN that in Fig. 5, tests of the acrylamide gel electrophoresis UV development of thing at random.

Fig. 7 .PS-ODN is the relation between the IC50 of thing size and anti-HSV-1 at random.To show the concrete size mapping of anti--active PS-ODN of HSV-1 from the IC50 value that Fig. 5 obtains with respect to every kind that tests Fig. 5.

Fig. 8. the plaque that uses HSV-1 (strain KOS) to carry out in the VERO cell reduces test.Tested the PS-ODN of the initiator codon of the ODN of unmodified, PS-ODN and sensing HSV-1 IE110 with stochastic sequence with REP 2013 (a), REP 2014 (b), REP 2015 (c), REP 2016 (d), REP 2017 (e), REP 2018 (f), REP 2019 (g), REP 2020 (h) and the REP 2021 (i) of rising concentration.The IC50 value that calculates from linear regression is documented in every width of cloth figure.

Fig. 9. by the isolating PS-ODN that in Fig. 8, tests of the acrylamide gel electrophoresis UV development of thing at random.

Figure 10 .PS-ODN is the relation between the IC50 of thing, PS-ODN stochastic sequence, PS-ODN HSV-1 IE110 sequence and anti-HSV-1 at random.To show the concrete size mapping of anti--active PS-ODN of HSV-1 from the IC50 value that Fig. 8 obtains with respect to every kind that tests Fig. 8.Comprised other IC50 value, to carry out the PS-ODN contrast of thing at random from Fig. 5.

Figure 11. the plaque that uses HSV-1 (strain KOS) to carry out in the VERO cell reduces test.With the rising concentration determination: the PS-ODN (REP 2024, [a]) that on 4 ribose of each end of oligomer, has the 2-O methyl to modify; The ODN that methylphosphonate modifies (REP 2026[b]) is arranged on 4 ester bonds of each end of oligomer; With length be the RNA PS-ODN of 20 bases (REP2059[C]) and 30 bases (REP2060[d]).The IC50 value that calculates from linear regression is documented in every width of cloth figure.

Figure 12. the plaque that uses HSV-2 (strain MS2) to carry out in the human fibroblasts reduces test.REP 1001 (a), REP 2001 (b) or REP 3007 (c) with rising concentration have handled infected cell.The IC50 value that calculates from linear regression is documented in every width of cloth figure.

Relation between the IC50 of Figure 13 .PS-ODN size and anti-HSV-2.To map with respect to the concrete size of the every kind of PS-ODN that tests Figure 12 from the IC50 value that Figure 12 obtains.

Figure 14. the plaque that uses HSV-2 (strain MS2) to carry out in the VERO cell reduces test.REP 2001 (a), REP 2002 (b) or REP 2003 (c), REP 2004 (d), REP 2005 (e), REP 2006 (f) and acycloguanosine (g) with rising concentration have been handled infected cell.The IC50 value that calculates from linear regression is documented in every width of cloth figure.

Relation between the IC50 of Figure 15 .PS-ODN size and anti-HSV-2.To show the concrete size mapping of anti--active PS-ODN of HSV-2 from the IC50 value that Figure 14 obtains with respect to every kind that tests Figure 14.The IC50 of acycloguanosine is used for clinical associated reference.

Figure 16. the plaque that uses CMV (strain AD169) to carry out in the VERO cell reduces test.REP 2004 (a) or REP 2006 (b) with rising concentration have handled infected cell.The IC50 value that calculates from linear regression is documented in every width of cloth figure.Relation mapping between the IC50 of PS-ODN size and anti-CMV is shown in (c).To map with respect to the concrete size of every kind of PS-ODN of test from figure (a) and IC50 value (b).

Figure 17. the plaque that uses CMV (strain AD169) to carry out in the VERO cell reduces test.Tested 3 kinds of clinical CMV treatments: gancyclovir (Gancyclovir) (a), phosphine formic acid (b) and cidofovir (c).Also use PS-ODN that REP 2003 (d), REP 2004 (e), REP 2006 (f) and the REP2007 (g) of rising concentration tested wide scope thing size at random.At last, tested the REP 2036 (Fomivirsen) of own synthetic (h) and commercial (i) that buys.The IC50 value that calculates from linear regression is documented in every width of cloth figure.

Relation between the IC50 of Figure 18 .PS-ODN size and anti-CMV.To show the concrete size mapping of anti--active PS-ODN of CMV from the IC50 value that Figure 17 obtains with respect to every kind that tests Figure 17.

Figure 19. use HIV-1 (strain NL4-3) in the MT4 cell, to carry out the CPE test.REP 2004 (a) or REP 2006 (b) with rising concentration have handled infected cell.The IC50 value that calculates from linear regression is documented in every width of cloth figure.The cytotoxicity profile of the MT4 cell of uninfection is expressed as REP 2004 (c) and REP 2006 (d).

Relation between the IC50 of Figure 20 .PS-ODN size and anti-HIV-1.To map with respect to the concrete size of the every kind of PS-ODN that tests Fig. 1 from the IC50 value that Fig. 1 obtains.

Figure 21. use HIV-1 (strain NL4-3) in the MT4 cell, to carry out the CPE test.REP 2004 (a) or REP 2006 (b) with rising concentration have handled infected cell.The IC50 value that calculates from linear regression is documented in every width of cloth figure.Represented REP 2004 (c) and REP 2006 (d) cytotoxicity collection of illustrative plates to the MT4 cell of uninfection.

Figure 21. use reorganization wild-type HIV-1 NL4-3 (strain CNDO) in the 293A cell, to carry out replicated test.Amprenavir (a), Indinavir (b), rltonavir (c), Saquinavir (d), REP 2003 (e), REP 2004 (f), REP 2006 (g) and REP 2007 (h) with rising concentration have handled infected cell.Article two, curve (black line and dotted line) has been represented the dose response curve of bacterial strain CNDO.

Figure 22. (a) from the IC50 value of Figure 21, and (b) relation between the IC50 of PS-ODN size and anti-Recombinant HIV-1.The IC50 value of (a) is mapped with respect to the concrete size of the every kind of PS-ODN that tests among Figure 21.

Figure 23. use the HIV-1 (strain MDRC4) of reorganization multi-medicine resistance in the 293A cell, to carry out replicated test.Amprenavir (a), Indinavir (b), rltonavir (c), Saquinavir (d), REP 2003 (e), REP 2004 (f), REP 2006 (g) and REP 2007 (h) with rising concentration have handled infected cell.The dose response curve of CNDO (wild-type) is expressed as dotted line, and the dose response curve of MDRC4 (drug resistance) is expressed as solid line.

Figure 24. (a) from the IC50 value of Figure 21 and 23, shown the multiple increase figure that the IC50 value multiple between the drug resistance (MDRC4) of wild-type (CNDO) and Recombinant HIV-1 bacterial strain increases and (b) calculates in (a).

Figure 25. use RSV (strain A2) in the Hep2 cell, to carry out the CPE test.REP 2004 (a), REP 2006 (b), REP 2007 (c) or ribavirin (d) with rising concentration have been handled infected cell.The IC50 value that calculates from linear regression is documented in every width of cloth figure.Represented REP2004 (e), REP 2006 (f), REP 2007 (g) or ribavirin (h) cytotoxicity collection of illustrative plates to the Hep2 cell of uninfection.

Relation between the IC50 of Figure 26 .PS-ODN size and anti-RSV.To show the concrete size mapping of anti--active PS-ODN of RSV from the IC50 value that Figure 25 obtains with respect to every kind that tests Figure 25.

Figure 27. use Coxsackie B virus 2 (strain Ohio-1) in the LLC-MK2 cell, to carry out the CPE test.REP 2006 (a) with rising concentration has handled infected cell.The cytotoxicity collection of illustrative plates of REP 2006 is shown in (b).

Figure 28 .A) the FP test that interacts, shown PS-ODN at random thing ( REP 2003,2004,2006 and 2007) from the PS-ODN of FBS competition 20 bases interactional ability of thing bait thing at random.Bigger thing at random can more effectively be competed.B) and C) DOTAP and cytofectin are to the serum protection of the REP2006 in the 293 A cells and the conveying that improves.D) and E) the serum protection of the REP 2006 that seals of DOTAP that detects by FP. or cytofectin.

Figure 29. detected the virolysis thing that is attached on the big or small bait thing of difference by fluorescence polarization.REP 2032-FL, REP 2003-FL and REP 2004FL have been tested from the lysate combination in the lysate of HSV-1 (a), HIV-1 (b) or RSV (c).

Figure 30. by fluorescence polarization detected PS-ODN at random thing to the avidity of virolysis thing.Use REP 2004-FL as the bait thing, challenged mixture formation with HSV-1 lysate (a), HIV-1 lysate (b) or RSV lysate (c) with REP 2003, REP 2004, REP 2006 or the REP 2007 of rising concentration.

Figure 31 .REP 2004-FL can be incorporated into HIV-1 p24gag and HIV-1 gp41.These two kinds of interactional abilities of pure protein of REP 2004-FL and rise have been tested by fluorescence polarization.

Figure 32. bait thing size is to p24 and the influence of gp41 bonded.Tested the ability of the bait thing of size that increase by fluorescence polarization in conjunction with p24gag and gp41.

Figure 33. tested the ability of double-stranded PS-ODN by fluorescence polarization in conjunction with the virolysis thing.(ss) or the thiophosphatephosphorothioate REP 2017 (fluorescently-labeled) of double-stranded (ds) and the analogue (2017U) of non-thioated thereof that have also prepared strand.Tested combining of these bait things and HSV-1 and HIV-1 virolysis thing.

Figure 34. by under the situation that has 250nM REP 2004-FL, cultivating the 293A cell 4 hours, detected the conveying of fluorescently-labeled PS-ODN in cell.After the cultivation, lysing cell has detected the relative fluorescence that discharges after the cracking from cell by fluorometry.

Figure 35. detected the ability of the 20-mer PS-ODN of different sequences compositions by fluorescence polarization in conjunction with the virolysis thing.Under the situation that has 1ug HSV-1 (a), HIV-1 (b) or RSV (c) lysate, hatch 3 ' have a PS-ODN of FITC mark.These PS-ODN in conjunction with collection of illustrative plates in all 3 kinds of virolysis things similar (seeing Figure 35).

Figure 36. by detecting these supernatant liquors inductive CPE in naive cell, indirect detection the VERO cell that infects from cowpox infect viral load in the clear liquid.Tested REP 2004,2006 and 2007 at 10uM, tested cidofovir at 50uM.

Figure 37. (A) use HSV-1 (bacterial strain KOS) in the VERO cell, to carry out plaque and reduce the IC50 value that test produces.REP 2006 (N40), REP 2028 (G40), REP2029 (A40), REP 2030 (T40) and REP 2031 (C40) with rising concentration have handled infected cell, to produce the IC50 value.(B) HSV-1 PRA has produced following IC50 value: N40 (REP 2006), AC20 (REP 2055), TC20 (REP 2056) or AG20 (REP 2057).

The abbreviation of selecting

ON: oligonucleotide

ODN: oligodeoxynucleotide

PS: thiophosphatephosphorothioate

PRA: plaque reduces test

PFU: plaque forming unit

INF A: influenza A virus

HIV: human immunodeficiency virus's (if not explanation comprises HIV-1 and HIV2)

HSV: hsv (if not explanation comprises HSV-2 and HSV-3)

RSV: respiratory syncytial virus

COX: Coxsackie virus

DHBV: duck hepatitis B virus

Description of Preferred Embodiments

The present invention relates to the discriminating and the application of the antiviral oligonucleotide that plays a role by non-sequence complementary mechanism, also comprise following discovery, for many viruses, the antiviral activity of big more oligonucleotide is strong more, length be 40 or the oligonucleotide of more a plurality of Nucleotide best typically.

As described in the background technology, after tested the antiviral activity of many antisense oligonucleotides (ON).But such antisense ON is sequence-specific, the length of about typically 16-20 Nucleotide.

As by embodiment 1 and 2 the result confirmed, the antivirus action of PS-ODN is not sequence-specific at random.Consider volume and the concentration of the PS-ODN that uses in those tests, almost impossible in theory is that the specific stochastic sequence that surpasses 1 copy is arranged in mixture.This means that these PS-ODN thing at random do not have the antisense effect.In a back embodiment, if being sequence-specific by PS-ODN, causes antivirus action, so such effect thereby can only cause by a molecule, this result is seemingly impossible.For example, for the ON of 40 base length thing at random, any particular sequence in this colony in theory only can represent 1/4 ⁴⁰Or 8.27 * 10 ^-25Total fraction.Known 1mol=6.022 * 10 ²³Individual molecule, and in fact our maximum is synthetic is to finish in the scale of 15 μ mol at present, can not have all possible sequences, and in addition, each sequence most likely exists as just a copy.Certainly, those skilled in the art can also use sequence-specific ON according to instruction of the present invention, but the non-sequence complementary activity of utilizing the present invention to find.Therefore, the invention is not restricted to non-sequence complementary ON, but abandon the disclosed in the prior art content that is used for the treatment of virus infection about sequence-specific antisense ON.

About applicable virus (comprising that for example, this paper discloses those of its data), along with the increase of thing size at random, its antiviral efficacy also increases.Should be pointed out that because at present based on the DNA synthetic restriction of phosphoramidite, bigger PS-ODN (for example 80-and 120-mer) has significant than the littler segmental pollution of size that needs.Observe more weak effect (based on each base) on bigger oligomer (80 and 120 base pairs), this has reflected the total length lower concentration of thing in these colonies at random, has also reflected the absorption that reduces in cell.If synthetic or purifying reasonable purity (75% total length) bigger thing at random (＞40 bases) if and/or promoted any the cell among these ODN to take in by delivery system, can realize big many raisings of antiviral activity.

In the present invention, thing (or other oligonucleotide) can include but not limited to following by the duplicating of several machine-processed blocking virus at random: 1. stop the absorption or the acceptor interaction of virus particle, thereby prevent infections; 2. participate in virus assembling or the packing (with the packing of viral DNA or RNA mutually compete) of viral genome in capsid, produce the defective virus particle; 3. the capsid formation in interruption and/or the prevention wrapping process or the interaction of capsid protein and other structural protein cause suppressing the release of virus or discharging the defective virus particle; 4. be attached to crucial virus component, and stop or reduce their activity; 5. be attached to the needed crucial host's component of virus multiplication.

Be not limited to realize the mechanism of virus inhibition of the present invention, as mentioned above, have several possible mechanism can explain and/or predict the inhibition activity of ON virus replication.Wherein first kind is, overall similar (aptameric) effect of ON makes them be attached on cell surface protein or the viral protein, stops the absorption and the fusion of virus.The size threshold value of having an effect can be by the result of needed some stored charge that interacts.

Second kind of possible mechanism is that ON can work by stoping viral packing and/or being assemblied in the cell.The ON that surpasses a certain size threshold value can compete or disturb normal capsid/nucleic acid interaction, stops the functional virus genomic packing in the new virus.Perhaps, ON can stop the formation of normal capsid, and this suitable virus particle that can stop the budding of normal virus, the stability that changes virus or prevention to depend on internalization is decomposed.

Although mechanism of action also imperfectly understands, test-results confirms, compares with proteinase inhibitor with clinical relevant acycloguanosine, gancyclovir, ribavirin, and ON of the present invention has shown stronger virus and suppressed effect.Therefore can be used for the treatment of or prophylaxis of viral infections according to ON of the present invention.The virus infection of treatment can be those that are caused by people, animal and plant virus.

The broad-spectrum disease resistance cytotoxic activity

According to conclusion discussed above and data as herein described, at random ON and ON at random thing as if can have the broad-spectrum disease resistance cytotoxic activity to virus, wherein virus genomic assembling and/or packing and/or involucrum are to duplicate needed step.Therefore, in order to check this hypothesis, selected several different big or small PS-ODN thing at random, to test the cell pattern of various virus infectiones.Many such tests have been described in the embodiment of this paper, comprise the test of carrying out with CMV, HIV-1, RSV, Coxsackie B virus 2, DHBV, Hantaan virus, parainfluenza virus and vaccinia virus, and in HSV-1 described in embodiment 1 and 2 and HSV-2 test.Although the oligonucleotide of some test has shown the high reactivity level, oligomer delivery system (for example DOTAP, fat transfection amine (lipofectamine) or few transfection amine (oligofectamine)) can produce stronger effect, particularly uses bigger (〉=40 bases) thing at random.

The active conclusion of broad-spectrum antiviral

The efficacy study of different virus shows, at random ON and at random thing multiple different virus has been shown inhibition activity.And following conclusion has been supported in these researchs: bigger thing at random shows stronger virus than littler thing at random and suppresses effect.This has confirmed at random ON or the ON mechanism that depends on common size and/or electric charge of thing activity in all envelope virus at random.

HSV and CMV are the double-stranded DNA viruses of herpetoviridae family, and HIV is the RNA viruses of Retroviridae, and RSV is the RNA viruses of Paramyxoviridae.Based on the ON fact that thing can be not limited to the above-mentioned mechanism of listing at random, generation suppresses the function of virus in multiple different virus, following mechanism is rational: A) ON/ON at random thing suppress virus infection by similar effect, prevent that virus and plasma membrane from merging; And/or B) ON/ON at random thing stop or participate in the assembling of virus particle or the packing of the viral DNA in the capsid, produce the defective virus particle; And/or C) ON/ON assembling and/or packing and/or required host protein or the component of genetic expression of thing viral interference at random.

The requirement of antiviral activity

As if because randomized dna sequence dna is enough to suppress virus, interesting is to study: whether can keep antiviral activity and whether can improve effect by being chosen in stochastic sequence or the particular sequence found in the viral genome under the situation that does not have thiophosphatephosphorothioate to modify.

Therefore, having studied DNA and RNA modifies the effect of the antiviral efficacy of thing at random.Because thing plays a role by non-sequence complementary mechanism at random, these experiments are used to test the influence that the slight variation of nucleic acid conformation and charge distribution resists viral effect.

Have the different IPs thuja acid in order to test/whether ODN that nucleosides is modified can suppress HSV-1, test REP 2024,2026,2059 and 2060 in HSV-1 PRA, as described in embodiment.REP2024 (this PS-ODN having on the ribose on 4 bases at ODN two ends 2-O-methyl modify), REP 2026 (having methylphosphonate to modify on the key between 4 bases of this PO-ODN at the ODN two ends), REP 2059 (length is the RNA PS-ODN thing at random of 20 bases) and REP 2060 (length is the RNA PS-ODN thing at random of 30 bases) have shown and have resisted-HSV-1 activity (seeing Figure 11).

In one embodiment of back, if the ON that antivirus action only is made up of DNA thiophosphatephosphorothioate main chain causes, so such effect can only cause by a molecule.But other main chain and modification have produced the male antiviral activity.Certainly, those skilled in the art can also use different chemical ON according to instruction of the present invention.As if the modification of ON (modifying such as but not limited to thiophosphatephosphorothioate) help antiviral activity.This be likely since ON electric charge that needs and/or DNA at medium and intracellular stable needs, it also may be because the chirality of PS-ODN.

Compound R EP 2026 shows antiviral activity, although its centre portions comprise the PO-Nucleotide of unmodified and 4 at the methyl-phosphorous acid ester bond at two ends to prevent degraded.This shows that PO-ODN can be as the antiviral drug that can not be degraded.This protection can be by modifying terminal Nucleotide and/or by using following suitable delivery system to realize.

Usually, the paired overall efficacy of the sequence set of the DNA of use has less effect, no matter is thing, stochastic sequence or specific HSV-1 sequence at random.But at intermediate length, the validity of HSV-1 sequence almost is 3 times of (see figure 10)s of stochastic sequence.These data show, although specific HSV sequence exists specific antisense functional, non-antisense mechanism described here (non-sequence complementary mechanism) can be represented this active major portion.In fact, when ON rose to 40 bases, all basically antiviral activities all were because non-antisense effect.

The more hypotoxicity of thing at random

A use ON purpose of thing at random is to reduce toxicity.Known different sequence can cause different reactions in animal, for example overall toxicity, with the interaction of serum protein and with immune interaction (Monteith etc. (1998) Toxicol Sci 46:365-375).The mixture of ON thereby can reduce toxic action is because the level of any particular sequence all can be very low, so not significant the interaction is possible because sequence or Nucleotide are formed.

Pharmaceutical composition

ON of the present invention is used for the treatment of (or prevention) therapeutic composition of virus disease or form of preparation, and it can be used for people or inhuman animal by administration's approval, and/or at specific virus or virus group.When with physiology on and/or pharmaceutically acceptable carrier when combining, these ON can be used as part of pharmaceutical compositions.The feature of carrier can depend on route of administration.Pharmaceutical composition of the present invention can also contain other the active factor and/or the reagent of energy enhanced activity.

The enforcement of the method for using or treating animal of the ON of the present invention that uses in pharmaceutical composition or preparation can realize by multiple conventional route, in absorption for example intraocular, per os, the intestines, suck or in skin, subcutaneous, intramuscular, endoperitoneal, sheath, endotracheal or intravenous injection.

Pharmaceutical composition of the present invention or oligonucleotide agent can also contain other the chemotherapeutics that is used for the treatment of virus disease, such as but not limited to: Rifampin, ribavirin, pleconaril (Pleconary), cidofovir, acycloguanosine, Penciclovir (pencyclovir), gancyclovir, cut down Xi Luowei (Valacyclovir), Famciclovir, phosphine formic acid, vidarabine, amantadine, zanamivir, oseltamivir, Resquimod, protease inhibitor, the HIV fusion inhibitor, Nucleotide HIVRT inhibitor (AZT for example, lamivudine, Abacavir), non-nucleotide HIV RT inhibitor, Doconosol, Interferon, rabbit, butylated hydroxytoluene (BHT) and hypericin.Other factor like this and/or reagent can be included in the pharmaceutical composition, for example produce synergy with ON of the present invention.

Pharmaceutical composition of the present invention or oligonucleotide agent can also contain polymkeric substance, such as but not limited to polyanion reagent, sulfated polysaccharides, heparin, dextran sulfate, multi-sulfate piperylene, polyvinyl alcohol sulfuric ester, acemannan (acemannan), multi-hydroxy carboxy acid's ester, sulfate cellulose, the polymkeric substance that contains sulfonation benzene or naphthalene nucleus and napsylate polymkeric substance (naphthalenesulfonate polymer), ethanoyl phthalyl Mierocrystalline cellulose, poly-L-Lysine, Sodium decanoic acid, cationic amphiphilic thing, cholic acid.Known polymer can influence virus particle and enter cell, is being by combination in some cases or is being adsorbed onto virus particle itself.This feature of antiviral polymeric can be used for ON competition to the combining or absorption of virus particle, the result compares in the born of the same parents that improved ON active with the outer activity of its born of the same parents.

Exemplary delivery system

We have detected the PS-ODN absorption of thing at random by cultured cells being exposed to fluorescently-labeled thing at random, are washing the fluorescence intensity of having measured after 2 times in the cracked cell then.After not carrying and be encapsulated in a kind of following delivery system: fat transfection amine based on lipid ^TM(Invitrogen), polyfect ^TM(Qiagen) and few transfection amine ^TM(Invitrogen), the cell that has detected the cell that is exposed to 250nM REP 2004-FL is taken in.After 4 hours, with PBS washed cell 2 times, and with MPER lytic reagent (PROMEGA) cracking.Figure 34 has shown the relative fluorescence output that obtains from the exposed cell that has and do not have to carry of equivalent.We find under the situation of the delivery of therapeutic agents that has all 3 kinds of tests, remarkable increase is arranged when the concentration ratio of PS-ODN is not carried in the born of the same parents.

Consistent in this test-results, the application of delivery system can increase the ON antiviral efficacy of thing at random significantly.In addition, they can be used to protect these compounds not to be subjected to the serum interaction, reduce side effect and make tissue and cell distribution maximizes.

Though PS-ODN is bigger than natural phosphodiester to the resistance of endogenous nuclease, they are not completely stable, can be degraded lentamente in blood and tissue.The restriction of PS oligonucleotide drug in clinical application is that they tend to activating complement after intravenously is used.Usually, liposome and other delivery system can be by reducing drug toxicity, be increased in the residence time in the blood plasma and carry (carrier of the vascular system by seeing through super infiltration exosmoses) more active medicine to strengthen the medicine therapeutic index of (comprising ON) to diseased tissue.And under the situation of PS-ODN, lipid encapsulated prevention is in the interaction (KLIMUK etc. (2000) J Pharmacol Exp Ther 292:480-488) of circulation time and potential protein binding site.

According to our result as herein described, a kind of method is to use the delivery system that can carry ON as herein described, such as but not limited to lipophilic molecule, polar lipid, liposome, unimolecular layer, bilayer, vesicle, programmable fusion vesicle (fusogenic vesicles), micella, cyclodextrin, PEG, iontophoresis, powder injection and nanoparticle (for example PIBCA, PIHCA, PHCA, gelatin, PEG-PLA).Use the purpose (except other) of such delivery system to reduce the toxicity of active compound in the animal and human, strengthen cell delivery, reduce IC50, increase action time and prevent the nonspecific serum protein that is attached to of oligonucleotide from the position of drug conveying.

We are verified, and the PS-ODN antiviral activity of thing at random increases along with the increase of size.And this activity is relevant with the avidity of the rising of viral protein (in the virolysis thing).Because it is well known, thiophosphatephosphorothioate is modified and is strengthened the interactional avidity of protein-dna, we are used to detect the interactional identical test based on FP with the virolysis thing, tested the bigger PS-ODN that increases at random thing (Figure 28 a) in conjunction with the ability of foetal calf serum (FBS).In this test, can be saturatedly in conjunction with under the condition of (mP value), with FBS and fluorescently-labeled 20 base PS-ODN thing complexing mutually at random of the non-heated and inactivated of 250ug.The unlabelled PS-ODN that increases size thing (REP 2003, REP 2004, REP 2006 and REP 2007) at random is used to compete the interaction of the bait thing of FBS and mark.The result of this test clearly illustrates that along with the PS-ODN increase of the size of thing at random, its avidity to FBS also increases.This result shows that PS-ODN that antiviral activity is the highest and proteic avidity also are the highest.

Known in the art, a main treatment problem of phosphorothioate antisense oligonucleotide is their side effect, this mainly is because itself and the interaction of albumen (particularly with serum protein) increase, as described by Kandimalla and colleague (Kandimalla etc. (1998) Bioorg.Med Chem.Lett.8:2103-2108).Our data sheet is understood the benefit of essence, with antiviral ON input cell, prevents the interaction of they and serum protein by suitable delivery system simultaneously.

In order to confirm the benefit of delivery system, we have tested 2 kinds of different conveying technologies, and they are based on the cytofectin and the DOTAP of liposome.The intracellular concentration of REP2006 by the fluorometry certification mark, we have detected the PS-ODN conveying (Figure 28 b, c) of thing REP 2006 (sealing with cytofectin or DOTAP) in the 293A cell at random under the situation that has high density serum (50%) to exist.These results show, carry the intracellular concentration that increases REP 2006, are further illustrated under the situation of DOTAP, and the level of REP 2006 has remarkable increase in the born of the same parents after 24 hours.At last, by DOTAP (28d) and cytofectin (28e) in testing based on the external interaction of FP, we have detected REP 2006 and the interactional protection of serum protein.Non-encapsulated REP 2006 can compete the combined with fluorescent oligomer from serum, but when sealing REP 2006 with DOTAP or cytofectin, it no longer can compete the serum combination.These data show, seal the serum interaction that can stop oligomer, and can cause more effective therapeutic action and side effect still less.

Another potential benefit of using delivery system is to prevent that ON and infective virus particle from interacting (for example absorption), and to prevent the expansion of virus infection by different mechanism, for example the cell of enhanced virus particle penetrates.

Another method is by delivery system is finished the conveying of cell-specific with improving to be associated with the molecule of the avidity of specific cells, and such molecule includes but not limited to antibody, receptors ligand, VITAMIN, hormone and peptide.

Face provides other selection of delivery system.

The ODN that connects

In certain embodiments, modify ON of the present invention in many ways, but do not damaged the ability that they suppress virus replication.For example, ON connects at their one or more nucleotide residues place or is attached to another part.Therefore, the modification of oligonucleotide of the present invention can comprise one or more parts or binding substances chemically are connected to Nucleotide, specific or nonspecific cytolemma transmission is taken in, strengthened to their energy enhanced activity, cell distribution or cell, perhaps prevent degraded or secretion, other useful feature perhaps is provided.Useful feature like this can (for example) comprise lower serum interaction, higher virus-protein-interacting, the pharmacokinetics character of being prepared the ability that is suitable for carrying, detectable signal, improvement and lower toxicity.Such binding substances group can covalently be attached to functional groups, for example first or second hydroxyl.For example, binding substances part can comprise lipophilic molecule, peptide, cholesterol, two cholesterol, antibody, PEG, albumen, water miscible VITAMIN, fat-soluble VITAMIN, the another kind of ON of steroid molecule, non-aromatics or improve any other molecule of activity and/or the bioavailability of ON.

More specifically, exemplary binding substances group of the present invention can comprise intercalator, reporter molecule, polyamines, polymeric amide, polyoxyethylene glycol, polyethers, SATE, tert-butyl-SATE, strengthen oligomer pharmacodynamic properties group and strengthen the group of the pharmacokinetics character of oligomer.Typical binding substances group comprises cholesterol, lipid, phosphatide, vitamin H, azophenlyene, folic acid (folate), phenanthridines, anthraquinone, acridine, fluorescein, rhodamine, tonka bean camphor, fluorescence nucleic acid base and dyestuff.

In the context of the present invention, the group of enhancing pharmacodynamic properties comprises the cell absorption that improves oligomer and/or strengthens the anti-degradation property of oligomer and/or prevent the interactional group of serum.In the context of the present invention, the group that can strengthen pharmacokinetics character comprises absorption, distribution, metabolism or the excretory group that can improve oligomer.Exemplary binding substances group is documented among the International Patent Application PCT/US92/09196 that submitted on October 23rd, 1992, and its full content is hereby expressly incorporated by reference.

The binding substances part can include but not limited to lipid part, for example cholesterol moiety (Letsinger etc., Proc.Natl.Acad.Sci.USA, 1989,86,6553-6556), cholic acid (Manoharan etc., Bioorg.Med Chem.Let., 1994,4,1053-1060), thioether, hexyl-S-trityl mercaptan (Manoharan etc., Ann.N.Y.Acad.Sci., 1992 for example, 660,306-309; Manoharan etc., Bioorg.Med Chem.Let., 1993,3,2765-2770), sulfo-cholesterol (Oberhauser etc., Nucl.Acids Res., 1992,20,533-538), aliphatic chain, for example dodecanediol or undecyl residue (Saison-Behmoaras etc., EMBO J., 1991,10,1111-1118; Kabanov etc., FEBS Lett., 1990,259,327-330; Svinarchuk etc., Biochimie, 1993,75,49-54), phosphatide, for example two-hexadecyl-rac-glycerine or triethyl-ammonium 1,2-two-O-hexadecyl-rac-glyceryl-3-H-phosphonic acid ester (Manoharan etc., Tetrahedron Lett., 1995,36,3651-3654; Shea etc., Nucl.Acids Res., 1990,18,3777-3783), polyamines or polyglycol chain (Manoharan etc., Nucleosides ﹠amp; Nucleotides, 1995,14,969-973) or diamantane acetic acid (Manoharan etc., Tetrahedron Lett., 1995,36,3651-3654), palmityl part (Mishra etc., Biochim.Biophys.Acta, 1995,1264,229-237) or stearylamine or hexyl aminocarbonyl-oxygen cholesterol moiety (Crooke etc., J.Pharmacol Exp.Ther., 1996,277,923-937.

Oligonucleotide of the present invention can also be attached to active medicine, such as but not limited to acetylsalicylic acid, warfarin, Phenylbutazone, Ibuprofen BP/EP, sutoprofen, fenbufen, Ketoprofen, (S)-(+)-Y-8004, carprofen, dansyl sarkosine, 2,3,5-Triiodobenzoic acid, Flufenamic Acid, folinic acid, benzo thiophene diazide (benzothiadiazide), chlorothiazide, diazepine, indomethicin, barbiturate(s) (ester), cephalosporins, sulfa drug, antidiabetic drug, antibacterium medicine or microbiotic.

The exemplary United States Patent (USP) of having described the preparation of exemplary oligonucleotide conjugates comprises that for example U.S. Patent number 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717,5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241,5,391,723; 5,416,203,5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, wherein each piece full text is hereby expressly incorporated by reference.

Another kind method is; modify by the charge neutralization adducts that cuts (for example s-ethanoyl sulfo--ethyl or s-pivasloyl sulfo--ethyl) with enzymatic; preparation is as the antiviral ON (Vives etc. of oligonucleotide before lipophilic; 1999, Nucl Acids Res 27:4071-4076).Verified modification like this can increase the absorption of ON in cell.

The design of nonspecific ON

In another scheme, the antiviral ON of design shows lower, the preferred minimum possible homology of genome with people (or other experimenter organism).Purpose is to obtain owing to will show minimum toxic ON with human or animal's genome sequence and the interaction of mRNA.The first step is to produce the ON of ideal length sequence, for example manually or more generally is to use computer program to pass through with random fashion pairing Nucleotide A, C, G, T.Second step was with ON sequence and human sequence storehouse (for example GenBank and/or all people's gene group databases) comparison.If desired, can repeat sequence production and comparison, have one or more sequences with experimenter's genome ideal low homology level with discriminating.Ideally, ON sequence and full gene group have minimum possible homology, also preferably minimize self-interaction simultaneously.

Has the active nonspecific ON of antisense

In another scheme, with antiviral nonspecific sequence part coupling antisense sequences part, to improve the activity of final ON.The invention describes the non-specific part of ON.Antisense part and virus mRNA complementation.

Has the abundant active nonspecific ON of motif of G-

In another scheme, with antiviral nonspecific sequence part coupling motif part, to improve the activity of final ON.The invention describes the non-specific part of ON.As unrestricted example, the motif part can comprise CpG, G tetrad and/or CG, and they are recited as immune stimulator in the literature.Agrawal etc. (2001) Curr.Cancer Drug Targets 3:197-209.

Fei Wosen-Ke Like ON

Another scheme is to use by a class or ON that a few class Fei Wosen-Ke Like Nucleotide/nucleosides is formed.Such ON can imitate PS-ODN, and its following characteristics is similar to PS-ODN:a) total charge; B) distance between the unit; C) chain length; D) pure dipole has the negative charge accumulation in a side; E) protein-bonded ability; F) in conjunction with the ability of viral protein; G) ability of penetration cell; H) acceptable therapeutic index; I) antiviral activity.This ON has preferred thiophosphatephosphorothioate main chain, but is not limited to it.The case history of Fei Wosen-Ke Like Nucleotide/nucleosides is at KOOL, and 2002, Acc.Chem.Res.35:936-943; With Takeshita etc., among (1987) J.Biol.Chem.262:10171-10179, the ODN that contains the synthetic abasic site has been described wherein.

Antiviral polymeric

Another scheme is to use the active polymkeric substance of imitation thiophosphatephosphorothioate ODN.As putting down in writing in the document, confirmed that several anionic polymers have antiviral inhibitor activity.These polymkeric substance belong to several types: sulfuric ester (dextrin and the dextran sulfate of (1) polysaccharide; Sulfate cellulose); (2) contain the polymkeric substance and the napsylate polymkeric substance of sulfonation benzene or naphthalene nucleus; (3) polycarboxylate (acrylate copolymer); With ethanoyl phthalyl Mierocrystalline cellulose (Neurath etc. (2002) BMC Infect Dis 2:27); (4) no base oligonucleotide (Takeshita etc., 1987, J.Biol.Chem.262:10171-10179).Put down in writing other example of non-nucleotide antiviral polymeric in the document.Polymkeric substance as herein described can imitate the PS-ODN described in the present invention, and its following characteristics is similar to PS-ODN:a) chain length; B) pure dipole has the negative charge accumulation in a side; C) protein-bonded ability; D) in conjunction with the ability of viral protein; E) acceptable therapeutic index; F) antiviral activity.In order to imitate the effect of PS-ODN, antiviral polymeric is polyanion preferably, and the distance-like between its unit is similar to PS-ODN.It can also have independently or with the ability of the combined penetration cell of delivery system.

The antiviral activity of double-stranded PS-ODN

Stochastic sequence (REP 2017) and its complement (PS modify or unmodified) are described fluorescently-labeled as other places, and have tested their HSV-1 and proteic abilities of HIV-1 in conjunction with purifying by fluorescence polarization as described in the present invention.Verified hybridization by acrylamide gel electrophoresis.Combination is not active in HSV-1 or HIV-1 lysate for the REP 2017 (2017U) of the unmodified of strand (ss) or double-stranded (ds).But the REP 2017 that strand or double-stranded PS modify can carry out HSV-1 and HIV-1 interact (seeing Figure 33).

According to result as herein described, a scheme is to use double-stranded ON as potent antiviral agent.Preferably, such ON has the thiophosphatephosphorothioate main chain, but that can also have other and/or other modification, and it can strengthen their conveying and/or antiviral activity and/or stability, as herein about as described in the ON of strand.

The in vitro tests of drug discovery

The exploitation of in vitro tests is based on fluorescence polarization and detects the ability of PS-ODN in conjunction with virus component, for example viral protein.When albumen (or another kind of interactant) was attached to fluorescently-labeled bait thing, the three dimensional fold (tumbling) of bait thing in solution can be hindered.The intrinsic increase of the polarisation of light that sends by the bait thing from mark has detected this folding obstruction.Therefore, enhanced polarization (being designated as zero dimension dimension (dimensionless measure) [mP]) is associated with the enhanced combination.

A kind of method is to use the thing at random as the PS-ODN of bait thing, and it is at 3 ' end FITC that used inflexibility connector (3 '-(6-fluorescein) CPG) mark.With this PS-ODN at random thing in test damping fluid (10mM Tris, pH7.2,80mM NaCl, 10mM EDTA, 100mM beta-mercaptoethanol and 1% polysorbas20), be diluted to 2nM.Then this oligomer is mixed with suitable interactant.In this case, we use HSV-1 (bacterial strain Maclntyre), the HIV-1 (bacterial strain Mn) of saccharose gradient purifying or the lysate of RSV (strains A 2), they are suspended in 0.5M KCl and 0.5%TritonX-100 (HSV-1 and HIV-1) or 10mM Tris, pH7.5,150mM NaCl is among 1mM EDTA and the 0.1%Triton X-100 (RSV).After the bait thing interacts,, from its mixture, displace the ability of bait thing to detect them with various unlabelled PS-ODN challenge mixtures.

In Figure 29, we have shown the tentative experiment of carrying out with 3 kinds of different big or small bait things: 6 (REP2032-FL), 10 (REP 2003-FL) and 20 bases (REP 2004-FL).Tested these bait things and HSV-1 (Figure 29 a), HIV-1 (Figure 29 b) and the interactional ability of RSV (Figure 29 c) lysate.Under the situation that has any virolysis thing, conjugation depends on the size of the bait thing of use, and 2004-FL shows maximum mP (combination) displacement under the situation that has the virolysis thing.We notice, this and the PS-ODN big or small dependent antiviral efficacy of thing at random are similar.Estimate the PS-ODN competition bait thing of different sizes and the interactional ability of lysate with this bait thing then.

In Figure 30, with the PS-ODN that increases progressively size challenged REP 2004-FL and HSV-1 (Figure 30 a), the interaction of HIV-1 (Figure 30 b) and RSV (Figure 30 c) lysate.For the virolysis thing of every kind of test, we notice that REP 2003 can not compete the bait thing to come out from lysate.As cause by REP 2004 (unlabelled bait thing) competition thing more weak relatively competition disclosed, the bait thing interacts very strong.But observe, when the size of competition thing PS-ODN surpassed 20 bases, the ability of its displacement bait thing became bigger.This shows that along with the PS-ODN increase of thing size at random, the avidity to protein ingredient in the virolysis thing also increases.This phenomenon reflected bigger PS-ODN at random thing to the enhancing of the antiviral activity of HSV-1, HSV-2, CMV, HIV-1 and RSV.

The effect of bait thing competition and the PS-ODN similarity between the antiviral activity of thing at random show that this test example is an antiviral activity good predict thing.This test is strong, execution and highly stable easily, this makes it become the extraordinary choice of the high flux screening of differentiating new antiviral molecule, described discriminating is not based on the discriminating of specific target site, and is based on they and the interactional ability of one or more components (for example viral protein).

Method as herein described is the novel cpd that is used to screen from any desirable source, for example from passing through combinatorial chemistry synthetic storehouse or passing through the isolating storehouse of purifying natural product.It can be used for a) detecting suitable size, modification and the main chain of new ON; B) the test novel molecular comprises new polymers; The prediction specific virus is to the susceptibility of New O N or novel cpd; Or d) proper sequence of detection compound is to suppress specific virus the biglyyest.

With bigger PS-ODN at random the enhanced lysate avidity of thing show that the PS-ODN antivirus action mechanism of thing at random is based on interaction with one or more viral protein components, its preventing infection or correct duplicating of virus particle.It shows that also this interaction is that electric charge (size) is dependent, and does not rely on sequence.Because these PS-ODN thing at random have big or small dependent activity to the multiple virus of crossing over several different families, we propose, and PS-ODN thing at random disturbs common, the dependent protein-protein interaction of electric charge, protein D NA/RNA to interact and/or other molecule-interaction of molecules.These interactions can include, but is not limited to:

A. the interaction between each capsid subunit in the capsid forming process;

B. the interaction between capsid/nucleocapsid protein and the viral genome;

C. the interaction between capsid and the glycoprotein in the budding process;

D. the interaction between glycoprotein and its acceptor in course of infection;

E. participate in the interaction between other viral key ingredient of virus replication.

Antiviral inhibition new mechanism has been represented in these of protein-protein interaction inhibition various, the while.

The effect of the paired lysate of PS-ODN sequence set

We have monitored not homotactic PS-ODN and the interactional ability of several virolysis things.In each case, as described earlier in this article, with PS-ODN FITC on 3 ' end mark of 20-mer.The PS-ODN of test is made up of A20, T20, G20, C20, AC10, AG10, TC10, TG10, REP 2004 and REP 2017.In these sequences each all is diluted to 4nM in the test damping fluid, and hatches under the situation that has 1ug HSV-1, HIV-1 or RSV lysate.Detected interaction by fluorescence polarization.

The interaction collection of illustrative plates of all cycle testss is with all the virolysis thing is similar, and this shows that the character of binding interactions is very similar.In every kind of lysate, the PS-ODN of homogeneous compositions (A20, G20, T20, C20) is the most weak interactant, and A20 is wherein the most weak interactant, forms remarkable border.PS-ODN about remaining test except TG10, as one man shows in every kind of lysate outside the strongest interaction, and they all show similar strong interaction (seeing Figure 35).

The PS-ODN target position of thing in HIV-I at random differentiates

As described in embodiment 9, by fluorescence polarization tested PS-ODN at random thing in conjunction with the proteic ability of the HIV-1 of purifying.Make the HIV-1 gp41 and the REP 2004-FL reaction (seeing Figure 31) of the HIV-1 p24 of purifying or the purifying of incremental change.We notice these two kinds of albumen, all have the dependent fluorescence polarization displacement of protein concentration, and this is indicating and these two kinds of proteic interactions.

Also use PS-ODN that the fluorescence version of REP 2032, REP 2003, REP 2004, REP 2006 and REP 2007 tested a certain size scope at random thing be attached to these proteic abilities (seeing Figure 32).We observe p24, p24 do not have big or small dependent interaction (see Figure 32 a), but we see really, the PS-ODN that surpasses 20 bases at random thing be lower than comparing of 20 bases, have the gp41 bonded to increase (seeing Figure 32 b).This shows, as PS-ODN when the length of thing surpasses 20 bases at random, the gp41 of a plurality of copies can be incorporated into each at random on the thing, strengthens their polarization.

This is significant observation, because it has confirmed bigger ON isolation structures albumen and limit the potentiality that they are used to form the validity of neovirion in viral building-up process.

The high-affinity oligonucleotide

Another scheme is the method for enrichment or the antiviral ON of purifying, and described ON is higher compared with the average ON avidity in the beginning ON storehouse to the avidity of virus component (for example viral protein).This method thereby one or more non-sequence complementary ON are provided, other will show one or more virus component enhanced avidity, for example have the 3D shape that helps so higher binding affinity.Ultimate principle is that although ON will combine with virus component as linear molecule, they can also be folded into the interactional 3D shape that can strengthen with such virus component.Be not limited to specific technology, in the following manner the ON of purifying or enrichment high-affinity.

A kind of method of the ON of one or more high-affinities of purifying comprises, the stationary phase medium that use has the bonded viral protein comes in conjunction with ON as affinity matrix, and it then can be at the following wash-out of the stringent condition that increases progressively (for example the salt of progressive concentration or other chaotropic agent and/or the temperature that increases progressively and/or pH change).Such method can for example followingly be carried out:

(a) the ON storehouse is loaded on the exchange column, described exchange column has one or more viral proteins or is attached to the virolysis thing of stationary phase;

(b) from post displacement (wash-out) bonded ON, for example by using substitutional solution, the salts solution that for example increases progressively;

(c) be collected in the ON fraction of different salt concn wash-outs;

(d) from different fractions, more preferably from the ON of the fraction of high salt concentration clone and order-checking wash-out, have bigger and binding affinity viral protein at the ON of high salt concentration wash-out; With

(e) activity of the ON of test order-checking in test, for example in conjunction with and/or viral inhibition test, during for example fluorescence polarization as herein described-combination tested, and/or in the cell virus inhibition test and/or in the animal virus inhibition test.

In second embodiment, derive and the method revised out can be used for the ON of purifying high-affinity from SELEX method (Morris etc. (1998) Biochemistry 95:2902-2907).A kind of enforcement of this method can followingly be carried out:

(a) provide initial ON storehouse material, for example, collect the ON at random that synthetic contains high number sequence, for example contain 10 ¹⁴～10 ¹⁶Individual different sequence.Each ON molecule contains the stochastic sequence fragment, at each terminal side joint primer binding sequence, to promote polymerase chain reaction (PCR).Because the nucleotide sequence of all basically molecules all is unique, the structure of the enormous quantity of having taken a sample in colony.These structures shape the biochemical property of each molecule, for example in conjunction with the ability of given viral target molecule;

(b) ON is contacted with one or more viral proteins or virolysis thing;

(c) use the isolation technique screening to be attached to ON on the viral protein, this technology can be separation and combination and unconjugated ON, and for example natural gel shift and nitrocellulose filter.These methods can never in the binding substances physically be isolated binding substances, so that reclaim according to qualifications in conjunction with those best sequences.In addition, can ideally target be attached on the solid carrier in conjunction with the ON of small protein in order to screen, and with this carrier as protein affinity purification matrix.Those can not can be washed by the bonded molecule, and the bonded molecule is then by free target wash-out, thereby have physically separated bonded and unconjugated material;

(d) the bonded ON of amplification wash-out, for example by using PCR, its use can with the primer of the flanking sequence hybridization of ON;

(e) in order to reclaim the ON of high binding affinity that shows with viral protein according to qualifications, step (b), (c) and (d) can carry out repeatedly (being the circulation or the bout of a plurality of enrichments and amplification).After several enrichments and the amplification circulation, colony is manifested by the sequence that shows the ideal biochemical property;

(f) one or more ON that are selected from enrichment circulation (for example last such circulation) are cloned and check order; With

(g) in test combination and/or the activity of the ON of test order-checking, for example at fluorescence polarization as herein described in conjunction with test and/or in the cell virus inhibition test and/or in the animal virus inhibition test.

Another scheme is to adopt improved montage synthetic method, sets up one-PS-ODN of one-pearl and one-PS2-ODN of one-pearl storehouse, as (2002) Nucl.Acids Res.30 (e132) such as Yang: as described in the 1-8.Can carry out combination and selection to the specific pearl of viral protein.The discriminating mark of the PCR-based by pearl that use to select can carry out the order-checking in nucleic acid base and any monothioester/dithio ester bond site.This method can be fast and is identified PS-ODN or the PS2-ODN that is attached on the viral protein easily, and shows effective antiviral properties.

Can be attached to the specific sequence on the viral protein in case determined amplification and the order-checking of each sequence (for example by) high-affinity, can select and synthesize (for example by chemistry or enzymatic synthetic) one or more such high-affinity sequences, so that the ON goods of high-affinity to be provided, can modify them to improve its activity, comprise the pharmacokinetics character that improves them.Can use the ON of such high-affinity in the present invention.

Prion disease

Another scheme is treatment, process control or the prevention that is used for prion disease in alternative embodiment of the present invention.This fatal neurodegenerative disease is communicable, can infect humans and animals.Think structural changes in the cell prion protein, the sick isomery of its itch PrPC, outbreak that PrPSC is prion disease and propagate in necessary step.The amyloid polymkeric substance is relevant with the neuropathology of prion disease.

Prion protein fragment and double-strandednucleic acid hatch the formation (Nandi etc. (2002), J Mol Biol 322:153-161) that causes the amyloid fiber.To the ON that albumen has avidity, for example thiophosphatephosphorothioate is used to compete or suppress the interaction of double-strandednucleic acid and PrPC, and stops the formation of amyloid polymkeric substance subsequently.The ON of different sizes like this can be used for suitable transporting pattern with different compositions, suffers from the patient of prion disease with treatment, or is used for the prevention under the high-risk situation.Can as described in (supra) such as Nandi by the folding variation of the amyloid polysaccharase of test under the situation that has test ON to exist, identify such interference ON.

The virus causing disease of inferring is learned

Another scheme is to be used for the treatment of in another embodiment of the invention or to prevent to have disease or the illness of learning as (but being not limited to) described in the following embodiments virus causing disease of inferring.Virus is the pathogenic thing of inferring in disease and the illness (itself and primary virus infection have nothing to do).For example, sacroiliitis and HCV (Olivieri etc. (2003) Rheum Dis Clin North Am 29:111-122), assays for parvovirus B 19, HIV, HSV, CMV, EBV are relevant with VZV (Stahl etc. (2000) ClinRheumatol 19:281-286).Also having identified other virus works in different diseases.For example, influenza A is (TAKAHASHI etc. (1999) in parkinsons disease, Jpn J InfectDis 52:89-98), coronavirus, EBV and other virus in multiple sclerosis (Talbot etc. (2001) Curr Top Microbiol Immunol 253:247-71); EBV, CMV and HSV-6 are at chronic fatigue syndrome (Lemer etc. (2002) Drugs Today 38:549-561); With paramyxovirus in asthma (Walter etc. (2002) J Clin Invest 110:165-175) with in Paget's disease; With HBV, HSV and influenza in Guilfain-Barre syndrome.

Because these etiologies, the virus of using the present invention to suppress to be correlated with can delay, slows down or prevent the development of corresponding disease or illness or some symptoms of this disease at least.

Oligonucleotides-modified and synthetic

As described in top summary, the oligonucleotide of modification is useful in the present invention.The oligonucleotide of such modification comprises the oligonucleotide of bonding between the main chain that for example contains modification or non-natural nucleosides.Oligonucleotide with main chain of modification is included in and remains with in the main chain and do not have those of phosphorus atom.

The oligonucleotide main chain of such modification comprises for example thiophosphatephosphorothioate, the chirality thiophosphatephosphorothioate, phosphorodithioate, phosphotriester, the aminoalkyl group phosphotriester, methyl and other phosphonate ester comprise 3 '-the alkylene phosphonic acids ester, 5 '-alkylene phosphonic acids ester and chiral phosphonate, phosphinate, phosphoramidate comprises 3 '-amino phosphoramidate and aminoalkyl group phosphoramidate, the thion phosphoramidate, the thion phosphonate ester, the thion alkyl phosphotriester, the seleno phosphoric acid ester, carborane base (carboranyl) phosphoric acid ester and have a borano-phosphoric acid ester of normal 3 '-5 ' key, the analogue of their 2 '-5 ' connection and have those of reversed polarity, wherein one or more Nucleotide internal keies be 3 ' to 3 ', 5 ' to 5 ' or 2 ' to 2 ' key.Oligonucleotide with reversed polarity typically is included in 3 '-Nucleotide internal key places is independent 3 at most ' to 3 ' key, and promptly independent counter-rotating nucleosides residue, it can be (this nucleic acid base lacks, and perhaps has hydroxyl in its position) of no base.Various salt, mixing salt and free acid form have also been comprised.

Preparation with oligonucleotide of aforesaid phosphorous key is documented in for example U.S. Patent number 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; In 5,672,697 and 5,625,050, wherein each piece full text is hereby expressly incorporated by reference.

Some oligonucleotide main chains that do not comprise the exemplary modification of phosphorus atom have by between short-chain alkyl or cycloalkyl nucleosides between bonding, blended heteroatoms and alkyl or cycloalkyl nucleosides bonding one or more short chain is heteroatomic or the heterocyclic nucleosides between the main chain that forms of bonding.They comprise those with following key: morpholino key (partly the sugar moieties from nucleosides forms); Siloxane main chain; Sulfide, sulfoxide and sulfone main chain; Formacetyl and thioformacetyl main chain; Methylene radical formacetyl and thioformacetyl main chain; Nuclear ethanoyl main chain; The main chain that contains alkenyl; Sulfamate backbone; Methylene radical imino-and methylene radical diazanyl main chain; Sulphonate and sulphonamide main chain; Amide backbone; Have blended N, O, S and CH with other ₂The component part.Particularly advantageous is the main chain key that comprises one or more charged parts.The United States Patent (USP) example of having described the preparation of aforementioned oligonucleotide comprises U.S. Patent number 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, wherein each piece full text is hereby expressly incorporated by reference.

The oligonucleotide of modifying can also contain the sugar moieties of one or more replacements.For example, such oligonucleotide can comprise one following 2 '-modify: OH; F; O-, S-or N-alkyl; O-, S-or N-alkenyl; O-, S-or N-alkynyl; Or O-alkyl-O-alkyl, wherein said alkyl, alkenyl and alkynyl can be that replace or unsubstituted C ₁To C ₁₀Alkyl or C ₂To C ₁₀Alkenyl and alkynyl or 2 '-O-(O-carborane-1-yl) methyl.Concrete example is O[(CH ₂) _nO] _mCH ₃, O (CH ₂)～OCH ₃, O (CH ₂) _nNH ₂, O (CH ₂) _nCH ₃, O (CH ₂) _nONH ₂And O (CH ₂) _nON[(CH ₂) _nCH ₃]] ₂, wherein n and m are 1 to 10.Other exemplary oligonucleotide comprise one following 2 '-modify: C ₁To C ₁₀The low alkyl group of low alkyl group, replacement, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH ₃, OCN, Cl, Br, CN, CF ₃, OCF ₃, SOCH ₃, SO ₂CH ₃, ONO ₂, NO ₂, N ₃, NH ₂, silyl, reporter group, the intercalator of Heterocyclylalkyl, heterocycle alkaryl, aminoalkyl group amino, poly-alkylamino, replacement, the group or be used to that is used to improve the pharmacokinetics character of oligonucleotide improve the group of the pharmacodynamic properties of oligonucleotide.Example comprises 2 '-methoxy ethoxy (2 '-O-CH ₂CH ₂OCH ₃, be also referred to as 2 '-O-(2-methoxy ethyl) or 2 '-MOE) (Martin etc., Helv.Chim.Acta, 1995,78,486-504) be the alkoxyl group alkoxy base; 2 '-dimethyl-amino oxygen base oxethyl, i.e. O (CH ₂) ₂ON (CH ₃) ₂Group, be also referred to as 2 '-DMAOE; With 2 '-the dimethylamino ethoxy oxyethyl group (be also referred to as 2 '-O-dimethylamino ethoxy ethyl or 2 '-DMAEOE), promptly 2 '-O-CH ₂-O-CH ₂-N (CH ₂) ₂

Other modification comprises the nucleic acid (LNAS) of locking, wherein 2 '-oh group be connected to 3 of sugar ring ' or 4 ' carbon atom on, form the dicyclo sugar moieties thus.Key can be the methylene radical (CH that connects 2 ' Sauerstoffatom and 4 ' carbon atom ₂-)～group, wherein n is 1 or 2.LNA and preparation thereof are documented among WO 98/39352 and the WO 99/14226, and it is hereby expressly incorporated by reference in full.

Other modification comprises that sulphur-nitrogen is bridge modified, for example at the nucleic acid of the locking described in (2001) Curr.Opin.Mol.Ther.3:239-243 such as Orum.

Other modification comprises 2 '-methoxyl group (2 '-O-CH ₃), 2 ' methoxy ethyl (2 '-O-CH ₂-CH ₃), 2 '-amino propoxy-(2 '-OCH ₂CH ₂CH ₂NH ₂), 2 '-allyl group (2 '-CH ₂-CH=CH ₂), 2 '-O-allyl group (2 '-O-CH ₂-CH=CH ₂) and 2 '-fluoro (2 '-F).2 ' modify can be arabino (on) position or nuclear (descending) position.Similarly modification can also be on other position, particularly 3 ' terminal nucleotide of oligonucleotide or 2 '-5 ' 3 ' position of the sugar of the oligonucleotide that connects and 5 ' position of 5 ' terminal nucleotide.Oligonucleotide can also have sugared dummy, for example replaces the cyclobutyl moiety of furan pentose base sugar.The exemplary United States Patent (USP) of having described the sugared structure of this modification comprises for example U.S. Patent number: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; With 5,700,920, wherein each piece full text is hereby expressly incorporated by reference.

Other modification comprises the ON concatermer, and it is made up of a plurality of oligonucleotide sequences that connect by connector.This connector can for example be made up of Nucleotide or the non-nucleotide unit modified.In some embodiments, this connector provides elasticity for the ON concatermer.Obtain ideal length by connecting littler oligonucleotide structure piece, use the method for the synthetic final molecule that such ON concatermer can facilitate.For example, can be with the connector (C of 12 carbon ₁₂Phosphoramidite) connects two or more ON concatermers, and length, stability and elasticity are provided.

As used herein, " unmodified " or " natural " base (nucleic acid base) comprises purine base adenine (A) and guanine (G) and pyrimidine bases thymus pyrimidine (T), cytosine(Cyt) (C) and uridylic (U).Oligonucleotide can also comprise base modification or replacement.The base of modifying comprises other synthetic and naturally occurring base, for example the 2-propyl group of the 6-methyl of 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, xanthoglobulin, 2-aminoadenine, VITAMIN B4 and guanine and other alkyl derivative, VITAMIN B4 and guanine and other alkyl derivative, 2-sulfo-uridylic, 2-thio-thymine and 2-sulfo-cytosine(Cyt), 5-halo uridylic and cytosine(Cyt), 5-proyl (C ≡ C-CH ₃) other alkynyl derivatives of uridylic and cytosine(Cyt) and pyrimidine base, 6-azo uridylic, cytosine(Cyt) and thymus pyrimidine, 5-uridylic (pseudouracil), 4-sulfo-uridylic, the 8-halo, 8-amino, 8-mercaptan, the 8-alkylthio, VITAMIN B4 and guanine that 8-hydroxyl and other 8-replace, the 5-halo is the 5-bromine particularly, uridylic and cytosine(Cyt) that 5-trifluoromethyl and other 5-replace, 7-methyl guanine and 7-methyladenine, the 2-F-VITAMIN B4,2-amino-VITAMIN B4, guanozola and 8-azaadenine, 7-deazaguanine and 7-denitrogenation VITAMIN B4 and 3-deazaguanine and 3-denitrogenation VITAMIN B4.The base of other modification comprises for example phenoxazine cytidine(C (1H-Mi Dingbing [5 of tricyclic pyrimidine, 4-b] [1,4] benzoxazine-2 (3H)-ketone), thiodiphenylamine cytidine(C (1H-Mi Dingbing [5,4-b] [1,4] benzothiazine-2 (3H)-ketone), the G-clip for example replaces De phenoxazine cytidine(C (9-(2-amino ethoxy)-H-Mi Dingbing [5 for example, 4-b] [1,4] benzoxazine-2 (3H)-ketone), carbazole cytidine(C (2H-Mi Dingbing [4,5b] indol-2-one), pyrido indoles cytidine(C (the H-pyrido [3 ', 2 ': 4,5] pyrrolo-[2,3-d] pyrimid-2-one).The base of modifying can also comprise such, and purine wherein or pyrimidine bases are replaced by other heterocycle, for example 7-denitrogenation-VITAMIN B4,7-deazaguanine nucleosides, 2-aminopyridine and 2-pyridone.Other nucleic acid base comprises: U.S. Patent number 3,687,808 described those, TheConcise Encyclopedia Of Polymer Science and Engineering, 858-859 page or leaf, Kroschwitz, J.I. compile .John Wiley and Son, 1990 those disclosed, Englisch etc., Angewandte Chemie, International Edition, 1991,30,613 those disclosed, and Sanghvi, Y.S., the 15th chapter, Antisense Research and Application, 289-302 page or leaf, Crooke, S.T. and Lebleu, B. compile CRC Press, 1993 those disclosed.

Other modification comprises the phosphorodithioic acid ester bond.Known phosphorodithioate ODN (PS2-ODN) and PS-ODN have similar protein binding avidity (Tonkinson etc. (1994) Antisense Res.Dev.4:269-278) (Cheng etc. (1997) J.Mol.Recogn.10:101-107), known possible ODN mechanism of action is to be bonded to viral protein, can comprise the phosphorodithioic acid ester bond ideally on antiviral ODN of the present invention.

Another scheme of modifying ODN is to produce three-dimensional definition or three-dimensional enriched O DN, as at (2000) Bioorg.Med Chem.8:275-284 such as Yu with described in (2002) FEBS Lett.25:48-52 such as Inagawa.ODN by ordinary method preparation is by by means of forming around the mixture that participates in the diastereomer of the asymmetry of the phosphorus atom of key between Nucleotide.This can influence the bonded stability between ODN and the virus component (for example viral protein).Data in the past show that protein binding is three-dimensional dependent (Yu etc.) apparently.Thereby the use solid defines or three-dimensional enriched O DN can improve their protein binding character and improve their antiviral efficacy.

Can be with the many different integration modes and the combination of level utilization modification (for example above-mentioned those).That is to say that specific modification does not need to be included on the key of each Nucleotide or oligonucleotide, can be in combination independent oligonucleotide or even independent Nucleotide in utilize different modifications.

Synthesizing of oligonucleotide

Can use methods known in the art to synthesize oligonucleotide of the present invention.For example, utilize the phosphoramidite chemistry with iodine oxidation of standard, can go up phosphodiester (P=O) oligonucleotide synthetic unsubstituted and that replace at automatic dna synthesizer (for example AppliedBiosystems model 380B).In order progressively to carry out the sulfo-of phosphorous acid ester bond, thiophosphatephosphorothioate (P=S) can be synthesized phosphodiester oligonucleotide, except the standard oxidation bottle being replaced with the 311-1 of 0.2M, 2-benzo two mercaptan-3-ketone 1 are outside the solution of 1-dioxide in acetonitrile.Sulfo-waiting step (thioation waitstep) can be increased to 68 seconds, carries out capping step (capping step) then.After cutting from the CPG post, 55 ℃, in dense ammonium hydroxide deblocking.(18 hours) can be by precipitating 2 times purification of oligonucleotides with 2.5 volume of ethanol (from 0.5M NaCl solution).

Can be as U.S. Patent number 5,508,270 described preparation phosphinate oligonucleotide; Can be as U.S. Patent number 4,469,863 described preparation phosphonate ester oligonucleotide; Can be as U.S. Patent number 5,610,289 and 5,625,050 described preparation 3 '-deoxidation-3 '-the methene phosphonate ester oligonucleotide; Can be as U.S. Patent number 5,256,775 and U.S. Patent number 5,366,878 described preparation phosphoramidite oligonucleotide; Can be as preparation alkylthio phosphonic ester oligonucleotide as described in disclosed PCT application PCT/US94/00902 and the PCT/US93/06976 (being disclosed as WO 94/17093 and WO 94/02499 respectively); Can be as U.S. Patent number 5,476,925 described preparations 3 '-deoxidation-3 '-amino phosphoramidate oligonucleotide; Can be as U.S. Patent number 5,023,243 described preparation phosphotriester oligonucleotide; Can be as U.S. Patent number 5,130,302 and 5,177,198 described preparation borano phosphoric acid ester oligonucleotide; Can be as U.S. Patent number 5,378,825,5,386,023,5,489,677,5,602,240 and 5, the oligonucleotide that 610,289 described preparation methylene radical methyl-iminos connect (being also referred to as the oligonucleotide that MMI connects), widow-Nucleotide (being also referred to as the oligomer nucleosides that acid amides-4 connects) that the oligonucleotide (being also referred to as the oligonucleotide that acid amides-3 connects) that the oligonucleotide that methylene radical dimethyl-hydrazo-connects (being also referred to as the oligonucleotide that MDII connects) is connected with the methylene radical carbonylamino is connected with the methene amido carbonyl, and blended backbone compounds (having the MMI and P=O or the P=S key that for example change); Can be as U.S. Patent number 5,264, the oligonucleotide that 562 and 5,264,564 described preparation formacetal are connected with thioformacetal; Can be as U.S. Patent number 5,223, the oligonucleotide that 618 described preparation oxyethane connect.Every the patent and the patent application of quoting are hereby expressly incorporated by reference in full.

Oligonucleotide agent and pharmaceutical composition

Can in oligonucleotide agent or pharmaceutical composition, prepare oligonucleotide of the present invention.Thereby, oligonucleotide of the present invention can also mix mutually with the mixture of other molecule, molecular structure or compound, seals, in conjunction with or related in addition, liposome for example, the molecule of receptor target, per os, rectum, partial or other preparation is taken in, is distributed and/or absorb with auxiliary.The exemplary United States Patent (USP) of preparation of having described the auxiliary agent of such absorption, distribution and/or absorption comprises for example U.S. Patent number 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; With 5,595,756, each is hereby expressly incorporated by reference in full.

Oligonucleotide of the present invention, preparation and composition comprise salt or any other compound of any pharmacy acceptable salt, ester or such ester, and it can be directly after being administered to animal (comprising the people) or bioactive metabolites or its resistates be provided indirectly.Therefore, for example, the application also comprises the pharmacy acceptable salt of the prodrug of compound of the present invention and pharmacy acceptable salt, such prodrug and other biochemical equivalents.

Term " prodrug " is meant the therapeutical agent that is prepared into inactive form, and it can change into activity form (being medicine) by the effect of endogenous enzyme or other chemical and/or condition in vivo or in its cell.In specific embodiments; the prodrug forms of oligonucleotide of the present invention is to be prepared into basis at WO such as Gosselin 93/24510 with at WO such as Imbach 94/26764 and U.S. Patent number 5; 770; SATE[(S-ethanoyl-2-the thio-ethyl of the method described in 713) phosphoric acid ester] derivative, it is hereby expressly incorporated by reference in full.

Term " pharmacy acceptable salt " is meant on the physiology of compound of the present invention and pharmacy acceptable salt: promptly kept the desirable biologic activity of parent compound and do not caused the salt of undesirable toxicology effect.Known many such pharmacy acceptable salts, and can be with in the present invention.

For oligonucleotide, the useful example of pharmacy acceptable salt includes but not limited to: with the salt that positively charged ion (for example sodium, potassium, ammonium, magnesium, calcium) forms, polyamines is spermine and spermidine etc. for example; Acid addition salt with mineral acid (for example spirit of salt, Hydrogen bromide, sulfuric acid, phosphoric acid, nitric acid etc.) formation; Salt with organic acid (for example, acetic acid, oxalic acid, tartrate, succsinic acid, toxilic acid, fumaric acid, glyconic acid, citric acid, oxysuccinic acid, xitix, phenylformic acid, tannic acid, palmitinic acid, alginic acid, polyglutamic acid, naphthene sulfonic acid, methylsulfonic acid, tosic acid, naphthalene disulfonic acid, polygalacturonic acid etc.) formation; With the salt that forms with element negatively charged ion (for example chlorine, bromine and iodine).

The present invention also comprises pharmaceutical composition and preparation, and it contains antiviral oligonucleotide of the present invention.Partial as required still treatment of whole body and the zone that will treat can be used such pharmaceutical composition in many ways.For example, can use (what comprise eye comprises vagina and conveying rectum with mucous membrane) partly; Lung, for example, comprise and pass through atomizer by sucking or being blown into powder or aerosol; Endotracheal; In the nose; Epidermis with transdermal; Per os; Or it is parenteral.Parenteral using comprises intravenous, endarterial, subcutaneous, endoperitoneal or intramuscular injection or inculcates; Or encephalic, for example in the sheath or intraventricular using.

The pharmaceutical composition and the preparation that are used for topical application can comprise transdermal patch, ointment, lotion, creme, gel, drops, suppository, sprays, liquid and powder.Conventional pharmaceutical carrier, water-based, powder or butyrous matrix, thickening material etc. can be need or ideal.Can also use cated condom, gloves etc.Preferred topical formulations comprises such, and oligonucleotide wherein of the present invention is to mix mutually with local agent delivery, for example lipid, liposome, lipid acid, fatty acid ester, steroide, sequestrant and tensio-active agent.Preferred lipid and liposome comprise neutral (for example dioleoyl phospholipid acyl group DOPE thanomin, two myristoyl phosphatidyl choline DMPC, distearyl phosphatidyl choline), anionic (for example two myristoyl phosphatidyl glycerine DMPG) and cationic (for example dioleoyl tetramethyl-aminopropyl DOTAP and dioleoyl phosphatidyl thanomin DOTMA).Oligonucleotide can be encapsulated in the liposome, or with its formation mixture, particularly with cationic-liposome.Perhaps, can make oligonucleotide and lipid complexing, particularly with cation lipid.Preferred lipid acid and ester include but not limited to arachidonic acid, oleic acid, eicosanoic acid, lauric acid (laurie acid), sad, capric acid, tetradecanoic acid, palmitinic acid, stearic acid, linolic acid, linolenic acid, dicaprate, three decylates, Rylo MG 19, Lauric acid, diester with glycerol, the single caprin of 1-, 1-dodecyl-aza-cycloheptane-2-ketone, fatty acyl carnitine, acyl group choline or C _1-10Alkyl ester (for example isopropyl myristic acid ester IPM), monoglyceride, triglyceride or its pharmacy acceptable salt.

Be used for the composition of dosage forms for oral administration and preparation comprise powder or particle, particulate, nano particle, at suspension or solution, capsule, gel capsule, anther sac, tablet or the micro-tablet of water or non-aqueous media.Thickening material, seasonings, thinner, emulsifying agent, dispersing auxiliary or tackiness agent can need.Preferred per os preparation is such, and oligonucleotide wherein of the present invention is used with one or more penetration enhancers, tensio-active agent and sequestrant.Exemplary tensio-active agent comprises lipid acid and/or its ester or salt, bile acide and/or its salt.Exemplary bile acide/salt comprises gallodesoxycholic acid (CDCA) and ursodesoxycholic acid (UDCA), cholic acid, Felacrinos, Septochol, glucose cholic acid (glucholic acid), N-cholylglycine (glycholic acid), glycodesoxycholic acid (glycodeoxycholicacid), taurocholate, tauroursodeoxycholic acid, ox sulphur-24,25-dihydro-Sodium Fusidate, sweet ammonia dihydro Sodium Fusidate (sodium glycodihydrofusidate).Exemplary lipid acid comprises arachidonic acid, undecanoic acid, oleic acid, lauric acid, sad, capric acid, tetradecanoic acid, palmitinic acid, stearic acid, linolic acid, linolenic acid, dicaprate, three decylates, Rylo MG 19, Lauric acid, diester with glycerol, the single caprin of 1-, 1-dodecyl-aza-cycloheptane-2-ketone, fatty acyl carnitine, acyl group choline or monoglyceride, triglyceride or its pharmacy acceptable salt (for example sodium salt).The further preferably combination of penetration enhancer, for example, fatty acid/salt and bile acide/salt combination.Particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA.Other exemplary penetration enhancer comprises polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether.Can carry oligonucleotide of the present invention with particle form per os ground, comprise that spray-dired particle or complexing form micron or nano particle.The oligonucleotide complexing agent comprises poly--amino acid; Poly-imines; Polyacrylic ester; Polyalkyl acrylate, polyoxy ethane (polyoxethanes), polyalkyl alpha-cyanacrylate; The gelatin of cationization, albumin, starch, acrylate, polyoxyethylene glycol (PEG) and starch; Polyalkyl alpha-cyanacrylate; The DEAE-deutero-gathers imines, short stalk mould polysaccharide (pollulans), Mierocrystalline cellulose and starch.Useful especially complexing agent comprises chitosan, N-trimethylammonium chitosan, poly-L-Lysine, polyhistidyl, polyorithine, poly-spermine, protamine, polyvinylpyridine, poly-sulfo-diethylamino methyl ethylidene P (TDAE), poly-amino-benzene ethene (for example to amino), poly-(MCA), poly-(ethyl cyanoacrylate), poly-(butyl cyanoacrylate), poly-(isobutyl cyanoacrylate), poly-(isohexyl cyanoacrylate), the DEAE-methacrylic ester, the DEAE-ethylhexyl acrylate, the DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethacrylate, poly-ethylhexyl acrylate, poly-(D, L-lactic acid), poly-(D, L-breast-co-oxyacetic acid (PLGA), alginate and polyoxyethylene glycol (PEG).

Be used for parenteral, that sheath is interior or the interior administration of ventricle composition and preparation and can comprise aseptic aqueous solution, it can also contain buffer reagent, thinner and other suitable additive, such as but not limited to penetration enhancer, carrier compound and other pharmaceutically acceptable carrier or vehicle.

Pharmaceutical composition of the present invention includes but not limited to solution, emulsion and contains the preparation of liposome.These compositions can generate from various ingredients, include but not limited to ready-formed liquid, self-emulsification solid and self-emulsifying semisolid.

Pharmaceutical preparation of the present invention can be conventional have the routine techniques preparation that it can be known according to pharmaceutical industry with unit dosage form.Such technology comprises the step that activeconstituents is combined with pharmaceutical carrier or vehicle.Usually, preparation is by with activeconstituents and liquid vehicle or ground solid carrier or the two equably and closely combination, and mix products prepares where necessary then.

Composition of the present invention can be made any multiple possible formulation, such as but not limited to tablet, capsule, gel capsule, liquid sugar sirup, soft gel, suppository and enema.Composition of the present invention can also be formed in the suspension in water-based, the non-aqueous or blending agent.Aqueous suspension can also contain the material that can improve suspension viscosity, comprises for example Xylo-Mucine, sorbyl alcohol and/or dextran.Suspension can also contain stablizer.

In one embodiment of the invention, foam can be made and be used as to pharmaceutical composition.The preparation that pharmaceutical foam comprises is such as but not limited to emulsion, micro emulsion, creme, gelifying agent and liposome.Although their character is substantially similar, these preparations have difference on the denseness of component and the finished product.The such composition and the preparation of preparation are that the technician of medicine and formulation art knows, and can be used to prepare composition of the present invention.

Emulsion

Preparation of the present invention and composition can prepare and make emulsion.A kind of typically liquid of emulsion is dispersed in the allos system in the another kind of liquid with droplet form (its diameter surpasses 0.1 μ m usually).(Idson, in Pharmaceutical Dosage Form, Lieberman, Rieger and Banker (LIDS.), 1988, Marcel Dekker, Inc., New York, N.Y. rolls up 1,199 page; Rosoff, inPharmaceutical Dosage Form, Lieberman, Rieger and Banker (volume), 1988, MarcelDekker, Inc., New York, N.Y. rolls up 1,245 page; Block in Pharmaceutical DosageForms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., NewYork, N.Y. rolls up 2,335 pages; Higuchi etc., in Remington ' s PharmaceuticalScience, Mack Publishing Co., Easton, Pa., 1985,301 pages).Emulsion often is the two-phase system, and it comprises 2 and closely mixes each other and the immiscible solution phase of dispersive.Usually, emulsion can be the form of water-in-oil (w/o) or oil-in-water (o/w).In small, broken bits and when being distributed in the body oil phase as fine droplet when water, the composition that obtains is called water-in-oil (w/o) emulsion.Perhaps, in small, broken bits and when being distributed to the body aqueous phase as fine droplet when oil phase, the composition that obtains is called oil-in-water (o/w) emulsion.Except disperse phase and active medicine, emulsion can contain other component, and it can be used as the solution in water, oil phase, and perhaps himself is as the phase of separating.When needing, in emulsion, can also there be drug excipient for example emulsifying agent, stablizer, dyestuff and antioxidant.Pharmaceutical emulsion can also be to contain the multiple emulsion that surpasses 2 phases, for example, and the situation of water-in-oil bag oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsion.Such compound formulation provides simple two-phase emulsion unexistent some advantage through regular meeting.When each oil droplet of the o/w emulsion in the multiple emulsion also was surrounded by little water droplet, this multiple emulsion formed W/O/W emulsion.Similarly, the system of the oil droplet of sealing in the water droplet of stabilization in oil phase constitutes o/w/o emulsion.

Emulsion is characterised in that less or does not have thermodynamic stability.Usually, the disperse phase of emulsion or discontinuous phase are dispersed in foreign minister or the external phase preferably, and maintain this state by means of the viscosity of emulsifying agent or preparation.Each of emulsion can be semisolid or solid mutually, as the situation of the ointment base and the creme of emulsion-type.Other method of stable emulsion need be used emulsifying agent, its may be combined in emulsion arbitrarily mutually in.Emulsifying agent can broadly be divided into 4 classes: synthetic tensio-active agent, naturally occurring emulsifying agent, adsorbing base and finely divided solid (Idson, in Pharmaceutical DosageForms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., NewYork, N.Y., roll up 1,199 page).

The synthetic tensio-active agent is also referred to as tensio-active agent, is widely used in the preparation of emulsion, has been documented in document (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., New York, N.Y., roll up 1,285 page; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), Marcel Dekker, Inc., New York, N.Y., 1988, roll up 1,199 page).Tensio-active agent is amphipathic typically, and contains hydrophilic and hydrophobic part.Wetting ability and the hydrophobic ratio with tensio-active agent is defined as hydrophilic/lipophilic than (HLB), and it is the classification and the appraisal tool of option table surface-active agent in the formulation preparation process.Character according to hydrophilic radical, tensio-active agent can be divided into different classes: non-ionic, anionic, cationic and amphoteric (Rieger, inPharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., New York, N.Y., volume is 1,285 page).

The naturally occurring emulsifying agent that uses in emulsion preparations comprises lanolin, beeswax, phosphatide, Yelkin TTS and gum arabic.The adsorbing base possess hydrophilic property so they can absorb water, formation w/o emulsion, and keeps their semi-solid denseness, for example anhydrous lanolin and wetting ability Vaseline.Solid in small, broken bits also has been used as the well emulsify agent, and is particularly combined and in adhesive article with tensio-active agent.They comprise the polarity inoganic solids, for example heavy metal hydroxide, the clay for example carbon or the Tristearoylglycerol of wilkinite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloid silicic acid magnalium, pigment and non-polar solid for example of swelling not.

Also comprise the non-emulsification of numerous species in emulsion preparations, they help the character of emulsion.This comprises fat, oil, wax, lipid acid, Fatty Alcohol(C12-C14 and C12-C18), fatty ester, wetting agent, hydrophilic colloid, sanitas and antioxidant (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., New York, N.Y., roll up 1,335 page; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., New York, N.Y. rolls up 1,199 page).

Hydrophilic colloid or hydro-colloid comprise naturally occurring natural gum and synthetic polymkeric substance, and for example polysaccharide is (for example, gum arabic, agar, alginic acid, carrageenin, guar gum, kuteera gum and tragacanth), derivatived cellulose (for example, carboxymethyl cellulose and carboxy-propyl cellulose) and synthetic polymkeric substance (for example, carbon polymers, ether of cellulose and carboxy vinyl polymer).They disperse in water or expand, and form colloidal solution, and it forms the strong interface film and come stable emulsion by the viscosity that increases the foreign minister by the drop round disperse phase.

Because emulsion often contains many compositions, for example carbohydrate, albumen, sterol and phosphatide, they can easily support microbial growth, so these preparations often contain sanitas.The sanitas that uses in the emulsion preparations of being everlasting comprises para methyl paraben, propylparaben, quaternary ammonium salt, benzalkonium chloride, p-Hydroxybenzoate and boric acid, also often adds antioxidant in emulsion preparations, with going bad of prevention preparation.The antioxidant that uses can be a free-radical scavengers, for example tocopherol, alkylgallates, butylated BHA, butylated hydroxytoluene, or reductive agent for example citric acid, tartrate and Yelkin TTS of xitix and sodium metabisulfite and antioxidant synergist for example.

The method of using emulsion preparations with parenteral approach and preparing them of percutaneous, per os has been documented in document (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p.199).Used the emulsion preparations of oral delivery widely, reason is the effect of convenience, absorption and the bioavailability aspect of said preparation.(Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p.245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, P.199).The caccagogue of mineral oil matrix, oil-soluble VITAMIN and higher fatty acid dietetic product often belong to as o/w emulsion per os the material used.

In one embodiment of the invention, the composition of oligonucleotide is to make micro emulsion.Micro emulsion can be defined as the system of water, oil and amphiphile, amphiphilic molecule, it is single optically isotropic and thermodynamically stable liquor (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p.245).Typically, micro emulsion is the system that is prepared as follows: at first oil is distributed in the aqueous tenside solution, adds the 4th component (the normally alcohol of medium chain degree) of q.s then, form transparent system.Therefore, also micro emulsion has been described as 2 can not mixing liquid thermodynamically stable, isotropic clarification dispersed system, it is by interfacial film stabilization (Leung and Shah, in:Controlled Release of Drugs:Polymers and Aggregate Systems, the Rosoff of surface active molecules, M., compile, 1989, VCH Publisher, New York, page or leaf 185-215).Usually by the combined preparation micro emulsion of 3～5 kinds of components, they comprise oil, water, tensio-active agent, cosurfactant and ionogen.Micro emulsion is that water-in-oil (w/o) or oil-in-water (o/w) type depend on the oil of use and character and the polar head of surfactant molecule and structure and how much packing (Schott of hydrocarbon tail of tensio-active agent, in Remington ' s Pharmaceutical Science, Mack Publishing Co., Easton, Pa., 1985, p.271).

Studied the phenomenological method that utilizes phasor widely, and the comprehensive theory (Rosoff, in Pharmaceutical DosageForms, the Lieberman that how to prepare micro emulsion about those skilled in the art can have been produced, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., NewYork, N.Y., volume 1, p.245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (volume), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p.335).Compare with conventional emulsion, the advantage of micro emulsion is can be with water-insoluble medicine dissolution in the thermodynamically stable drop preparation that forms simultaneously.

The tensio-active agent that uses in the preparation of micro emulsion comprises but is not limited to ionic surface active agent, nonionogenic tenside, Brij 96, polyoxyethylene oleyl ether, polyglycerol fatty acid ester, four monolaurins (ML31O), four Rylo MG 19s (MO310), six Rylo MG 19s (PO310), six glycerine, five oleic acid esters (PO500), ten monocaprins (MCA750), ten Rylo MG 19s (MO750), decaglycerol sequioleate (SO750), SY-Glyster DAO 750 (DA0750), they use separately or are used in combination with cosurfactant.Cosurfactant is short chain alcohol normally, for example ethanol, 1-propyl alcohol and 1-butanols, and it can strengthen the flowability at interface by penetrating the tensio-active agent film and setting up disordered film (because having produced void space in surfactant molecule) subsequently.But, can not use cosurfactant to prepare micro emulsion, the self-emulsifying micro-emulsion system that does not have alcohol is known in the art.Water is the derivative of aqueous solution, glycerine, PEG300, PEG400, Polyglycerine, propylene glycol and the ethylene glycol of (but being not limited to) water, medicine typically.Oil phase can include but not limited to following substances, for example Captex 300, Captex 355, Capmul MCM, fatty acid ester, medium chain (C ₈-C ₁₂) single-, two-and the C of the glyceryl ester of Witepsol W-S 55, the ethylating glycerol fatty acid ester of polyoxy, Fatty Alcohol(C12-C14 and C12-C18), Pegylation, saturated Pegylation ₈-C ₁₀Glyceryl ester, vegetables oil and silicone oil.

From the angle of medicine dissolution with the absorption that strengthens medicine, micro emulsion is to make us interested especially.Advised using micro emulsion (o/w and w/o) to strengthen bioavailability (Constantinides etc., Pharmaceutical Research, 1994,11, the 1385-1390 of the medicine (comprising peptide) of per os based on lipid; Ritschet, Metli.Find.Exp.Clin.Pharmacol, 1993,13,205).The advantage that micro emulsion provides is: improved medicine dissolution, prevent medicine by enzymic hydrolysis, may strengthen drug absorption (because tensio-active agent inductive membrane fluidity and infiltrative variation), preparation easily, easily Orally administered with solid dosage, improved clinical efficacy and reduced toxicity (Constantinides etc., Pharmaceutical Research, 1994,11,1385; Ho etc., J.Pharm.Set, 1996,85,138-143).When envrionment temperature is admixed together with their component, usually can be formed naturally micro emulsion.When preparation heat-labile medicine, peptide or oligonucleotide, this is particularly advantageous.In makeup and medicinal application field, also micro emulsion is used for the transdermal delivery active ingredient effectively.Expect that micro emulsion composition of the present invention and preparation will help strengthening oligonucleotide and nucleic acid absorbs from GI whole body, and improve oligonucleotide and the partial cell absorption of nucleic acid in gi tract, vagina, oral cavity and other administered area.

Micro emulsion of the present invention can also contain other component and additive, and for example sorbitan monostearate (Grill 3), Labrasol and penetration enhancer are with the character of improving preparation and the absorption that strengthens oligonucleotide of the present invention and nucleic acid.The penetration enhancer that uses in micro emulsion of the present invention can be divided into a kind of in the 5 big classes: tensio-active agent, lipid acid, biliary salts, sequestrant and non-chelating nonsurfactant (Lee etc., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92).

Liposome

Except micro emulsion, also have many organized surfactant structures, people have carried out research and have been used for pharmaceutical preparation them.This comprises unimolecular layer, micella, bilayer and vesicle.Vesicle can provide specificity, and the action time of prolong drug conveying.Thereby as used herein, term " liposome " is meant the vesicle of being made up of the amphiphilic lipids that is arranged in one or more spherical bilayers, promptly liposome be individual layer or the multiwalled vesicle, it has the film that forms from lipophilic substance and aqueous interior.The water-based part typically contains the composition that will carry.In order to pass complete mammal skin, lipid vesicles must be passed a series of pore under the influence of suitable transdermal gradient, and the diameter of each is less than 50nm.Therefore, it is desirable to use liposome, it is that height is out of shape and can passes such pore.The other factors of liposome comprises the volume of water of fat surface charge and liposome.

Other advantage of liposome comprises: the liposome that obtains from natural phospholipid is biocompatible and biodegradable; Liposome can comprise the water and the liposoluble medicine of wide scope; Liposome can prevent to be encapsulated in metabolism and degraded (Rosoff, in Pharmaceutical DosageForms, Lieberman, the Rieger and the Banker (volume) of the medicine in its inner chamber, 1988, Marcel Dekker, Inc., NewYork, N.Y., volume 1, p.245).

About topical application, confirmed that liposome compares with other preparation and have several advantages.These advantages comprise: reduced with the high whole body of drug administration and absorb relevant side effect, increased the medicine used and be delivered into the ability in the skin in the accumulation of target thing with the medicine (hydrophilic and hydrophobic) of wide scope.The compound that comprises anodyne, antibody, hormone and high-molecular weight DNA has been administered to skin, can cause the target of upper epidermis usually.

Liposome can be divided into 2 big classes.Cationic-liposome is positively charged liposome, and itself and electronegative dna molecular interact and form stabilized complex.Positively charged DNA/ liposome complex can be incorporated into electronegative cell surface, and includes in the endosome.Because the acid pH in the endosome, liposome breaks, the inclusion that discharges them in tenuigenin (Wang etc., Biochem.Biophys.Res.Commun., 1987,147,980-985).

The pH-sensitivity or electronegative liposome can capture dna, rather than with its complexing.Because DNA and lipid have similar electric charge, they repel mutually rather than form mixture.DNA thereby be captured to the aqueous interior of these liposomes.Used pH-sensitive lipid body, for example, the DNA of the thymidine nucleoside kinase gene that is used for encoding be delivered into the cells in culture individual layer (Zhou etc., Journal of Controlled Relase 1992,19,269-274).

The main liposome composition of one class comprises phosphatide, except the phosphatidyl choline of natural generation.The neutral liposome composition for example can form from two myristoyl phosphatidyl choline (DMPC) or two palmitoyl phosphatidyl choline (DPPC).The anionic liposome composition forms from two myristoyl phosphatidyl glycerine usually, and negatively charged ion fusion liposome mainly is to form from dioleoyl phospholipid acyl ethanol amine (DOPE).The liposome composition of other type is to form from phosphatidyl choline (PC), for example soybean PC and egg PC.Another kind of is to form from the mixture of phosphatide and/or phosphatidyl choline and/or cholesterol.

Several researchs have been estimated liposomal pharmaceutical preparation and have been carried to the part of skin.The liposome that will contain Interferon, rabbit is applied on the guinea pig skin, can alleviate skin bleb ulcer, and carrying Interferon, rabbit by alternate manner (for example as solution or emulsion) then is invalid (Weiner etc., Journal of DrugTargeting, 1992,2,405-410).And the Interferon, rabbit used as the part of the Liposomal formulation effect of using to the Interferon, rabbit that uses aqueous systems has been tested in another research, and conclusion is, Liposomal formulation is used more superior (du Plessis etc., Antiviral Research, 1992 than water-based, 18,259-265).

Also after tested non-ionic liposome system, in effectiveness, particularly contain the system of non-ionic tensio-active agent and cholesterol to determine them to dermal delivery of drugs.Use contains Novasone ^TMI (GLYCERYL DILAURATE/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome ^TMThe non-ionic Liposomal formulation of II (distearin/cholesterol/polyoxyethylene-10-stearyl ether) is delivered into ciclosporin-A in the mouse corium.Surface as a result, so non-ionic liposome system can promote the deposition (S.T.P.Pharma.SCI. such as Hu, 1994,4,6,466) of ciclosporin-A in different skin layers effectively.

Liposome also comprises " stable on the space " liposome, as used herein, this term is meant the liposome that contains one or more special lipids, and in the time of in sneaking into liposome, it can cause comparing with the liposome that does not have this special lipid the cycle life of raising.The example of stabilized liposomes is such on the space, and wherein the part of the lipid part of the formation vesicle of liposome comprises one or more glycolipids, for example single sialyl Sphingolipids,sialo G _M1, or be derived from one or more hydrophilic polymers, for example polyoxyethylene glycol (PEG) part.Be not bound to any specific theory, believe for containing Sphingolipids,sialo, sphingophospholipid or being derived from stabilized liposomes on the space of lipid of PEG, the increase of the circulating half-life of stabilized liposomes is owing to the absorption (Allen etc. that reduced in the cell of reticuloendothelial system (RES) on these spaces, FEBS Lett., 1987,223,42; Wu etc., Cancer Research, 1993,53,3765).

The various liposomes that comprise one or more glycolipids have been reported in Papahadjopoulos etc., Ann.N.Y.Acad.Sci., 1987,507,64 (single sialyl Sphingolipids,sialo G _M1, semi-lactosi brain glycosides sulfuric ester and phosphatidyl inositol); Gabizon etc., Proc.Natl.Acad.Sci.USA., 1988,85,6949; Allen etc., U.S. Patent number 4,837,028 and international application open WO88/04924 (sphingophospholipid and Sphingolipids,sialo G _M1Or semi-lactosi brain glycosides sulfuric ester); Webb etc., U.S. Patent number 5,543,152 (sphingophospholipid); Lim etc., WO 97/13499 (1,2-sn-two myristoyl phosphatidyl choline).

Comprise liposome with one or more hydrophilic polymer deutero-lipids and preparation method thereof and be documented in, for example, Sunamoto etc., Bull.Chem.Soc.Jpn., 1980,53,2778 (they contain peg moiety for nonionic detergent, 2C1215G); Illum etc., FEBS Lett., 1984,167,79 (hydrophilic coatings that contain the granules of polystyrene of polyglycol); Sears, U.S. Patent number 4,426,330 and 4,534,899 (the synthetic phosphatide of the carboxyl modified by connecting polyalkylene glycol (for example PEG)); Klibanov etc., FEBS Lett., 1990,268,235 (with PEG or PEG stearate deutero-phosphatidyl thanomin (PE)); Blume etc., Biochimica et Biophysica Acta, 1990,1029,91 (PEG-deutero-phosphatide, DSPE-PEG for example is from being combined to form of distearyl phosphatidyl thanomin (DSPE) and PEG); Fisher, european patent number EP 0 445 131 B1 and WO90/04384 (at the bonded peg moiety of outer liposome surface covalency); Woodle etc., U.S. Patent number 5,013,556 and 5,356,633 and Martin etc., U.S. Patent number 5,213,804 and european patent number EP 0 496 813 B1 (the liposome composition that contains the 1-20 molar percentage) with PEG deutero-PE; Martin etc., WO 91/05545 and U.S. Patent number 5,225,212 and Zalipsky etc., WO94/20073 (liposome that contains many other lipid-polymer conjugates); Choi etc., WO96/10391 (liposome that comprises the ceramide lipid that PEG-modifies); Miyazaki etc., U.S. Patent number 5,540,935 and Tagawa etc., U.S. Patent number 5,556,948 (liposomes that contain PEG, its functional part that can further be used in their surfaces is derived).

The liposome that comprises nucleic acid is documented in, for example, and Thierry etc., WO 96/40062 (high-molecular weight nucleic acid is encapsulated into method in the liposome); Tagawa etc., U.S. Patent number 5,264,221 (the protein-bonded liposomes that contain RNA); Rahman etc., U.S. Patent number 5,665,710 (oligodeoxynucleotide is encapsulated into method in the liposome); Love etc., WO 97/04787 (liposome that comprises antisense oligonucleotide).

The liposome of another kind of type, carrier (transfersomes) but be the lipid aggregate of high deformation, it is attractive (Cevc etc., 1998, BiochimBiophys Acta.1368 (2): 201-15) as the drug conveying instrument.Carrier can be called lipid liquid, but their high deformation, so can pass the hole littler than drop.Transmit physical efficiency and adapt to the environment that uses them, for example, they be shape adaptations, selfreparing, often not the piecewise near their target position and often automatic loading.Carrier be can make, for example, surface-boundary promoting agent, normally tensio-active agent added by liposome composition to standard.

Tensio-active agent

Tensio-active agent is widely used for preparation, example emulsion (comprising micro emulsion) and liposome.The character of many dissimilar tensio-active agents (natural and synthetic) is classified and the common methods of arranging is by using hydrophilic/lipophilic than (HLB).The character of hydrophilic radical (being also referred to as " head ") provides the most useful mode (Rieger, in Pharmaceutical Dosage Forms, the Marcel Dekker for the different surfaces promoting agent classification of using in preparation, Inc., New York, N.Y., 1988, p.285).

If surfactant molecule is not Ionized, it is classified as non-ionic tensio-active agent.Non-ionic tensio-active agent is widely used in medicine and the cosmetic product, is available in the pH of wide region value, with the structure difference, and typical HLB value from 2 to about 18.Non-ionic tensio-active agent comprises non-ionic ester, for example the ester of glycol ester, propylene glycol ester, glyceryl ester, polyglycerol ester, sorbitan ester, sucrose ester and ethoxylation; With non-ionic alkylolamide and ether, for example fatty alcohol ethoxylate, propenoxylated pure and mild ethoxylation/propenoxylated block polymer is also included within such.Polyoxyethylene surfactant be non-ionic surfactant-based in the most frequently used member.

When dissolving or the surfactant molecule that has negative charge when being dispersed in the water are called anionic.Anion surfactant comprises carboxylate for example soap, acyl group breast acylate, amino acid whose acyl group acid amides; sulfuric ester is the alkyl sulfuric ester of alkyl sulfuric ester and ethoxylation for example; sulphonate is benzene sulfonamide acid esters, the different thiosulfates of acyl group, acyl group laurate and sulfosuccinic ester for example, and phosphoric acid ester.Alkyl sulfuric ester and soap are the most frequently used anion surfactants.

The surfactant molecule that has positive charge when dissolving or being dispersed in the water is called cationic.Cats product comprises the amine of quaternary ammonium salt and ethoxylation, and quaternary ammonium salt is the most frequently used.

The surfactant molecule that can have positive charge or negative charge is called amphoteric.The amphoteric tensio-active agent comprises alkylamide, N-alkyl betaine and the phosphatide of acrylic acid derivative, replacement.

The application of tensio-active agent in medicament production, preparation and emulsion has been documented in Rieger, inPharmaceutical Dosage Forms, and Marcel Dekker, Inc., New York, N.Y., 1988, p.285.

Penetration enhancer

In some embodiment, penetration enhancer uses in composition or therewith, to increase the conveying to zoodermic nucleic acid (particularly oligonucleotide).Most drug is to exist in solution with Ionized and form nonionicization.But, have only liposoluble or lipophilic medicine can easily pass cytolemma usually.Have been found that if handle the cytolemma that will pass, even non-lipophilic medicine also can pass this film with penetration enhancer.Except auxiliary non-lipophilic medicine passes the diffusion of cytolemma, penetration enhancer can also strengthen the lipophilic drug permeability.

Penetration enhancer can classify as one of 5 big classes, promptly tensio-active agent, lipid acid, biliary salts, sequestrant and non-chelating nonsurfactant (Lee etc., Critical Reviews in Therapeutic DrugCarrier Systems, 1991, p.92).Be described in greater detail below each class penetration enhancer.

Tensio-active agent: relevant with the present invention, tensio-active agent is a chemical entities, and in the time of in being dissolved into aqueous solution, it can reduce the surface tension of solution or the interfacial tension between aqueous solution and other liquid, and the result has strengthened the oligonucleotide that passes mucous membrane and absorbed.These penetration enhancers for example comprise sodium lauryl sulphate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee etc., CriticalReviews in Therapeutic Drug Carrier System, 1991, p.92); And emulsion of perfluororganic compounds, FC-43.Takahashi etc. for example, J.Pharm.Pharmacol., 1988,40,252), each piece full text is hereby expressly incorporated by reference.

Lipid acid: can for example comprise oleic acid, lauric acid, capric acid (n-capric acid), tetradecanoic acid, palmitinic acid, stearic acid, linolic acid, linolenic acid, dicaprate, three decylates, Rylo MG 19 (the single oleoyl of 1--rac-glycerine), Lauric acid, diester with glycerol, sad, arachidonic acid, the single caprin of 1-, 1-dodecyl-aza-cycloheptane-2-ketone, fatty acyl carnitine, acyl group choline, their C as the various lipid acid of penetration enhancer and their derivative _1-10Alkyl ester (for example methyl, sec.-propyl and the tertiary butyl) and their list-and two glycerates (being oleic acid ester, laurate, decylate, myristinate, cetylate, stearate, linoleate etc.) (Lee etc., Critical Reviews in TherapeuticDrug Carrier System, 1991, p.92; Muranishi, Critical Reviews in TherapeuticDrug Carrier System, 1990,7,1-33; EI Hariri etc., J.Pharm.Pharmacol., 1992,44,651-654), each piece full text is hereby expressly incorporated by reference.

Biliary salts: biliary physiological action comprises dispersion and the absorption (Brunton that promotes lipid and liposoluble vitamin, Chapter 38 in:Goodman and Gilman ' s The Pharmacological Basis ofTherapeutic, the 9th edition, volumes such as Hardman, Mcgraw-Hill, New York, 1996, pp.934-935).Various natural biliary saltss and their synthetic derivative are as penetration enhancer.Therefore, term " biliary salts " comprises any naturally occurring bile component and their any synthesis of derivatives.Biliary salts of the present invention comprises for example cholic acid (or its pharmaceutically acceptable sodium salt, Sodium cholic acid), Felacrinos (Suprachol), Septochol (Sodium desoxycholate), glucose cholic acid (glucose Sodium cholic acid), N-cholylglycine (Sodium glycocholate), glycodesoxycholic acid (glycodesoxycholic acid sodium), taurocholate (Taurocholic acid sodium salt), tauroursodeoxycholic acid (sodium taurodeoxycholate), gallodesoxycholic acid (gallodesoxycholic acid sodium), ursodesoxycholic acid (UDCA), ox sulphur-24,25-dihydro-Sodium Fusidate (STDHF), sweet ammonia dihydro Sodium Fusidate and polyoxyethylene-9-lauryl ether (POE) (Lee etc., Critical Reviews inTherapeutic Drug Carrier System, 1991,92 pages; Swinyard, 39 chapters In:Remington ' s Pharmaceutical Science, 18 editions, Gennaro compiles Mack PublishingCo., Easton, Pa., 1990,782-783 page or leaf; Muranishi, Critical Reviews inTherapeutic Drug Carrier System, 1990,7,1-33; Yamamoto etc., J.Pharm.Exp.Ther., 1992,263,25; Yamashita etc., J.Pharm:.Sci., 1990,79,579-583).

Sequestrant: in context, can think sequestrant be can from solution, remove metal ion (by with its formation complex compound) compound, the result has strengthened the absorption that oligonucleotide sees through mucous membrane.About they application as penetration enhancer of the present invention, sequestrant also has the attendant advantages as deoxyribonuclease inhibitor, because the catalysis of the DNA nuclease that great majority characterize needs the metal ion of divalence, thereby the agent that can be chelated suppresses (Jarrett, J.Chromatogr., 1993,618,315-339).Without limits, sequestrant comprises N-aminoacyl derivative (the enamine) (Lee etc. of N-acyl derivative, laureth-9 and the beta-diketon of disodium ethylene diamine tetraacetate (EDTA), citric acid, salicylate (for example sodium salicylate, 5-methoxyl group salicylate and homovanillic acid salt (homovanilate)), collagen, Critical Reviews in Therapeutic Drug Carrier System, 1991,92 pages; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990,7,1-33; Buur etc., J.Control Rel., 1990,14,43-51).

Non-chelating nonsurfactant: as used herein, it is such compound that the penetrating of non-chelating nonsurfactant strengthens compound, it does not show significant sequestrant or surfactant activity, but still can increase the absorption (Muranishi that oligonucleotide sees through the digestion organs mucous membrane, CriticalReviews in Therapeutic Drug Carrier Systems, 1990,7,1-33).The example of such penetration enhancer comprises undersaturated ring urea, 1-alkyl-and 1-alkenyl nitrogen heterocyclic-alkane ketone derivatives (Lee etc., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, the 92 pages); With the anti-inflammatory agent of non-steroids, for example diclofenac sodium, indomethacin and Phenylbutazone (Yamashita etc., J.Pharm.Pharmacol., 1987,39,621-626).

The reagent that the oligonucleotide that can also add in medicine of the present invention and other composition and preparation to increase cell levels is taken in.For example, also known cation lipid is lipofectin reagent (Junichi etc., U.S. Patent number 5,705 for example, 188), positively charged ion glycerol derivative and polycation molecule for example polylysine (Lollo etc., PCT the applies for WO 97/30731) cell that can strengthen oligonucleotide take in.

Penetrating of the nucleic acid that can utilize other reagent to strengthen to use comprises glycol for example ethylene glycol and propylene glycol, and the pyrroles is 2-pyrroles, azone (azones) and terpene Li such as limonene and piperitone for example.

Carrier

Some composition of the present invention also contains carrier compound in preparation.As used herein, " carrier compound " or " carrier " is meant nucleic acid or its analogue, it is inert (being not biologically active itself), but be considered to nucleic acid in the process in vivo, it can reduce the bioavailability of the nucleic acid of biologically active, for example the nucleic acid by degradation bioactive or promote it to remove realization from circulation.The using jointly of nucleic acid and carrier compound (a kind of material in back is often excessive) can be reduced the amount of the nucleic acid that reclaims in the outer storage of liver, kidney or other circulation in fact.For example, when with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetyl amide base-4 '-different sulfo-cyano group-Stilbene-2, when the 2-disulfonic acid is used jointly, can partly reduce the recovery (Miyao etc. of thiophosphatephosphorothioate oligonucleotide in hepatic tissue, Antisense Res.Dev., 1995,5,115-121; Takakura etc., Antisense ﹠amp; Nucl.Acid Drug Dev., 1996,6,177-183), each piece full text is hereby expressly incorporated by reference.

Vehicle

Different with carrier compound, " pharmaceutical carrier " or " vehicle " is inert carrier on pharmaceutically acceptable solvent, suspensoid or any other the pharmacology, and it is used for carrying one or more nucleic acid, liquid or solid typically to animal.When with other combination of components of nucleic acid and certain drug composition,, select pharmaceutical carrier that ideal volume, denseness etc. are provided usually with reference to the administering mode that is intended to.Typical pharmaceutical carrier is including but not limited to tackiness agent (for example pregelatinised W-Gum, Polyvinylpyrolidone (PVP) or Vltra tears etc.); Weighting agent (for example lactose and other sugar, Microcrystalline Cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylic ester or secondary calcium phosphate etc.); Lubricant (for example stearate of Magnesium Stearate, talcum, silica, colloid silica, stearic acid, metal, reductive vegetables oil, W-Gum, polyoxyethylene glycol, Sodium Benzoate, sodium-acetate etc.); Disintegrating agent (for example starch, sodium starch glycollate (sodium starch glycotate) etc.); And wetting agent (for example sodium lauryl sulphate etc.).

Be suitable for that parenteral is used outward and can also can not be used to prepare composition of the present invention with the pharmaceutically acceptable organic or inorganic vehicle that poisonous reaction takes place nucleic acid.Suitable pharmaceutically acceptable carrier includes but not limited to water, salts solution, alcohol, polyoxyethylene glycol, gelatin, lactose, amylose starch, Magnesium Stearate, talcum, silicic acid, sticking paraffin, Walocel MT 20.000PV, Polyvinylpyrolidone (PVP) etc.

The preparation that is used for the topical application of nucleic acid can be included in aseptic and non-sterile aqueous solution, the non-aqueous solution of usual vehicle (for example alcohol), or the nucleic acid solution in the liquid or solid oil matrix, and described conventional solvent is alcohol for example.Solution can also contain buffer reagent, thinner and other suitable additive.Can use the pharmaceutically acceptable organic or inorganic vehicle that is suitable for that parenteral is used outward and poisonous reaction can not take place with nucleic acid.

Other pharmaceutical composition component

This composition can also contain the component of using always of other well known consumption in pharmaceutical composition.Thereby, for example, composition can contain other, compatible pharmaceutically activated material, for example anti-itch agent, astringent matter, local anesthetic or anti-inflammatory agent, perhaps can contain at physics and prepare other useful in the various formulations of composition of the present invention material, for example dyestuff, seasonings, sanitas, oxidation inhibitor, opalizer, thickening material and stablizer.But when having added such material, they should not disturb the biological activity of composition component of the present invention irrelevantly.Preparation can be aseptic, can mix with auxiliary agent when needed, for example lubricant, sanitas, stablizer, wetting agent, emulsifying agent, the salt that is used to regulate osmotic pressure, buffer reagent, tinting material, correctives and/or aromatic substances etc., they not with preparation in nucleic acid deleterious interaction takes place.

Aqueous suspension can contain the material that can improve suspension viscosity, comprises for example Xylo-Mucine, sorbyl alcohol and/or dextran and/or stablizer.

Certain embodiments of the present invention provide pharmaceutical composition, its contain (a) one or more antiviral oligonucleotide and (b) one or more other pass through the chemotherapeutics that different mechanisms plays a role.

The example of such chemotherapeutics is including but not limited to daunorubicin, daunomycin, dactinomycin, Dx, epirubicin, idarubicin, esorubicin, bleomycin, Mafosfamide, ifosfamide, cytosine arabinoside, the Dichloroethyl nitrourea, busulfan, ametycin, dactinomycin, Plicamycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, Dacarbazine, Procarbazine, altretamine, pentamethylmelamine, mitoxantrone, amsacrine, Chlorambucil, the methylcyclohexyl nitrourea, mustargen, melphalan, endoxan, Ismipur, 6-thioguanine, cytosine arabinoside, the 5-aza-cytidine, hydroxyurea, deoxycoformycin, 4-hydroxyl peroxide endoxan, 5-fluorouracil (5-FU), 5-fluoro IUDR (5-FUdR), Rheumatrex (MTX), colchicine, safe plain, vincristine(VCR), vinealeucoblastine(VLB), Etoposide (VP-16), trimetrexate, irinotecan, Hycamtin, gemcitabine, teniposide, cis-platinum and stilboestrol (DES).Usually referring to, TheMerck Manual of Diagnosis and Therapy, the 15th edition, 1987, the 1206-1228 page or leaf, Berkow etc. compile Rahway, NJ.When using with compound of the present invention, such chemotherapeutics individually (for example 5-FU and oligonucleotide), in turn (for example use 5-FU and oligonucleotide to use MTX and oligonucleotide for some time after for some time again) or be used in combination with one or more other such chemotherapeutics (for example 5-EU, MTX and oligonucleotide or 5-FU, radiotherapy and oligonucleotide).Antiphlogiston includes but not limited to antiphlogiston and the corticosteroid and the antiviral drug of non-steroids, includes but not limited to ribavirin, cidofovir, vidarabine, acycloguanosine and ganciclovir, also can be combined in the composition of the present invention.Usually referring to, The Merck Manual ofDiagnosis and Therapy, the 15th edition, Berkow etc. compile, and 1987, Rahway, NJ., 2499-2506 and 46-49 page or leaf).Other non-oligonucleotide chemotherapeutics also within the scope of the invention.The compound of two or more combinations can use together or in turn.

Embodiment

Embodiment 1: hsv

Hsv (HSV) influences quite a few crowd.The present invention finds, at random ODN or ODN at random thing can suppress the infection of viral (for example HSV).Find by the cell HSV replicated test that in VERO cell (infect HSV-1 (strain KOS) and HSV-2 (strain MS2) responsive), carries out, can suppress duplicating of HSV-1 and HSV-2 with the PS-ODN of HSV replication orgin complementary strand.The infectivity that surprisingly, also can suppress virus with people (343 ARS) and plasmid (pBR322/pUC) starting point complementary contrast PS-ODN.With stochastic sequence PS-ODN and PS-ODN at random the experiment of thing show that the inhibition of virus infection strengthens along with the increase of ODN size.These data show that ON is the potent antiviral agent of therapeutic treatment virus infection.

The contriver thinks that the potential mechanism that stops virus (for example HHV) to be propagated is to have stoped duplicating of its DNA.Given this, will import infected cell with the replication orgin complementary thiophosphatephosphorothioate oligonucleotide (ODN) of HSV1 and HSV2.These ODN can cause forming the DNA triploid in the virus replication starting point, block the related of necessary trans-acting factor and viral dna replication.Described the afterclap of these experiments in this article, they show that in the experiment example, the effectiveness that ODN suppresses virus infection increases along with the increase of their size (length).

The inhibition of HSV-1

Reduce the ability that has detected PS-ODN inhibition HSV-1 in the test (PRA) at plaque.In MEM (minimal essential medium)+10% foetal calf serum (having replenished gentamicin, vancomycin and amphotericin B), at 37 ℃ and 5%CO ₂Following African green monkey kidney (VERO) cell of cultivating unlimited breeding.Seed cells in the 12 hole flat boards, its density is can generate the cell monolayer that converges in growth after 4 days.Reach converge after, substratum changed into only contains 5% serum+aforesaid fill-in, and under the situation that has test compounds to exist with cellular exposure in HSV-1 (bacterial strain KOS, about altogether 40-60PFU) 90 minutes.Virus replaces with new " covering " substratum with substratum after exposing, and it contains 5% serum, 1% human normal immunoglobulin, aforesaid fill-in and test compounds.Infected the back 3-4 days, and infected culture was carried out formalin fixed and toluene purple (cresylviolet) dyeing, and carry out plaque counting.

All ON (unless otherwise indicated) are at University of Calgary Core DNAServices lab synthetic.ON (seeing Table 1) is in the synthetic macro preparation of 1 or 15 μ mol, and in 50cm Sephadex G-25 post get on protection and desalination.By the ON that UV becomes the shadow gel electrophoresis analysis to obtain, contain about 95%, the n-1 of total length and n-2 oligomer and 5% short oligomer kind (suppose they have at random lack) at the most after measured.Synthetic for oligomer at random, VITAMIN B4, guanosine, cytosine(Cyt) and the thymidine amidite of equimolar amount is admixed together, so that the randomness maximum of in building-up process, integrating in each position of ODN.

Whether can suppress HSV-1 in order to test PS-ODN, in HSV-1 PRA, test REP1001,2001 and 3007.Expection has only REP 2001 will show any activity, because this PS-ODN points to the replication orgin (other 2 kinds are the replication orgin that points to people and plasmid) of HSV.But, the active (see figure 1) of anti--HSV-1 that 3 kinds of all PS-ODN show.And the effectiveness of anti--HSV-1 effect depends on the big or small (see figure 2) of oligomer.

In order to confirm anti--active big or small dependency of HSV-1 and relative sequence independence of PS-ODN, we have tested the PS-ODN ( REP 2002,2003,2004,2005 and 2006) of different sizes.By each base is synthesized " swing " (N), make every kind of PS-ODN in fact represent a group to have the different random sequence of identical size, for these PS-ODN provide inertia about the sequence-specific effect, these PS-ODN are called " thing at random ".When test in HSV-1 PRA during these oligomers, we find, 10 or still less the oligomer of base do not have detectable anti--the HSV-1 activity, but along with the size of PS-ODN is increased to 10 more than the base, rendeing a service also increases (IC ₅₀Reduce, see Fig. 3 and 4).We are also noted that the IC of the PS-ODN that surpasses 20 bases ₅₀Value is starkly lower than anti--HSV-1 medicine-acycloguanosine (see figure 4) of accepting clinically.

In order to define anti--active effective magnitude range of HSV-1 of PS-ODN better, the PS-ODN that we have tested the magnitude range (10～120 bases) that covers broad is thing (seeing Fig. 5 and 6) at random.We find, the oligomer of 12 and bigger base have detectable anti--the HSV-1 activity, to the effectiveness of HSV-1 also along with the PS-ODN of the increase length of thing (at least up to 120 bases) and increasing at random.But, at the PS-ODN that surpasses 40 bases at random in the thing, every increase base size, the littler (see figure 7) of the increase of effectiveness.

In order to contrast the non-PS-ODN effectiveness of thing, stochastic sequence PS-ODN and HSV-1 specific sequence PS-ODN at random, we have tested in size is this modification of 3 types (seeing Fig. 8 and 9) among the ODN of 10,20 and 40 bases.The ODN of unmodified thing does not at random have detectable resisting-HSV-1 activity (seeing Fig. 8 a-c) in the size of test.Stochastic sequence and specific HSV-1 sequence PS-ODN show big or small dependent resisting-HSV-1 activity (for these modifications any, do not observe activity in 10 bases, see Fig. 8 d and g).Stochastic sequence, specific HSV-1 sequence and at random the contrast (see figure 10) of thing PS-ODN show, for length is the PS-ODN of 20 bases, anti--HSV-1 activity that specific HSV-1 sequence has enhanced, but in the length of 40 bases, all modifications of thing, stochastic sequence or specific HSV-1 sequence are identical to the validity of HSV-1 at random.

As far as we know, this is the IC of the PS-ODN of reported first to HSV-1 ₅₀Be low to moderate 0.059 μ M and 0.043 μ M.

The inhibition of embodiment 2:HSV-2

In PRA, detected the ability of PS-ODN inhibition HSV-2.In MEM+10% foetal calf serum (having replenished gentamicin, vancomycin and amphotericin B), at 37 ℃ and 5%CO ₂Following African green monkey kidney (VERO) cell of cultivating unlimited breeding.Seed cells in the 12 hole flat boards, its density is can generate the cell monolayer that converges in growth after 4 days.Reach converge after, substratum changed into only contains 5% serum+aforesaid fill-in, and under the situation that has test compounds to exist with cellular exposure in HSV-2 (bacterial strain MS2, about altogether 40-60PFU) 90 minutes.Virus replaces with new " covering " substratum with substratum after exposing, and it contains 5% serum, 1% human normal immunoglobulin, aforesaid fill-in and test compounds.Infected the back 3-4 days, and infected culture was carried out formalin fixed and the purple dyeing of toluene, and carry out plaque counting.

Whether can suppress HSV-2 in order to test PS-ODN, in HSV-2 PRA, test REP1001,2001 and 3007.Expection has only REP 2001 will show any activity, because this PS-ODN points to the replication orgin (other 2 kinds are the replication orgin that points to people and plasmid) of HSV-1/2.But 3 kinds of all PS-ODN show anti--HSV-2 activity (seeing Figure 12).And the effectiveness of anti--HSV-2 effect depends on the size of PS-ODN and is independent of sequence (seeing Figure 13).

In order to confirm anti--active big or small dependency of HSV-2 and sequence independence of PS-ODN, we have tested the PS-ODN ( REP 2001,2002,2003,2004,2005 and 2006) of different sizes.By each base is synthesized " swing " (N), make every kind of PS-ODN in fact represent a group to have the different random sequence of identical size, for these PS-ODN provide inertia about the sequence-specific effect, these PS-ODN are called " thing at random ".When test in HSV-2 PRA during these PS-ODN, we find, 10 or still less the PS-ODN of base do not have detectable anti--the HSV-2 activity, but along with the size of PS-ODN is increased to 10 more than the base, rendeing a service also increases (IC ₅₀Reduce, see Figure 14 and 15).We are also noted that the IC of the PS-ODN that surpasses 20 bases ₅₀Value is starkly lower than anti--HSV-2 medicine-acycloguanosine of accepting clinically ^TM(seeing Figure 15).

As far as we know, this is the IC of the PS-ODN of reported first to HSV-2 ₅₀Be low to moderate 0.012 μ M.

In order to determine whether nonspecific sequence composition is influential to the antiviral activity of ON, tested that several sizes are equal to but formed differentiated PS-ODN anti--HSV-1 activity in HSV-1 PRA in its sequence.The PS-ODN of test is REP 2006 (N20), REP 2028 (G40), REP 2029 (A40), REP 2030 (T40) and REP 2031 (C40).The IC that obtains from HSV-1 PRA ₅₀Value (seeing Figure 37) shows, REP 2006 (N40) obviously is the most activated in all cycle tests, and REP 2029 (A40) then is minimum active.We are also noted that the activity of all other PS-ODN obviously not as N40, they according to the ordering of effect be N40＞C40＞T40＞A40＞＞G40.

We have also tested has the effect (seeing Figure 37 b) that different sequences becomes the different PS ODN of (containing 2 kinds of different Nucleotide).PS-ODN at random thing (REP 2006) to the effect of HSV-1 obviously than AC20 (REP 2055), TC20 (REP 2056) or AG20 (REP 2057) height, their effect is arranged as follows: N40＞AG＞AC＞TC.These data show, although antivirus action is non-sequence complementary, some nonspecific sequence is formed (being C40 and N40) and had the most effective antiviral activity.We think can be by this phenomenon of following facts explain, though promptly kept inherent protein binding ability, combination viral protein still less in sequence high-affinity ground such as C40, A40, T40 and G40 may be owing to formed some restrictive tertiary structures in these sequences.On the other hand, because the random nature of N40 has limited the ability of its high-affinity ground in conjunction with the antiviral protein of wide scope, this helps its powerful antiviral activity.

Embodiment 3:CMV suppresses

Reduce the ability that has detected PS-ODN inhibition CMV in the test (PRA) at plaque.This test is identical with the test that is used to test anti-HSV-1 and anti--HSV-2, just with CMV (strains A D169) as the virus inoculation thing, with the human fibroblasts as cell host.

In order to test anti--active big or small dependency of CMV and sequence independence of PS-ODN, the PS-ODN that we have tested different sizes is thing (seeing Figure 16 a, b) at random.When these PS-ODN of test in CMV PRA, we find that along with the increase of PS-ODN size, rendeing a service also increases (IC ₅₀Reduce, see Figure 16 c).

For the active effective magnitude range of the anti-CMV that is illustrated more clearly in PS-ODN, the PS-ODN that we have tested covering broad magnitude range (10～80 bases) is thing at random.We have also comprised several small molecules CMV therapeutical agents of accepting clinically (gancyclovir, phosphine formic acid and cidofovir) and the antisense therapy agent (Fomivirsen of 2 kinds of commercially available CMV retinitiss ^TMThat bought on the market and synthetic by University of Calgary) (seeing Figure 17).We find, although the PS-ODN that increases at random the thing size cause the enhanced effect, this is saturated (seeing Figure 18) when acting on 40 bases.And, the PS-ODN of 20,40 and 80 bases at random thing all obviously than the test any small molecules therapeutical agent more effective (Figure 17).In addition, the PS-ODN of 40 and 80 bases at random thing compare Fomivirsen ^TMMore effective.

As far as we know, this is the IC of the PS-ODN of reported first to CMV ₅₀Be low to moderate 0.067 μ M.

The inhibition of embodiment 4:HIV-1

Detected the PS-ODN ability of thing inhibition HIV-1 at random by 2 different tests:

Cytopathic effect (CPE)

By using the degree of MTT dyestuff report cellular metabolism, the monitoring cytopathic effect.In having replenished antibiotic MEM+10% foetal calf serum, at 37 ℃ and 5%CO ₂Middle human lymphocyte (MT4) cell of cultivating unlimited breeding.Seed cells in the substratum of suitable test compounds of containing of 96 hole flat boards, hatched 2 hours.After with the test compounds preincubate, Xiang Kongzhong adds HIV-1 (strain NL4-3) (0.0002 TCID ₅₀/ cell).After hatching 6 days in addition, transform supervision CPE by MTT.Under the situation of virus inoculation not, detect cytotoxicity over 6 days by hatching medicine.For the MTT absorption value is changed into the % survival rate, the absorption value of uninfection, untreated cell is set at 100%, absorption value infected, untreated cell is set at 0%.

Replicated test (RA)

In human embryo kidney (HEK) (293A) cell of unlimited breeding, monitored the replication of HIV.These cells are with 2 kinds of plasmid cotransfections.A kind of plasmid contains the wild-type HIV-1 genome (NL4-3) (differentiate and be strain CNDO) of the reorganization with the env gene that is interrupted by the luciferase expression box, and another kind of plasmid contains the env gene from murine leukemia virus (MLV).These two kinds of plasmids provide all protein factors, and their translation backs generate sophisticated embedded virus, and it contains all the HIV-1 components except the protein product that generates from MLV env gene translation.From the virus particle of these cells produce is infective and reproducible, but the next generation that can not produce the infectious virus particle, because they lack the env gene product.

After the transfection 24 hours,, be applied in the 96 hole flat boards these cell trypsinized.After cell has adhered to, the washing substratum, and replace with the substratum that contains test compounds.Continue in addition to produce virus 24 hours.Gather in the crops supernatant liquor then, be used for double infection and dye 293A cell originally.Identify infected naive cell by the luciferase gene product.Luciferase positive cells quantity is the yardstick of duplicating of Recombinant HIV-1 and/or gradient of infection.Have the HIV-1 genome of several point mutation (having notified the resistance of inducing) by use to several dissimilar anti-HIV medicines, can also be with the resistances of this experimental test to many anti-HIV-1 medicines of accepting clinically.To not have the inhibition per-cent of detectable luciferase positive cells to be set at 100%, the quantity of the positive cell in infected, untreated control group is 0%.

For active big or small dependency of the anti-HIV-1 of testing PS-ODN and sequence independence, the PS-ODN that we have tested different sizes is thing at random.When these PS-ODN of test in HIV-1 CPE test, we find that along with the increase of PS-ODN size, rendeing a service also increases (IC ₅₀Reduce, see Figure 19 a, b and 20).We be also noted that PS-ODN at random thing in this test, do not show remarkable toxicity (seeing Figure 19 c, d) to host cell.

As far as we know, this is the IC of the PS-ODN of reported first to HIV-1 ₅₀Be low to moderate 0.011 μ M.

For the active effective magnitude range of the anti-HIV-1 that is illustrated more clearly in PS-ODN, the PS-ODN that we have tested more covering broad magnitude range (10～80 bases) by the RA that uses wild-type HIV-1 (reorganization NL 4-3 (CNDO)) is thing at random.In addition, we have also tested 4 kinds and have been used for clinical proteinase inhibitor (amprenavir (aprenavir), Indinavir, rltonavir and Saquinavir) at present.We find, the PS-ODN of 10 and bigger base thing at random has anti-HIV-1 activity, and anti-HIV-1 effect also along with PS-ODN at random thing length increase and increase still saturated when 40 bases (seeing Figure 21 e-h and Figure 22 b).And, 40 with the PS-ODN of 80 bases at random thing effect almost with 4 kinds of clinical contrasts identical (seeing Figure 21 a-d and 22a).

As far as we know, this is the IC of the PS-ODN of reported first to HIV-1 ₅₀Be low to moderate 0.014 μ M.

In order to test the PS-ODN ability of the drug resistance strain of thing inhibition HIV at random, we use the reorganization MDRC4 strain of HIV-1 to duplicate above-mentioned test.This recombinant strain is to showing significant resistance from least 16 kinds of all kinds different medicines of accepting clinically: nucleotide RT inhibitor, non-nucleotide RT inhibitor and proteinase inhibitor.All PS-ODN are the performance and they identical (seeing Figure 23 e-h) to the wild-type strain of thing antagonism strain at random.But 3 kinds of reductions (seeing Figure 23 a-d and 24) that show the effect of mutant strain in 4 kinds of proteinase inhibitor are so thing is more effective to this resistance strain than these medicines at random for the PS-ODN of present 40 and 80 bases.

The inhibition of embodiment 5:RSV

Monitor CPE (indirect detection of cellular metabolism) by alamar blue, detected the PS-ODN ability of thing inhibition RSV at random.In the MEM+5% foetal calf serum, at 37 ℃ and 5%CO ₂Cultivator laryngocarcinoma (Hep2) cell.Seed cells in the 96 hole flat boards, its density is to produce the cell monolayer that converges after 5-6 days in growth.After the inoculation, exist under the situation that reduces the volume test compounds, with RSV (strain A2,10 ^8.2TCID ₅₀/ ml) cells infected 2 hours.After hatching, substratum is changed, and added test compounds.Infected back 6 days, and changed monitoring CPE by the fluorescence that detects alamar blue.Change the toxicity of monitoring test compounds in the Hep2 cell by the cell 7 days of handling uninfection and the alamar blue that detects in these cells.Alamar blue reading in cell uninfection, untreated is set at 100% survival rate, and the reading in infected, untreated cell is set at 0% survival rate.

In order to confirm anti--active big or small dependency of RSV and sequence independence of PS-ODN, the PS-ODN that we have tested different sizes is thing at random.In addition, we tested accept clinically be used for rsv infection, ribavirin (Virazole ^TM) therapeutical agent.When testing in RSV CPE test, we find that along with the PS-ODN increase of thing size at random, effect also increases, but when 40 base sizes saturated (seeing Figure 25 a-c and 26).The PS-ODN that we are also noted that 20,40 and 80 bases is the IC of thing at random ₅₀Value is obviously than anti--RSV medicine-ribavirin lower (seeing Figure 25 a-d and 26) of accepting clinically.PS-ODN thing does not at random show toxicity in the Hep2 cell, but ribavirin obviously toxic (Figure 25 e-h is seen in therapeutic index=2.08).

As far as we know, this is the IC of the PS-ODN of reported first to RSV-1 ₅₀Be low to moderate 0.015 μ M.

Embodiment 6: the inhibition of Coxsackie B virus 2

Monitor CPE (indirect detection of cellular metabolism) by alamar blue, detected the PS-ODN ability of thing inhibition COX B2 at random.In the MEM+5% foetal calf serum, at 37 ℃ and 5%CO ₂Cultivate rhesus monkey kidney (LLC-MK2) cell.Seed cells in the 96 hole flat boards, its density is to produce the cell monolayer that converges after 5-6 days in growth.After the inoculation, under the situation that has the test compounds that reduces volume, with COX B2 (strain Ohio-1,10 ^7.8TCID ₅₀/ ml) cells infected 2 hours.After hatching, substratum is changed, and added test compounds.Infected back 6 days, and changed monitoring CPE by the fluorescence that detects alamarblue.Change the toxicity of monitoring test compounds in the LLC-MK2 cell by the cell 7 days of handling uninfection and the alamar blue that detects in these cells.Alamar blue reading in cell uninfection, untreated is set at 100% survival rate, and the reading in infected, untreated cell is set at 0% survival rate.

We have tested anti--COX B2 activity of REP 2006 in COX B2 CPE test.We find, although show some mild toxicity (seeing Figure 27 b) in the LLC-MK2 cell, this PS-ODN thing at random can make infected LLC-MK2 cell partly be rescued from COX B2 Infection Status (to see Figure 27 a).

Embodiment 7: the inhibition of vaccinia virus

We use the cowpox infection model to measure the potential effect of our compound to poxvirus (comprising variola virus).By alamar blue monitoring CPE (indirect detection of cellular metabolism), detected the PS-ODN ability of thing inhibition cowpox at random.In the MEM+5% foetal calf serum, at 37 ℃ and 5%CO ₂Cultivation of Vero.Seed cells in the 96 hole flat boards, its density is to produce the cell monolayer that converges after 5-6 days in growth.After the inoculation, under the situation that has the test compounds that reduces volume, with cowpox (10 ^7.9TCID ₅₀/ ml) cells infected 2 hours.After hatching, substratum is changed, and added test compounds (except cidofovir is 50 μ M, all at 10 μ M).Infected back 5 days, and collected supernatant liquor.Again infect the VERO cell and monitor CPE infecting again to change by the fluorescence that detects alamar blue in back 7 days by supernatant liquor, detect the viral load in the supernatant liquor with dilution in 1: 100.

The PS-ODN that we have tested different sizes is thing ( REP 2004,2006 and 2007) at random.In addition, we have tested and have been used for known valid therapeutical agent-cidofovir (Vistide that cowpox infects ^TM).When in cowpox CPE test, testing, we find, REP 2004,2006 and 2007 treatment all show antiviral activity (that is, the supernatant liquor of generation shows the CPE of minimizing after infecting again), but this specific activity during with cidofovir observed a little less than (seeing Figure 36).

The inhibition of embodiment 8:DHBV, parainfluenza virus-3 virus and Hantaan virus.

Because DHBV, parainfluenza virus-3 virus and Hantaan virus can not easily produce detectable plaque or CPE, we utilize the fluorescence kitchen range to form unit (FFFU) and have tested the effect of REP 2006 in these viruses.In this test, REP 2006 (final concentration is 10 μ M) is mixed mutually with the virus that is adsorbed onto subsequently on the cell.After the absorption, infected cell was hatched 7-14 days again, at this moment fix them with methyl alcohol.Immunofluorescence microscopy by at suitable virus antigen has detected the virus replication district.For the test 3 kinds of viruses in each, concrete experiment condition and result are as described below:

Virus	Cell host	Be used for the antibody that FFFU detects	FFFU number (no medicine)	FFFU number (10 μ M REP 2006)
					DHBV (HBV surrogate)	Nascent duck liver cell	Mouse anti-DHBV IgG	?163+/-38.5	?0
Parainfluenza-3	The LLC-MK2 cell	Mouse anti-PI3 IgG	?288+/-126	?0
					Hantaan virus (strain Prospect Hill)	VERO E6 cell	Mouse anti-SinNombre nucleoprotein IgG	?232.3+/-38.17	?0

This raw data shows that when 10 μ M, REP 2006 suppresses DHBV, parainfluenza virus-2 and Hantaan virus effectively.Our expection, given strong reaction in tentative experiment, IC ₅₀Value can be lower.These data supported PS-ODN at random thing be used for the treatment of the effect that the people of Hantaan virus and hepatitis B (closely related with DHBV) infects, and the ultimate principle of children's's bronchiolitis that immediate treatment RSV and parainfluenza virus-3 cause is provided, it may not need the difference diagnosis when the treatment beginning.

Embodiment 9: present non-reacted virus

Up to now, when not using delivery system, drug regimen or chemically modified in the viral system below, we also do not observe the PS-ODN detectable antiviral efficacy of thing (10 μ M at the most) at random:

Virus	Strain	Cell host	The test example
				Influenza A	?H3N2	Mdck cell	Plaque reduces
Coronavirus (SARS	MHV2 (mouse)	The NCTC-1496 cell	Plaque reduces

Surrogate)	MHV-A59 (mouse) HCoV-OC43 (people)	DBT cell HRT-18 cell
				BVDV (HCV surrogate)	NA	The BT cell	The CPE of alamar blue
Rhinovirus	HGP	The HeLa cell	The CPE of alamar blue
				Adenovirus	People Ad5	The 293A cell	Plaque reduces

In this test method, we do not confirm activity.But the disappearance of antiviral activity may be because the lower cell-penetrating of PS-ODN under this test conditions.But, carried out other and tested and finish these viral efficacy outcomes.When using delivery system (for example Liposomal formulation) in order to improve its intracellular concentration, these viruses can react to PS-ODN.In addition, when the antiviral drug (for example as herein described) with other made up, PS-ODN can show these viral antiviral efficacies.The chemically modified that is used to improve intracellular concentration can also be used to providing to these viral PS-ODN activity.

Because we have strong evidence, promptly the charge characteristic of PS-ODN is important for the virus that suppresses from several different families, and we expect that the dependent mechanism of the electric charge of this inhibition virus activity has the active potentiality that suppress all envelope virus.Its corollary is, do not detect at embodiment 9 those listed viral antiviral efficacies and show that the interactional undercapacity between PS-ODN and these the viral structural protein is to stop the interaction of viral protein in these virus replication.Realization is to change the charge characteristic (for example replacing phosphorothioate bond at DNA with phosphorodithioate) of DNA or antiviral polymeric, thereby strengthen their avidity to viral protein at a kind of mode of these viral effects.

Embodiment 10: detect the test whether oligonucleotide mainly plays a role by the non-sequence complementary mode of action

If can satisfy any one standard in 3 following tests, think that then target ON (for example ODN) mainly plays a role by the non-sequence complementary mode of action.

The part degeneracy effect that test #1-resists viral effect

This test is used to detect specific ON sequence at the antiviral activity of its partial sequence during by degeneracy.Kept its following activity if having the degeneracy ON of identical chemical property, thought that then it is mainly to play a role by the non-sequence complementary mode of action.To make the ON degeneracy according to following rule:

L _ONBase number among the=original ON

X=wants the base number (but having the chemical property identical with original ON) on each end of oligomer of degeneracy

If L _ONBe odd number, X=L so _ON/ 4

If L _ONBe even number, X=(L so _ON/ 4) integral part+1

Each degeneracy base should be according to the appropriate parties science of law be synthetic arbitrarily, the synthetic PS-ODN methodology of thing at random that is used for for example as herein described.

If claim ON the member of herpetoviridae, Retroviridae or Paramyxoviridae family is had antiviral activity, will use virus family as herein described, preferably use the test of described virus strain to generate IC ₅₀If claim ON the member of the top concrete virus family of not mentioning is had antiviral activity, then the antiviral efficacy test of accepting by pharmaceutical industry generates IC ₅₀Value.Use minimum 7 compound concentrations to generate IC ₅₀Value has 3 or more point in the linearity region of dose response curve.Use this test, with the IC of described ON ₅₀Contrast with its degeneracy copy.If 25 and the IC of the degeneracy ON of the ON of base still less ₅₀Bigger below 2 times than original ON, perhaps 26 or more the polybase base (based on minimum three re-detections, standard deviation be no more than mean value 15%) the IC of degeneracy ON of ON ₅₀Bigger below 10 than original ON, will be understood that so ON mainly plays a role by the non-sequence complementary mode of action.

Test #2-is the effect contrast of thing at random

This test is used for contrasting the antiviral efficacy of the antiviral efficacy of ON and the ON of thing at random that is equal to size and identical chemical property having of identical virus or virus family.

If claim ON the member of herpetoviridae, Retroviridae or Paramyxoviridae family is had antiviral activity, will use virus family as herein described, preferably use the test of described virus strain to generate IC ₅₀If claim ON the member of the top concrete virus family of not mentioning is had antiviral activity, then the antiviral efficacy test of accepting by pharmaceutical industry generates IC ₅₀Use minimum 7 compound concentrations to generate IC ₅₀Value has 3 or more point in the linearity region of dose response curve.Use this test, with the IC of ON ₅₀Be equal to the size and the ON of identical chemical property at random thing contrast.If 25 and the IC of the degeneracy ON of the ON of base still less ₅₀Bigger below 2 times than original ON, perhaps 26 or more the polybase base (based on minimum three re-detections, standard deviation be no more than mean value 15%) the IC of degeneracy ON of ON ₅₀Bigger below 10 times than original ON, will be understood that so ON mainly plays a role by the non-sequence complementary mode of action.

The effect contrast of test #3-different virus family

This test is used to contrast ON to the effect of target virus (its genome and ON homology) and the ON effect to second kind of virus (its genome and ON do not have homology).In many cases, different viruses will be selected from the virus family different with the virus family of target virus.The equal length of use in 2 kinds of viruses and the IC of the ON that obtains from 2 kinds of viruses of the active stdn of the thing at random of chemical property ₅₀Value has contrasted the relative reactivity of the ON in target virus and the second kind of virus.

Thereby, if claim ON certain virus is had antiviral activity, then use one of the test of herpetoviridae as herein described, Retroviridae or Paramyxoviridae family or other test known in the art in this virus, to determine IC ₅₀Generation.Similarly, use a kind of virus as herein described (sequence of its genome and ON does not have homology) test, with the IC that generates at the ON of second kind of virus ₅₀Also generated and be equal to size and the thing at random of chemical property IC every kind of virus ₅₀With thing at random to the IC of 2 kinds of viruses ₅₀The IC of the following concrete ON of effect stdn ₅₀Value:

1. to the ON and the IC of thing at random of first kind (homologous) virus ₅₀Carry out algebraic transformation, make the IC of thing at random ₅₀Be 1 now.

2. to the ON and the IC of thing at random of second kind (nonhomologous) virus ₅₀Carry out algebraic transformation, make the IC of thing at random ₅₀Be 1 now.

3. use the IC of the ON in the homology virus of conversion ₅₀Remove the IC of the ON in the non-homogeneous virus of conversion ₅₀, the IC of calculating ON in homologous and nonhomologous virus ₅₀Multiple difference.

Be lower than the ON of 25 bases for length,, will be understood that ON plays a role by the non-sequence complementary mode of action if multiple difference is lower than 2.For length is 25 bases or bigger ON, if multiple difference is lower than 10, will be understood that ON plays a role by the non-sequence complementary mode of action.

Test #4: the effect of different virus family

This test is used for determining whether ON has medicine sample activity to virus, the sequence of wherein said ON not with virus genomic any part homology.Thereby, should use one of test of herpetoviridae as herein described, Retroviridae or Paramyxoviridae to detect ON, make test ON sequence not with the virus genomic any part homology that will use.Should use minimum 7 ON concentration to generate IC ₅₀Value has 3 or more point in linearity range.If the dose response curve that obtains indication medicine sample activity (it typically shows and is decay or sigmoid curve, and along with the reduction of ON concentration, antiviral efficacy also reduces) and the IC that generates from described curve ₅₀Be lower than 1 μ M, will be understood that ON has medicine sample activity.If think that ON has medicine sample activity to virus, and ON will be understood that it is to play a role by the non-sequence complementary mode of action not with this virus complementation thereby do not have the activity that depends on complementary sequence.

The threshold value of Shi Yonging in these trials

At scientific research or industrial circle, all do not have science or empirical basis design antisense ON greater than 25 bases.In addition, as far as we know, also less than the ON preparation of using in anyone test, it uses the ON greater than 25 Nucleotide.

In view of these facts, we have set up 2 different threshold values, we with them with sequence definition for mainly playing a role by the non-sequence complementary mode of action.For 25 and the oligomer of base still less, if to be considered to mainly be to play a role by antisense mechanism, the antiviral activity of ON must be the thing at random of identical chemical property or at least 2 times of degeneracy ON.If antisense ON is not thing or degeneracy ON at least 2 times at random, our conclusion is so, its active mostly can be owing to the mode of action of non-antisense.

For the ON of 26 and bigger base, if be considered to play a role by antisense mechanism, the antiviral activity of ON must be the thing at random of identical chemical property or at least 10 times (1log) of degeneracy ON.We about the ultimate principle of this bigger threshold value are, state in view of the present antisense ON design in this area, can reasonably suppose 26 bases and bigger and claim that the oligomer with antiviral activity is (optimum length of common acceptable antisense ON is between 16 and 21 bases) of utilizing invention knowledge as herein described to design.

Threshold value described in the superincumbent test 1～3 is default threshold value.If specify that other threshold value also can be used for contrasting above-mentioned test 1～3.Therefore, for example, being lower than the ON of 25 bases and/or length for length is 25 or the ON of polybase base more, if specify, be used for detecting threshold value that whether ON mainly play a role by the non-sequence complementary mode of action and can be 10 times, 8 times, 6 times, 5 times, 4 times, 3 times, 2 times, 1.5 times or equate any.Threshold value described in the superincumbent test 4 also is default threshold value.If specify, be used for detecting threshold value that whether ON of test 4 mainly play a role by the non-sequence complementary mode of action and can be IC less than 1 μ M, 0.8 μ M, 0.6 μ M, 0.5 μ M, 0.4 μ M, 0.3 μ M, 0.2 μ M or 0.1 μ M ₅₀Similarly, although default be that any that satisfy in above-mentioned 4 tests is just enough, if specify, can require ON when default threshold value, can satisfy any 2 (for example, test 1﹠amp; 2,1﹠amp; 3,1﹠amp; 4,2﹠amp; 3,2﹠amp; 4,3﹠amp; 4) or any 3 (1﹠amp; 2﹠amp; 3,1﹠amp; 3﹠amp; 4,2﹠amp; 3﹠amp; 4) or whole 4 tests, if perhaps specify, in aforesaid another threshold value.

Antivirus test to herpetoviridae

The following plaque that carries out reduces test:

For HSV-1 or HSV-2, in the MEM that has replenished 10% heat-inactivated foetal calf serum and gentamicin, vancomycin and amphotericin B, at 37 ℃ and 5%CO ₂VERO cell (ATCC#CCL-81) is grown in 12 hole tissue culturing plates (NUNC or equivalent) converge down.Reach converge after, change substratum into aforesaid 5% foetal calf serum and the antibiotic substratum of containing, it has added HSV-1 (strain KOS, altogether 40-60PFU) or HSV-2 (strain MS2,40-60PFU altogether).Virus absorption was carried out 90 minutes, and after this washed cell replaces with new " covering " substratum, and it contains 5% foetal calf serum and 1% human normal immunoglobulin.Absorption back 3-4 days is used the formalin fixed cell, and carry out plaque counting after formalin fixed.

For CMV, as in HSV-1/2 test about cultivator inoblast as described in the VERO cell.Nutrient media components is identical with absorption/covering method, but following exception is arranged:

1. in adsorption process, use CMV (strain AD169,40-60PFU altogether) cells infected.

2. in covering substratum, 1% human normal immunoglobulin is replaced with the 4%sea-plaque agarose.

For other herpetoviridae, in plaque is tested as mentioned above, in adsorption process, use suitable cell host and the virus of 40-60PFU to test.

Formed identifiable plaque under the situation that is not having compound when off-test if having only, this test is only effectively.

IC ₅₀Be the concentration of comparing with untreated contrast when having 50% plaque.

In absorption and overwrite procedure, all there is the compound that to test.

Antivirus test to Retroviridae

The following detection of carrying out the total p24 in the supernatant liquor of the cell that HIV-1 infects:

Under the situation that has compound to exist, with the former generation isolate infected person PBMC of HIV-1.After this other culturing cell 7 days in the fresh culture that has replenished compound then uses commercial p24 ELISA test kit (BIOMERIEUX or equivalent) to detect p24 level in the supernatant liquor.

If have only the p24 accumulation is arranged in the tissue culture supernatant liquor of infected, untreated cell, this test is only effectively.

IC ₅₀The amount that is detectable p24 is 50% o'clock a concentration of the amount of the p24 in the untreated contrast.

All there is the compound that to test in the substratum in adsorption process and after absorption.

Antivirus test to Paramyxoviridae

For RSV, following detection CPE:

Inoculation Hep2 cell in 96 hole flat boards is in the MEM+5% foetal calf serum, at 37 ℃ and 5%CO ₂Following overnight incubation.Next day is with RSV (strain A2,10 ^8.2TCID ₅₀/ ml is with 100 μ l/ holes) came cells infected in 2 hours by adsorbing.After the absorption, change substratum, grow after 7 days, Alamar Blue dyestuff is detected CPE to the conversion of its fluorescence adducts by viable cell.

Be 10% o'clock of the conversion that measures in the cell at uninfection there not being the CPE in infected cell under the situation of compound to measure (detecting as transforming by Alamar Blue) only, this test is only effectively.

In order to carry out IC ₅₀Contrast will observed level of conversion be set at 100%CPE in infected cell, observed level of conversion is set at 0%CPE in the cell of uninfection.Therefore, IC ₅₀It is the compound concentration when generating 50%CPE.

All there is the compound that to test in the substratum in adsorption process and after absorption.

All patents of quoting in specification sheets and other document all are the state of the art that is used for illustrating those skilled in the art, they are hereby expressly incorporated by reference in full, comprise any form and figure,, be suitable for too if every piece of document is whole separately incorporated by reference.

Those skilled in the art can easily understand, the present invention fully be applicable to realize mentioning and wherein inherent target and advantage.Method, variation and the composition of the present representative as preferred embodiment as herein described are exemplary, are not intended to limiting the scope of the invention.Those skilled in the art can change and other application, and this is limited by the scope of claim all in spirit of the present invention.

Those skilled in the art can easily understand, can carry out different substituting and variation to invention as herein described, and not depart from scope and spirit of the present invention.For example, can the synthesis condition and the composition of oligonucleotide be changed.Thereby, other such embodiment also the present invention and below the scope of claim in.

When lacking key element that one or more arbitrarily this paper do not have to specify, restriction, also can realize the invention that this paper explains suitably.Therefore, for example, in each situation of this paper, term " comprises ", " basically by ... form " and " comprising " in any one can replace with in other 2 one.Term that has adopted and statement are as illustrative and not restrictive term, use such term and express and be not intended to get rid of listed and any equivalent described feature or its part, but should be appreciated that in the scope of the present invention that requires and to carry out various variations.Thereby, be to be understood that, although it is concrete open that the present invention has been undertaken by embodiment preferred and best features, but those skilled in the art can use the modification and the variant of notion disclosed herein, will be understood that such modification and variant are also in the appended invention scope that claim limited.

In addition, when the feature of describing of the present invention or aspect relate to Ma Kushi group or other alternative group, those skilled in the art will appreciate that the present invention has also described any member of Ma Kushi group or other group or member's subgroup thus.

In addition, unless opposite explanation is arranged, when mentioning various numerical value in embodiments, as the end points of scope other embodiment has been described by getting any 2 different values.Such scope is also in scope disclosed by the invention.

Therefore, other embodiment also scope of the present invention and below claim in.

The description of table 1-oligonucleotide

REP 1001 is from the 20mer of people's autonomously replicating sequence

Sequence T T G A T A A A T A G T A C T A G G A C

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2001 is from the 22mer of HSV-1 replication orgin

Sequence G A A G C G T T C G C A C T T C G T C C C A

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 3007 is from the 16mer of pUC19/pBR322 replication orgin

Sequence C T T G C G G T A T T C G G A A

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2002 5mer are thing at random

Sequence N N N N N

PS??????????.?.?.?.?.

REP 2032 6mer are thing at random

Sequence N N N N N N

PS??????????.?.?.?.?.?.

REP 2003 10mer are thing at random

Sequence N N N N N N N N N N

PS??????????.?.?.?.?.?.?.?.?.?.

REP 2009 12mer are thing at random

Sequence N N N N N N N N N N N N

PS??????????.?.?.?.?.?.?.?.?.?.?.?.

REP 2010 14mer are thing at random

Sequence N N N N N N N N N N N N N N

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2011 16mer are thing at random

Sequence N N N N N N N N N N N N N N N N

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2012 18mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2004 20mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2005 30mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2006 40mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2007 80mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N ₅₀

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

Sequence N N N N N N N N N N N N N N N N N N N N ₅₀

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

PEP 2008 120mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N ₅₀

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

Sequence N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N ₁₂₀

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2013 10mer are thing at random

Sequence N N N N N N N N N N

Do not have and modify

REP 2014 20mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N

Do not have and modify

REP 2015 40mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N

Do not have and modify

REP 2016 10mer stochastic sequences

Sequence T C C G A A G A C G

PS??????????.?.?.?.?.?.?.?.?.?.

REP 2017 20mer stochastic sequences

Sequence A C A C C T C C G A A G A C G A T A A C

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2018 40mer stochastic sequences

Sequence C T A C A G A C A T A C A C C T C C G A A G A C G A T A A C A C T A G A C A T A

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2019 concentrates on the 10mer sequence of HSV-1 IE110 albumen (NCBI registration number X04614) initiator codon

Sequence C C C C C

PS??????????.?.?.?.?.?.?.?.?.?.

REP 2020 concentrates on the 20mer sequence of HSV-1 IE110 albumen (NCBI registration number X04614) initiator codon

Sequence T A C G A C C C C C

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2021 concentrates on the 40mer sequence of HSV-1 IE110 albumen (NCBI registration number X04614) initiator codon

Sequence T C C A G C C G C A T A C G A C C C C C

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2024 40mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

2-OMe???????.?.?.?.?????????????????????????????????????????????????????????????????.?.?.?.

REP 2026 40mer are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N

PCH3????????.?.?.?.?????????????????????????????????????????????????????????????????.?.?.?.

The 21mer of the antisense thing that is purchased (vitravine/ Fomivirsen) of REP 2036 anti-CMV, domestic synthetic

Sequence G C G T T T G C T C T T C T T C T T G C G

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

The 21mer of the antisense thing that is purchased (vitravine/ Fomivirsen) of the anti-CMV of REP 2036 is purchased (cGMP)

Sequence G C G T T T G C T C T T C T T C T T G C G

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

A20?????????20mer

Sequence A A A A A A A A A A A A A A A A A A A A-FITC

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

G20?????????20mer

Sequence G G G G G G G G G G G G G G G G G G G G-FITC

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

C20?????????20mer

Sequence C C C C C C C C C C C C C C C C C C C C-FITC

PS??????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

T20????????20mer

Sequence T T T T T T T T T T T T T T T T T T T T-FITC

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

AC10???????20mer

Sequence A C A C A C A C A C A C A C A C A C A C-FITC

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

AG10???????20mer

Sequence A G A G A G A G A G A G A G A G A G A G-FITC

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

TC10???????20mer

Sequence T C T C T C T C T C T C T C T C T C T C-FITC

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

TG10???????20mer

Sequence T G T G T G T G T G T G T G T G T G T G-FITC

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP?2029???40mer

Sequence A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP?2028???40mer

Sequence G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP?2031???40mer

Sequence C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP?2030???40mer

Sequence T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP?2055???40mer

Sequence A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP?2056???40mer

Sequence T C T C T C T C T C T C T C T C T C T C T C T C T C T C T C T C T C T C T C T C

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP?2057???40mer

Sequence A G A G A G A G A G A G A G A G A G A G A G A G A G A G A G A G A G A G A G A G

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2O59 20mer RNA is thing at random

Sequence N N N N N N N N N N N N N N N N N N N N

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

REP 2060 30mer RNA are thing at random

Sequence N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N

PS?????????.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.?.

Claims (137)

1. antiviral oligonucleotide agent, it contains at least a antiviral oligonucleotide, and the antiviral activity of wherein said oligonucleotide mainly produces by the non-sequence complementary mode of action.

2. according to the antiviral oligonucleotide agent of claim 1, it contains the mixture of at least 2 kinds of different antiviral oligonucleotide.

3. antiviral oligonucleotide agent of thing at random, it contains at least one antiviral oligonucleotide of thing at random, and the antiviral activity of wherein said thing at random mainly produces by the non-sequence complementary mode of action.

4. according to the antiviral oligonucleotide of claim 3 thing preparation at random, it contains the mixture of the antiviral thing at random of at least 2 kinds of different lengthss.

5. oligonucleotide agent with antiviral activity of anti-target virus, it contains at least a antiviral oligonucleotide, the length of wherein said oligonucleotide is at least 29 Nucleotide, and any part of the genome sequence of the sequence of described oligonucleotide and described target virus is not complementary.

6. oligonucleotide agent with antiviral activity of anti-target virus, it contains at least a antiviral oligonucleotide, the length of wherein said oligonucleotide is at least 6 Nucleotide, and any part of the genome sequence of the sequence of described oligonucleotide and described target virus is not complementary, and is not to be made up of the abundant sequence of polyA, polyC, polyG, polyT, G tetrad or G-basically.

7. according to each the oligonucleotide agent among the claim 1-6, wherein said preparation is to the IC of target virus ₅₀Be 0.10 μ M or littler.

8. according to each the oligonucleotide agent among the claim 1-6, wherein said preparation is to the IC of target virus ₅₀Be 0.05 μ M or littler.

9. according to each the oligonucleotide agent among the claim 1-6, wherein said preparation is to the IC of target virus ₅₀Be 0.025 μ M or littler.

10. according to each the oligonucleotide agent among the claim 1-6, wherein said preparation is to the IC of target virus ₅₀Be 0.015 μ M or littler.

11. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target dna virus.

12. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide targeted rna virus.

13. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target herpetoviridae.

14. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target HSV-1.

15. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target HSV-2.

16. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target CMV.

17. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Hepadnaviridae.

18. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target HBV.

19. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Parvoviridae.

20. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Poxviridae.

21. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Papillomaviridae.

22. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target adenovirus section.

23. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Retroviridae.

24. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target HIV-1.

25. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target HIV-2.

26. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Paramyxoviridae.

27. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target RSV.

28. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target parainfluenza virus.

29. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target bunyaviridae.

30. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target Hantaan virus.

31. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target picornaviridae.

32. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target Coxsackie virus.

33. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target rhinovirus.

34. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target flaviviridae.

35. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target yellow fever virus.

36. according to each the oligonucleotide agent among the claim 1-10; Wherein said oligonucleotide target dengue virus.

37. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target west nile virus.

38. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target hepatitis C virus.

39. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target filovirus section.

40. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target Ebola virus.

41. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target Marburg virus.

42. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target orthomyxoviridae family.

43. according to each the oligonucleotide agent among the claim 1-10, wherein said oligonucleotide target influenza virus.

44. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Togaviridae.

45. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target coronaviridae.

46. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Reoviridae.

47. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Rhabdoviridae.

48. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target Arenaviridae.

49. according to each the oligonucleotide agent among the claim 1-10, the member of wherein said oligonucleotide target calciviridae.

50. according to each the oligonucleotide agent in claim 1～4 and 6～49, wherein said oligonucleotide is the length of at least 6 Nucleotide.

51. according to each the oligonucleotide agent in claim 1～4 and 6～49, wherein said oligonucleotide is the length of at least 10 Nucleotide.

52. according to each the oligonucleotide agent in claim 1～4 and 6～49, wherein said oligonucleotide is the length of at least 20 Nucleotide.

53. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 29 Nucleotide.

54. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 32 Nucleotide.

55. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 34 Nucleotide.

56. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 36 Nucleotide.

57. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 38 Nucleotide.

58. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 40 Nucleotide.

59. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 46 Nucleotide.

60. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 50 Nucleotide.

61. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 80 Nucleotide.

62. according to each the oligonucleotide agent in the claim 1～49, wherein said oligonucleotide is the length of at least 120 Nucleotide.

63. according to each the oligonucleotide agent in the claim 1～62, wherein said oligonucleotide comprises at least one phosphodiester bond.

64. according to each the oligonucleotide agent in the claim 1～62, wherein said oligonucleotide comprises at least one chemical structure and modifies.

65. according to each the oligonucleotide agent in the claim 1～62, wherein each described oligonucleotide comprises at least one phosphorothioate bond.

66. according to each the oligonucleotide agent in the claim 1～62, wherein each described oligonucleotide comprises at least one phosphorothioate bond and delivery system.

67. according to each the oligonucleotide agent in the claim 1～62, wherein each described oligonucleotide comprises at least one phosphorothioate bond and liposome delivery system.

68. according to each the oligonucleotide agent in the claim 1～62, wherein said oligonucleotide comprises at least one 2 '-O methyl of ribose part is modified.

69. according to each the oligonucleotide agent in the claim 1～62, wherein said oligonucleotide comprise at least one to 2 of ribose part '-modify.

70. according to each the oligonucleotide agent in the claim 1～62, wherein said oligonucleotide comprises at least one methyl-phosphorous acid ester bond.

71. according to each the oligonucleotide agent in the claim 1～62, wherein each described oligonucleotide comprises at least one phosphorodithioic acid ester bond.

72. according to each the oligonucleotide agent in the claim 1～62, wherein each described oligonucleotide comprises at least one phosphorodithioic acid ester bond and delivery system.

73. according to each the oligonucleotide agent in the claim 1～62, wherein each described oligonucleotide comprises at least one phosphorodithioic acid ester bond and liposome delivery system.

74. according to each the oligonucleotide agent in the claim 1～62, the concatermers that wherein said oligonucleotide is made up of two or more oligonucleotide sequences that connect by connector.

75. according to each the oligonucleotide agent in the claim 1～62, wherein said oligonucleotide connects at one or more nucleotide residues place or is attached on the molecule to obtain one or more features, the feature of described molecular modification oligonucleotide, described feature is selected from higher stability, lower serum interacts, higher cell is taken in, higher viral protein interacts, the ability of improving that is suitable for carrying by preparation, detectable signal, higher antiviral activity, better medicament dynamic metabolism character, specific tissue distribution, lower toxicity.

76. according to each the oligonucleotide agent in the claim 1～62, wherein said oligonucleotide is double-stranded.

77. according to each the oligonucleotide agent in the claim 1～62, wherein said oligonucleotide is double-stranded or strand, and comprises the base that at least one can interact and hybridize by Fei Wosen-Ke Like.

78. according to each the oligonucleotide agent in the claim 1～77, wherein said oligonucleotide comprises at least one G tetrad motif part.

79. according to each the oligonucleotide agent in the claim 1～77, wherein said oligonucleotide comprises at least one CpG motif part.

80. according to each the oligonucleotide agent in claim 1～4 and 7～77, wherein said oligonucleotide comprises and virus mRNA complementary part.

81. according to each the oligonucleotide agent in the claim 1～77, wherein said oligonucleotide is in conjunction with one or more virus components.

82. according to each the oligonucleotide agent in the claim 1～77, wherein said oligonucleotide and one or more host's component interactions, wherein said interaction causes the inhibition of virus activity or generation.

83. according to each the oligonucleotide agent in claim 1～4 and 7～77, wherein the sequence of the described oligonucleotide of at least a portion is to be derived from viral genome.

84. according to each the oligonucleotide agent in claim 1～4 and 7～77, wherein the sequence of the described oligonucleotide of at least a portion is to be derived from viral genome, and has the antiviral activity of the mode of action that mainly is non-sequence complementarity.

85. according to each the oligonucleotide agent in claim 1～4 and 7～77, wherein the sequence of the described oligonucleotide of at least a portion is to be derived from viral packaging sequence or to participate in similar interactional other virus sequence.

86. according to each the oligonucleotide agent in the claim 1～77, the wherein sequence participation of the described oligonucleotide of at least a portion and virus component or host's component or the similar interaction of the two.

87. according to each the oligonucleotide agent in the claim 1～77, wherein the sequence of the described oligonucleotide of at least a portion comprises polyA, polyC, polyG, polyT, polyAC, polyAG, polyAT, polyCG, polyCT or polyGT.

88. according to each the oligonucleotide agent in the claim 1～77, wherein the sequence of the described oligonucleotide of at least a portion comprises two or more tumor-necrosis factor glycoproteinss.

89. according to each the oligonucleotide agent in claim 1 and 5～88, it contains the mixture of at least 2 kinds of different antiviral oligonucleotide.

90. 9 oligonucleotide agent according to Claim 8, it contains the mixture of at least 10 kinds of different antiviral oligonucleotide.

91. 9 oligonucleotide agent according to Claim 8, it contains the mixture of at least 100 kinds of different antiviral oligonucleotide.

92. 9 oligonucleotide agent according to Claim 8, it contains the mixture of at least 1000 kinds of different antiviral oligonucleotide.

93. 9 oligonucleotide agent according to Claim 8, it contains the mixture of at least 106 kinds of different antiviral oligonucleotide.

94. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 6 Nucleotide.

95. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 10 Nucleotide.

96. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 20 Nucleotide.

97. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 29 Nucleotide.

98. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 32 Nucleotide.

99. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 34 Nucleotide.

100. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 36 Nucleotide.

101. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 38 Nucleotide.

102. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 40 Nucleotide.

103. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 50 Nucleotide.

104. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 80 Nucleotide.

105. 9 oligonucleotide agent according to Claim 8, the length that wherein most of described different oligonucleotide are at least 120 Nucleotide.

106. an antiviral medicinal composition, it comprises:

Acceptable each antiviral oligonucleotides according in the claim 1～105 at least a pharmacology of treatment significant quantity, the antiviral activity of wherein said oligonucleotide is mainly by non-sequence complementary mode of action generation; With

Pharmaceutically acceptable carrier.

107. the antiviral medicinal composition according to claim 105 is used for the treatment of, controls or prevents virus causing disease to learn disease.

108. the antiviral medicinal composition according to claim 105 is used for the treatment of, controls or prevents prion disease.

109., be used for carrying by being selected from following mode according to the antiviral medicinal composition of claim 105: absorption intraocular, per os, intestines, suction, percutaneous injection, subcutaneous injection, intramuscular injection, peritoneal injection, intrathecal injection, intratracheal injection and intravenous injection.

110. according to the antiviral medicinal composition of claim 105, wherein said composition also comprises delivery system.

111. according to the antiviral medicinal composition of claim 105, wherein said composition also comprises Liposomal formulation.

112. according to claim 110 or 111 antiviral medicinal compositions, the cell of wherein said delivery system or Liposomal formulation targeting specific or specific tissue.

113. according to the antiviral medicinal composition of claim 105, wherein said composition also comprises at least a other antiviral drug in combination.

114. according to the antiviral medicinal composition of claim 105, wherein said composition also comprises the antiviral polymeric of non-nucleotide in combination.

115. test kit, it is included at least a in the packing of mark each antiviral oligonucleotide or antiviral oligonucleotide agent according in the claim 1～105, the antiviral activity of wherein said oligonucleotide mainly produces by the non-sequence complementary mode of action, and the label on described packing has illustrated that described antiviral oligonucleotide can be used for resisting at least a virus.

116. according to the test kit of claim 115, wherein said test kit contains the mixture of at least 2 kinds of different antiviral oligonucleotide.

117. according to the test kit of claim 115, wherein said test kit is used for the people by administration's approval.

118. according to the test kit of claim 115, wherein said test kit is used at least a inhuman animal by administration's approval.

119. a screening is used as the method for the antiviral oligonucleotides of antiviral agent, it comprises:

Synthetic many different random oligonucleotides;

The inhibition virus of testing described oligonucleotide produces the activity of the ability of infectious virus particle,

Select described active oligonucleotide to be used as antiviral agent with pharmaceutically acceptable level.

120. according to the method for claim 119, wherein said different random oligonucleotide comprises the thing at random of different lengths.

121. according to the method for claim 119, wherein said different random oligonucleotide comprises the oligonucleotide of one group of different lengths, every kind of oligonucleotide in described group comprises the sequence of the short oligonucleotide in described group.

122. according to the method for claim 119, wherein said different random oligonucleotide comprises many oligonucleotide, it contains the at random thing fragment of length at least 6 Nucleotide.

123. prevention or treatment experimenter's the method for virus infection, it comprises acceptable each oligonucleotide according in the claim 1～105 at least a pharmacology to experimenter's administering therapeutic significant quantity of this treatment of needs.

124. according to the method for claim 123, wherein said experimenter is the people.

125. according to the method for claim 123, wherein said experimenter is inhuman animal.

126. according to the method for claim 123, wherein said experimenter is a plant.

127. the method for cancer that a prophylaxis treatment causes in people or inhuman animal, it comprises at least a each the oligonucleotide according in the claim 1～105 of using acceptable on the pharmacology, treatment significant quantity to the people of this treatment of needs or inhuman animal.

128. according to the method for claim 127, wherein said oligonucleotide is to be administered to the people.

129. differentiate the screening method that changes oligonucleotide and at least a virus component bonded compound for one kind, described method comprises:

In the reaction that separates, have and situation that compound not screened exists under, make described oligonucleotide contact described virus component; With

Determine to compare with the situation that does not have described compound in the situation that has described compound, whether described oligonucleotide there are differences with combining of described virus component, and the existence of described difference represents that described compound has changed combining of described oligonucleotide and described virus component.

130. the novel antiviral compound that the method by claim 129 identifies.

131. a method that is purified into from oligonucleotide library in conjunction with the oligonucleotide of at least a virus component, it comprises:

Make described storehouse contact at least a virus component;

From described virus component, displace the bonded oligonucleotide in described storehouse; With

The oligonucleotide that collection displaces.

132. the method for claim 131 also comprises the bonded oligonucleotide from described stationary phase medium collection is checked order and tests its antiviral activity.

133. one kind enrichment is in conjunction with the method for the oligonucleotide of at least a virus component from oligonucleotide library, it comprises:

Make described storehouse contact at least a virus component; With

Amplification is attached to the oligonucleotide of described virus component, obtains the oligonucleotide library of enrichment.

134. the method for claim 133 wherein uses the oligonucleotide library of described enrichment to carry out at least once other contact and amplification as oligonucleotide library.

135. the method for claim 133 or 134 also comprises the oligonucleotide in the oligonucleotide library of described enrichment is checked order and tests antiviral activity.

136. antiviral oligonucleotide goods, it comprises one or more oligonucleotide that use each the method in the claim 131～135 to differentiate, the described oligonucleotide in the wherein said oligonucleotide goods is that show higher than the average binding affinity of the oligonucleotide in the initial oligonucleotide library with average binding affinity at least a virus component.

137. the antiviral oligonucleotide goods of claim 136, the average binding affinity of wherein said oligonucleotide be the oligonucleotide in the initial oligonucleotide library average binding affinity to 2 times.

Images